cancer_type,TMB (FMOne mutation burden per MB),Neoantigen burden per MB,Immune phenotype,response_label,user_question,full_query
BLCA,18.0,4.68627451,excluded,NR,"For my White male patient with bladder urothelial carcinoma, whose bladder biopsy reveals key aspects of the tumor immune microenvironment and a tumor mutational burden of 18.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my White male patient with bladder urothelial carcinoma, whose bladder biopsy reveals key aspects of the tumor immune microenvironment and a tumor mutational burden of 18.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? Assess the transcriptomic profile of the tumor microenvironment using the COMPASS tool to predict treatment response. When doing so, concentrate on immune deficiency markers—specifically natural killer (NK) cells, exhausted T cells, general B cells, and plasma cells. Integrate these markers with the COMPASS prediction and provide a rationale based on transcriptomic evidence to determine the likelihood of a positive treatment response, highlighting relevant gene expression features and their implications for immune function.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0257bb-ar-0257bbb.pkl. "
BLCA,1.0,0.31372549,desert,NR,"For my Caucasian patient with Bladder Urothelial Carcinoma (BLCA), whose tumor biopsy revealed a transcriptomic profile of the immune microenvironment and a tumor mutation burden (TMB) of 1.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For my Caucasian patient with Bladder Urothelial Carcinoma (BLCA), whose tumor biopsy revealed a transcriptomic profile of the immune microenvironment and a tumor mutation burden (TMB) of 1.0, what is the likelihood of a favorable response to Atezolizumab therapy? Evaluate the tumor microenvironment's transcriptomic profile using the COMPASS tool to forecast treatment efficacy. While doing so, specifically focus on the expression markers for immune deficiencies—including natural killer (NK) cells, exhausted T cells, general B cells, and plasma cells. Combine the marker analysis with the COMPASS output and support your prediction with transcriptomic evidence, emphasizing key gene expression patterns and their implications for immune function.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-025b45-ar-025b45c.pkl. "
BLCA,44.0,6.196078431,inflamed,NR,"For a Caucasian female diagnosed with bladder urothelial carcinoma, how do the transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden of 44.0 inform the likelihood of a positive response to atezolizumab therapy?","For a Caucasian female diagnosed with bladder urothelial carcinoma, how do the transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden of 44.0 inform the likelihood of a positive response to atezolizumab therapy? Assess the tumor microenvironment's transcriptome using the COMPASS tool to predict treatment response. Focus particularly on gene markers indicative of immune deficiencies, specifically those related to natural killer cells, exhausted T cells, B cells, and plasma cells. Combine the COMPASS results with a detailed analysis of these marker expression patterns, and use the transcriptomic data to support your predictive assessment regarding the immune functional status.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-032c64-ar-032c642.pkl. "
BLCA,2.0,1.470588235,excluded,NR,"For my Caucasian female patient with bladder urothelial carcinoma, whose lymph node biopsy revealed a transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden of 2.0, what is the estimated likelihood of a positive response to atezolizumab therapy?","For my Caucasian female patient with bladder urothelial carcinoma, whose lymph node biopsy revealed a transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden of 2.0, what is the estimated likelihood of a positive response to atezolizumab therapy? Review the tumor microenvironment’s transcriptomic profile using the COMPASS tool to predict treatment response. Focus on evaluating gene markers that indicate immune deficiencies, particularly those related to natural killer cells, exhausted T cells, B cells, and plasma cells. Integrate the COMPASS findings with a detailed analysis of these specific marker expression patterns to support your assessment of the overall immune function.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0571f1-ar-0571f17.pkl. "
BLCA,8.0,,inflamed,R,"For this white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was characterized via transcriptomic profiling and has a TMB of 8.0, what is the expected likelihood of a positive response to Atezolizumab therapy?","For this white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was characterized via transcriptomic profiling and has a TMB of 8.0, what is the expected likelihood of a positive response to Atezolizumab therapy? Please analyze the transcriptomic profile of the tumor microenvironment using the COMPASS tool to estimate the patient's treatment response. Specifically, focus on gene markers associated with immune deficiencies, with particular attention to markers of natural killer cells, exhausted T cells, B cells, and plasma cells. Combine the COMPASS analysis with a thorough evaluation of these marker expressions to support your overall assessment of the immune function.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-065890-ar-0658907.pkl. "
BLCA,6.0,0.921568627,,R,"For my White female patient with bladder urothelial carcinoma, whose tumor immune microenvironment was characterized via transcriptomic profiling from a bladder biopsy and who has a tumor mutation burden of 6.0, what is the anticipated response rate to Atezolizumab therapy?","For my White female patient with bladder urothelial carcinoma, whose tumor immune microenvironment was characterized via transcriptomic profiling from a bladder biopsy and who has a tumor mutation burden of 6.0, what is the anticipated response rate to Atezolizumab therapy? Please evaluate the transcriptomic data from the tumor microenvironment using the COMPASS tool to estimate the patient's treatment response. Focus on gene markers linked to immune deficiencies—specifically those associated with natural killer cells, exhausted T cells, B cells, and plasma cells. Integrate the COMPASS results with a detailed assessment of these marker expressions to inform your overall evaluation of the patient's immune function.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0684af-ar-0684af7.pkl. "
BLCA,11.0,0.745098039,excluded,R,"For my Caucasian patient with Bladder Urothelial Carcinoma (BLCA), I have obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and the patient’s tumor mutation burden (TMB) is 11.0. Based on these parameters, what is the likelihood of a positive response to Atezolizumab therapy?","For my Caucasian patient with Bladder Urothelial Carcinoma (BLCA), I have obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and the patient’s tumor mutation burden (TMB) is 11.0. Based on these parameters, what is the likelihood of a positive response to Atezolizumab therapy? Review the transcriptomic data from the tumor microenvironment using the COMPASS tool to predict the patient’s treatment response. In your analysis, pay particular attention to gene markers associated with immune deficiencies—specifically those related to natural killer cells, exhausted T cells, B cells, and plasma cells. Integrate the COMPASS findings with a comprehensive evaluation of these marker expressions to determine the overall status of the patient's immune function.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-075e03-ar-075e037.pkl. "
BLCA,18.0,2.117647059,excluded,R,"For my Caucasian male patient with confirmed bladder urothelial carcinoma, I have obtained transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden (TMB) is 18.0. Based on these findings, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","For my Caucasian male patient with confirmed bladder urothelial carcinoma, I have obtained transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden (TMB) is 18.0. Based on these findings, what is the anticipated likelihood of a favorable response to Atezolizumab therapy? Analyze the tumor microenvironment’s transcriptomic data using the COMPASS tool to predict the patient’s response to treatment. As you conduct your review, carefully examine gene expression markers indicative of immune deficiencies, particularly those related to natural killer cells, exhausted T cells, B cells, and plasma cells. Combine the COMPASS results with a detailed assessment of these markers to form a complete evaluation of the patient’s immune function.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-07a93a-ar-07a93a2.pkl. "
BLCA,,,excluded,NR,"For a White female patient with bladder urothelial carcinoma (BLCA), how predictive is her tumor biopsy transcriptomic profile of the immune microenvironment—especially given her reported TMB value of “nan”—in forecasting a favorable response to Atezolizumab therapy?","For a White female patient with bladder urothelial carcinoma (BLCA), how predictive is her tumor biopsy transcriptomic profile of the immune microenvironment—especially given her reported TMB value of “nan”—in forecasting a favorable response to Atezolizumab therapy? Review the tumor microenvironment transcriptome using the COMPASS tool to predict the patient’s treatment response. As part of this analysis, focus on gene expression markers that indicate immune deficiencies, particularly those associated with natural killer cells, exhausted T cells, B cells, and plasma cells. Integrate the COMPASS findings with a detailed evaluation of these markers to obtain a comprehensive assessment of the patient’s immune function.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-08cce2-ar-08cce2f.pkl. "
BLCA,,,inflamed,NR,"For my white male patient with bladder urothelial carcinoma, a transcriptomic profile of the tumor immune microenvironment was obtained from a nanobiopsy, and the tumor mutation burden (TMB) is nan. Based on these parameters, what is the predicted likelihood of a positive response to atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, a transcriptomic profile of the tumor immune microenvironment was obtained from a nanobiopsy, and the tumor mutation burden (TMB) is nan. Based on these parameters, what is the predicted likelihood of a positive response to atezolizumab therapy? Clinically, please analyze the tumor microenvironment transcriptome employing the COMPASS tool to forecast the patient’s treatment response. Emphasize evaluating gene expression markers that suggest immune deficiencies, especially those related to natural killer cells, exhausted T cells, B cells, and plasma cells. Then, combine the COMPASS outcomes with a thorough assessment of these markers to arrive at a detailed evaluation of the patient’s immune function.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-09c84e-ar-09c84ec.pkl. "
BLCA,2.0,0.215686275,,NR,"For my white male patient diagnosed with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and his tumor mutational burden is 2.0. Based on these parameters, what is the expected likelihood of a positive response to atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and his tumor mutational burden is 2.0. Based on these parameters, what is the expected likelihood of a positive response to atezolizumab therapy? Please use the COMPASS tool to analyze transcriptome data from the tumor microenvironment in order to predict treatment response. Focus on gene expression markers associated with immune deficiencies, particularly those related to natural killer cells, exhausted T cells, B cells, and plasma cells. Then, integrate the COMPASS results with this marker assessment to provide a comprehensive evaluation of the patient’s immune function.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0a0f2b-ar-0a0f2ba.pkl. "
BLCA,8.0,1.274509804,excluded,NR,"For a white male patient with bladder urothelial carcinoma who has undergone transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy and exhibits a tumor mutational burden of 8.0, what is the anticipated likelihood of achieving a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who has undergone transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy and exhibits a tumor mutational burden of 8.0, what is the anticipated likelihood of achieving a positive response to Atezolizumab therapy? Use the COMPASS tool to analyze transcriptome data from the tumor microenvironment to predict treatment response. Specifically, assess gene expression markers linked to immune deficiencies—focusing especially on natural killer cells, exhausted T cells, B cells, and plasma cells. Then, combine the COMPASS findings with this marker evaluation to generate a detailed assessment of the patient’s immune function.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0a7c20-ar-0a7c209.pkl. "
BLCA,,,,NR,"For my white female patient diagnosed with bladder urothelial carcinoma, we performed transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy. With the tumor mutational burden currently unavailable, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my white female patient diagnosed with bladder urothelial carcinoma, we performed transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy. With the tumor mutational burden currently unavailable, what is the estimated likelihood of a positive response to Atezolizumab therapy? Apply the COMPASS tool to transcriptome data from the tumor microenvironment to estimate treatment response. Specifically, examine gene expression markers associated with immune deficiencies, with particular attention to natural killer cells, exhausted T cells, B cells, and plasma cells. Integrate the results from the COMPASS analysis with these marker evaluations to provide a comprehensive assessment of the patient's immune function.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0bdb34-ar-0bdb342.pkl. "
BLCA,9.0,,excluded,NR,"For my white male patient with confirmed bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile was obtained from a ureter biopsy and who has a tumor mutation burden of 9.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my white male patient with confirmed bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile was obtained from a ureter biopsy and who has a tumor mutation burden of 9.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? Use the COMPASS tool to analyze transcriptome data from the tumor microenvironment for estimating treatment response. Focus on evaluating gene expression markers linked to immune deficiencies, especially those related to natural killer cells, exhausted T cells, B cells, and plasma cells. Then, integrate the COMPASS findings with these marker assessments to develop a thorough evaluation of the patient’s immune function.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0ce9c9-ar-0ce9c98.pkl. "
BLCA,4.0,0.137254902,desert,NR,"For a white female patient with bladder urothelial carcinoma, a bladder biopsy provided a detailed transcriptomic profile of the tumor immune microenvironment, and her tumor mutation burden is 4.0. Based on these parameters, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, a bladder biopsy provided a detailed transcriptomic profile of the tumor immune microenvironment, and her tumor mutation burden is 4.0. Based on these parameters, what is the estimated likelihood of a positive response to Atezolizumab therapy? Utilize the COMPASS tool to analyze transcriptome data obtained from the tumor microenvironment to estimate treatment response. Emphasize the assessment of gene expression markers associated with immune deficiencies, particularly those linked to natural killer cells, exhausted T cells, B cells, and plasma cells. Then, combine the insights from the COMPASS analysis with these marker evaluations to provide a comprehensive appraisal of the patient’s immune function.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0d855c-ar-0d855cf.pkl. "
BLCA,32.0,4.098039216,excluded,NR,"In a Caucasian male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a ureter biopsy revealed a tumor mutational burden of 32.0. Based on these parameters, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a ureter biopsy revealed a tumor mutational burden of 32.0. Based on these parameters, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS tool to evaluate transcriptome data from the tumor microenvironment in order to estimate the patient's treatment response. In your analysis, focus on gene expression markers that indicate immune deficiencies—specifically those related to natural killer cells, exhausted T cells, B cells, and plasma cells. Then, integrate the findings from the COMPASS evaluation with the assessment of these markers to provide a thorough review of the patient’s immune function.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-0f956e-ar-0f956e7.pkl. "
BLCA,21.0,3.529411765,desert,NR,"For my white male patient diagnosed with bladder urothelial carcinoma who has a tumor mutation burden of 21.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the likelihood of a favorable response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma who has a tumor mutation burden of 21.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS tool to analyze transcriptome data from the tumor microenvironment for assessing the patient's treatment response. Focus on evaluating gene expression markers related to immune deficiencies, particularly those associated with natural killer cells, exhausted T cells, B cells, and plasma cells. Then, integrate these findings with the COMPASS results to provide a comprehensive review of the patient's immune function.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-110501-ar-110501d.pkl. "
BLCA,10.0,1.078431373,inflamed,NR,"For my white male patient with bladder urothelial carcinoma, a kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment, and the tumor mutation burden is 10.0. Based on these findings, what is the estimated likelihood that he will respond favorably to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, a kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment, and the tumor mutation burden is 10.0. Based on these findings, what is the estimated likelihood that he will respond favorably to Atezolizumab therapy? Utilize the COMPASS tool to analyze transcriptome data from the tumor microenvironment in order to evaluate the patient's treatment response. Specifically, assess gene expression markers that indicate immune deficiencies, focusing on natural killer cells, exhausted T cells, B cells, and plasma cells. Then, consolidate these findings with the COMPASS analysis to form a comprehensive evaluation of the patient's immune function.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-12502d-ar-12502d9.pkl. "
BLCA,38.0,6.68627451,desert,R,"For a white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 38 based on transcriptomic analysis of the tumor immune microenvironment from his bladder biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden of 38 based on transcriptomic analysis of the tumor immune microenvironment from his bladder biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS tool to evaluate transcriptome data from the tumor microenvironment, focusing on gene markers associated with immune deficiencies. Specifically, analyze indicators for natural killer cells, exhausted T cells, B cells, and plasma cells. Integrate these results with the overall COMPASS analysis to develop a comprehensive assessment of the patient’s immune function and treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-149386-ar-1493861.pkl. "
BLCA,7.0,0.568627451,excluded,R,"For our white female patient diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden of 7.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the estimated likelihood of a positive therapeutic response to Atezolizumab?","For our white female patient diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden of 7.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the estimated likelihood of a positive therapeutic response to Atezolizumab? Please analyze the transcriptome data from the tumor microenvironment using the COMPASS tool. Emphasize evaluating gene markers that signal immune deficiencies. In your assessment, pay particular attention to the activity and presence of natural killer cells, exhausted T cells, B cells, and plasma cells. Then, integrate these findings with the broader COMPASS analysis to form a comprehensive evaluation of the patient's immune function and potential treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-14df63-ar-14df63a.pkl. "
BLCA,5.0,0.274509804,excluded,NR,"For my Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), the transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden (TMB) of 5.0. Based on these findings, what is the likelihood that he will benefit from Atezolizumab therapy?","For my Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), the transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy shows a tumor mutational burden (TMB) of 5.0. Based on these findings, what is the likelihood that he will benefit from Atezolizumab therapy? Please use the COMPASS tool to analyze the tumor microenvironment's transcriptome data. Focus on identifying gene markers that indicate immune deficiencies, especially those related to natural killer cells, exhausted T cells, B cells, and plasma cells. Once this specific analysis is complete, integrate these findings into the broader COMPASS evaluation to provide a comprehensive overview of the patient's immune function and their potential response to treatment.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-166a41-ar-166a419.pkl. "
BLCA,15.0,,desert,NR,"For my white male patient diagnosed with bladder urothelial carcinoma, who exhibits a tumor mutational burden of 15.0 and whose tumor immune microenvironment has been profiled via transcriptomics from a bladder biopsy, what is the probability of a favorable response to atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, who exhibits a tumor mutational burden of 15.0 and whose tumor immune microenvironment has been profiled via transcriptomics from a bladder biopsy, what is the probability of a favorable response to atezolizumab therapy? Please use the COMPASS tool to evaluate the transcriptomic data of the tumor microenvironment. In this analysis, specifically focus on identifying gene expression markers that suggest deficiencies in immune function, with special attention to natural killer cells, exhausted T cells, B cells, and plasma cells. After completing this targeted analysis, incorporate your findings into the overall COMPASS assessment to provide a comprehensive evaluation of the patient's immune status and potential treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-180398-ar-1803982.pkl. "
BLCA,,0.215686275,excluded,NR,"For my white male patient with bladder urothelial carcinoma who underwent transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy—and whose tumor mutation burden is reported as ""nan""—what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma who underwent transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy—and whose tumor mutation burden is reported as ""nan""—what is the estimated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS tool to analyze the tumor microenvironment’s transcriptomic data. Your analysis should focus on identifying gene expression markers that indicate impaired immune function, with an emphasis on natural killer cells, exhausted T cells, B cells, and plasma cells. Once you have completed this targeted analysis, integrate your findings into the overall COMPASS assessment to provide a comprehensive evaluation of the patient's immune status and potential treatment response.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-181b63-ar-181b638.pkl. "
BLCA,,,,NR,"For a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment transcriptomic profile was obtained via a lung biopsy and whose tumor mutational burden is reported as ""nan,"" what is the anticipated likelihood of a positive response to atezolizumab therapy?","For a Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA) whose tumor immune microenvironment transcriptomic profile was obtained via a lung biopsy and whose tumor mutational burden is reported as ""nan,"" what is the anticipated likelihood of a positive response to atezolizumab therapy? Utilize the COMPASS tool to examine the transcriptomic data from the tumor microenvironment. Focus specifically on identifying gene expression markers that suggest dysfunctional immune responses, particularly in natural killer cells, exhausted T cells, B cells, and plasma cells. Once these markers are identified, incorporate your findings into the broader COMPASS evaluation to offer a thorough assessment of the patient’s immune status and potential treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-187e05-ar-187e056.pkl. "
BLCA,18.0,2.039215686,excluded,NR,"In a white male patient diagnosed with bladder urothelial carcinoma (BLCA) with a tumor mutation burden (TMB) of 18.0 and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","In a white male patient diagnosed with bladder urothelial carcinoma (BLCA) with a tumor mutation burden (TMB) of 18.0 and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Apply the COMPASS tool to analyze transcriptomic data from the tumor microenvironment. Specifically, focus on identifying gene expression markers that indicate dysfunctional immune responses in natural killer cells, exhausted T cells, B cells, and plasma cells. After identifying these markers, integrate your findings into the overall COMPASS evaluation to provide a comprehensive assessment of the patient’s immune status and guide potential treatment outcomes.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-18a4da-ar-18a4dab.pkl. "
BLCA,7.0,0.392156863,inflamed,NR,"For my Black or African American patient diagnosed with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment was performed on a ureter biopsy sample. With a tumor mutation burden of 7.0, what is the anticipated likelihood of a favorable response to atezolizumab therapy?","For my Black or African American patient diagnosed with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment was performed on a ureter biopsy sample. With a tumor mutation burden of 7.0, what is the anticipated likelihood of a favorable response to atezolizumab therapy? Use the COMPASS tool to assess transcriptomic data from the tumor microenvironment. Your focus should be on identifying gene expression markers that reflect dysfunctional immune responses in natural killer cells, exhausted T cells, B cells, and plasma cells. Once these markers are determined, incorporate the results into the overall COMPASS evaluation to generate a comprehensive profile of the patient’s immune status, which can inform subsequent treatment decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-18b935-ar-18b9351.pkl. "
BLCA,19.0,1.803921569,,NR,"For my white male patient with bladder urothelial carcinoma, whose bladder biopsy shows a transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden of 19.0, what is the estimated likelihood of a positive response to atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, whose bladder biopsy shows a transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden of 19.0, what is the estimated likelihood of a positive response to atezolizumab therapy? Please apply the COMPASS tool to analyze transcriptomic data from the tumor microenvironment. Focus especially on detecting gene expression markers that indicate a dysfunctional immune response in natural killer cells, exhausted T cells, B cells, and plasma cells. Once these markers are identified, integrate the findings into the comprehensive COMPASS assessment to create a detailed profile of the patient’s immune status, which will help guide future treatment options.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-18bc10-ar-18bc107.pkl. "
BLCA,5.0,0.470588235,excluded,NR,"For my white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from his bladder biopsy shows a tumor mutational burden of 5.0. Based on these findings, what is the estimated likelihood that he will respond favorably to atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from his bladder biopsy shows a tumor mutational burden of 5.0. Based on these findings, what is the estimated likelihood that he will respond favorably to atezolizumab therapy? Please use the COMPASS tool to examine transcriptomic data from the tumor microenvironment. In your assessment, prioritize identifying gene expression markers associated with dysfunctional immune responses in natural killer cells, exhausted T cells, B cells, and plasma cells. Once these markers have been determined, incorporate them into the overall COMPASS evaluation to develop a detailed profile of the patient's immune status, which will inform subsequent treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-18be5b-ar-18be5b3.pkl. "
BLCA,5.0,0.431372549,excluded,NR,"For a Caucasian patient with bladder urothelial carcinoma who has undergone transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy and presents with a tumor mutational burden of 5.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a Caucasian patient with bladder urothelial carcinoma who has undergone transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy and presents with a tumor mutational burden of 5.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please utilize the COMPASS tool to analyze transcriptomic data from the tumor microenvironment. When reviewing the data, focus on identifying gene expression markers that indicate dysfunctional immune responses, specifically in natural killer cells, exhausted T cells, B cells, and plasma cells. Once these markers have been identified, incorporate them into the overall COMPASS assessment to build a comprehensive profile of the patient’s immune status, which will help guide your subsequent treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-19fec8-ar-19fec8f.pkl. "
BLCA,8.0,1.176470588,excluded,NR,"For a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 8.0. Based on this information, what is the estimated likelihood of a meaningful response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 8.0. Based on this information, what is the estimated likelihood of a meaningful response to Atezolizumab therapy? Use the COMPASS tool to evaluate transcriptomic data derived from the tumor microenvironment. Focus your analysis on identifying gene expression markers that are indicative of dysfunctional immune responses, particularly within natural killer cells, exhausted T cells, B cells, and plasma cells. Once identified, integrate these markers into your overall COMPASS assessment to construct a detailed profile of the patient’s immune status, which will support informed treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1a87df-ar-1a87df7.pkl. "
BLCA,13.0,0.294117647,desert,NR,"For my white female patient with bladder urothelial carcinoma who has a tumor mutation burden of 13.0 and a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy, what is the likelihood of a favorable response to Atezolizumab therapy?","For my white female patient with bladder urothelial carcinoma who has a tumor mutation burden of 13.0 and a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy, what is the likelihood of a favorable response to Atezolizumab therapy? Please perform a transcriptomic analysis on the tumor microenvironment using the COMPASS tool. Specifically, identify gene expression markers that indicate dysfunctional immune responses in natural killer cells, exhausted T cells, B cells, and plasma cells. After identifying these markers, integrate them into your overall COMPASS assessment to compile a comprehensive profile of the patient's immune status to guide treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1ab1b2-ar-1ab1b28.pkl. "
BLCA,16.0,1.862745098,excluded,R,"For a White male patient with bladder urothelial carcinoma who has a tumor immune microenvironment transcriptomic profile obtained from a kidney biopsy and a TMB of 16.0, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a White male patient with bladder urothelial carcinoma who has a tumor immune microenvironment transcriptomic profile obtained from a kidney biopsy and a TMB of 16.0, what is the expected likelihood of a positive response to Atezolizumab therapy? Utilize the COMPASS tool to conduct a transcriptomic analysis of the tumor microenvironment. In your analysis, specifically identify gene expression markers that are indicative of dysfunctional responses in natural killer cells, exhausted T cells, B cells, and plasma cells. Once these markers have been identified, integrate them into your overall COMPASS assessment to develop a comprehensive immune profile for the patient, which will inform treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1abf01-ar-1abf01d.pkl. "
BLCA,2.0,0.647058824,excluded,NR,"In a white male patient with bladder urothelial carcinoma (BLCA) exhibiting a tumor mutation burden of 2.0, and with transcriptomic profiling of the tumor immune microenvironment obtained from a kidney biopsy, what is the likelihood of a positive response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA) exhibiting a tumor mutation burden of 2.0, and with transcriptomic profiling of the tumor immune microenvironment obtained from a kidney biopsy, what is the likelihood of a positive response to atezolizumab therapy? Please use the COMPASS tool to perform a transcriptomic analysis of the tumor microenvironment. In your study, focus on detecting gene expression markers that indicate dysfunctional activity in natural killer cells, exhausted T cells, B cells, and plasma cells. Once these markers have been identified, incorporate them into your overall COMPASS assessment to create a detailed immune profile that will guide treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1ac4e3-ar-1ac4e3d.pkl. "
BLCA,,,excluded,NR,"For my White female patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but the tumor mutation burden (TMB) data is not available. Based on these parameters, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For my White female patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but the tumor mutation burden (TMB) data is not available. Based on these parameters, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please apply the COMPASS tool for transcriptomic analysis of the tumor microenvironment. Your investigation should concentrate on identifying gene expression markers associated with impaired functions in natural killer cells, exhausted T cells, B cells, and plasma cells. After pinpointing these markers, integrate your findings into the comprehensive COMPASS assessment to develop a detailed immune profile that will assist in treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1c0ecf-ar-1c0ecfb.pkl. "
BLCA,7.0,0.549019608,excluded,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment revealed a tumor mutational burden of 7.0, what is the expected likelihood of a favorable response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment revealed a tumor mutational burden of 7.0, what is the expected likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS tool to perform a transcriptomic assessment of the tumor microenvironment. Focus on identifying gene expression markers that signal dysfunctional activity in natural killer cells, exhausted T cells, B cells, and plasma cells. Once these markers are identified, incorporate the results into the overall COMPASS evaluation to construct a detailed immune profile to guide treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1c8b08-ar-1c8b086.pkl. "
BLCA,20.0,4.019607843,desert,NR,"For a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 20.0 and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the expected likelihood of a favorable response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 20.0 and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the expected likelihood of a favorable response to atezolizumab therapy? Please use the COMPASS tool to conduct a transcriptomic analysis of the tumor microenvironment. In this assessment, prioritize the detection of gene expression markers that indicate impaired activity in natural killer cells, as well as exhausted T cells, B cells, and plasma cells. Once these markers are identified, integrate the data into the overall COMPASS evaluation to develop a comprehensive immune profile that will help guide treatment decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1dda30-ar-1dda30f.pkl. "
BLCA,5.0,1.431372549,inflamed,NR,"For a white female patient with bladder urothelial carcinoma (BLCA) and a tumor mutation burden of 5.0, whose bladder biopsy transcriptomic analysis revealed details of the tumor immune microenvironment, what is the likelihood of a positive response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma (BLCA) and a tumor mutation burden of 5.0, whose bladder biopsy transcriptomic analysis revealed details of the tumor immune microenvironment, what is the likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS tool to perform a transcriptomic analysis of the tumor microenvironment. Specifically, focus on identifying gene expression markers that suggest impaired functionality in natural killer cells, as well as markers indicative of exhaustion in T cells, B cells, and plasma cells. Once these markers are determined, integrate them into the overall COMPASS evaluation to create a comprehensive immune profile that will inform treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1e9c4d-ar-1e9c4d1.pkl. "
BLCA,38.0,4.509803922,inflamed,R,"For my white male patient with bladder urothelial carcinoma, the tumor transcriptomic profiling of the immune microenvironment from the bladder biopsy revealed a tumor mutational burden of 38.0. Based on these findings, what is the likelihood that he will respond favorably to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, the tumor transcriptomic profiling of the immune microenvironment from the bladder biopsy revealed a tumor mutational burden of 38.0. Based on these findings, what is the likelihood that he will respond favorably to Atezolizumab therapy? Please use the COMPASS tool to perform a transcriptomic analysis of the tumor microenvironment. In your assessment, specifically identify gene expression markers that indicate impaired functionality in natural killer cells and markers that suggest exhaustion in T cells, B cells, and plasma cells. Once these markers are identified, integrate them into the overall COMPASS evaluation to develop a comprehensive immune profile that will support treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1f66db-ar-1f66db5.pkl. "
BLCA,6.0,0.549019608,desert,NR,"For my Caucasian patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 6.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the likelihood of a positive response to atezolizumab therapy?","For my Caucasian patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 6.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the likelihood of a positive response to atezolizumab therapy? Use the COMPASS tool to conduct a transcriptomic analysis of the tumor microenvironment. Specifically, identify gene expression markers that indicate impaired function in natural killer cells, as well as markers suggestive of exhaustion in T cells, B cells, and plasma cells. Incorporate these findings into the overall COMPASS evaluation to develop a comprehensive immune profile that will inform treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1f83eb-ar-1f83ebd.pkl. "
BLCA,8.0,1.235294118,inflamed,NR,"For my white male patient diagnosed with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden is 8.0. Based on these parameters, how likely is he to have a positive response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden is 8.0. Based on these parameters, how likely is he to have a positive response to Atezolizumab therapy? Use the COMPASS tool to perform a transcriptomic analysis focused on the tumor microenvironment. Specifically, identify gene expression markers associated with reduced natural killer cell activity and markers that suggest exhaustion in T cells, B cells, and plasma cells. Integrate these observations into the overall COMPASS assessment to create a detailed immune profile that will guide treatment decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-1fa6bc-ar-1fa6bcb.pkl. "
BLCA,13.0,2.392156863,inflamed,R,"For a Caucasian patient with bladder urothelial carcinoma who has a tumor mutational burden of 13.0 and transcriptomic data from a bladder biopsy characterizing the immune microenvironment, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a Caucasian patient with bladder urothelial carcinoma who has a tumor mutational burden of 13.0 and transcriptomic data from a bladder biopsy characterizing the immune microenvironment, what is the estimated likelihood of a positive response to Atezolizumab therapy? Utilize the COMPASS tool to conduct a transcriptomic analysis specifically targeting the tumor microenvironment. Focus on identifying gene expression markers that indicate reduced activity of natural killer cells, as well as markers that suggest exhaustion in T cells, B cells, and plasma cells. Then, incorporate these findings into the overall COMPASS assessment to develop a detailed immune profile, which will help inform treatment decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-203dcf-ar-203dcf1.pkl. "
BLCA,5.0,0.294117647,excluded,NR,"For my White male patient with bladder urothelial carcinoma (BLCA), who has a transcriptomic profile of the tumor immune microenvironment obtained via a kidney biopsy and a tumor mutation burden (TMB) of 5.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For my White male patient with bladder urothelial carcinoma (BLCA), who has a transcriptomic profile of the tumor immune microenvironment obtained via a kidney biopsy and a tumor mutation burden (TMB) of 5.0, what is the likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS tool to perform a transcriptomic analysis of the tumor microenvironment. Specifically, identify gene expression markers that indicate diminished activity of natural killer cells and markers that suggest exhaustion in T cells, B cells, and plasma cells. Once these markers are determined, integrate them into the overall COMPASS analysis to construct a detailed immune profile, which will help guide treatment decision-making.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2070b4-ar-2070b41.pkl. "
BLCA,5.0,0.235294118,desert,NR,"In a white female patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden of 5.0. Based on these findings, what is the likelihood that she will respond favorably to atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden of 5.0. Based on these findings, what is the likelihood that she will respond favorably to atezolizumab therapy? Please use the COMPASS tool to perform a transcriptomic analysis of the tumor microenvironment. Focus on identifying gene expression markers that reveal reduced activity in natural killer cells, as well as markers that signal exhaustion in T cells, B cells, and plasma cells. Once these markers have been identified, integrate them into the broader COMPASS analysis to develop a comprehensive immune profile that will inform our treatment decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-230959-ar-2309593.pkl. "
BLCA,5.0,0.333333333,excluded,NR,"For a white female patient diagnosed with bladder urothelial carcinoma, whose kidney biopsy transcriptomic profile of the tumor immune microenvironment shows a tumor mutational burden of 5.0, what is the likelihood of a positive response to atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma, whose kidney biopsy transcriptomic profile of the tumor immune microenvironment shows a tumor mutational burden of 5.0, what is the likelihood of a positive response to atezolizumab therapy? Use the COMPASS tool to conduct a transcriptomic analysis of the tumor microenvironment. Concentrate on detecting gene expression markers that indicate diminished activity in natural killer cells and markers associated with T cell, B cell, and plasma cell exhaustion. After identifying these markers, incorporate them into the overall COMPASS analysis to build a detailed immune profile that will aid in guiding our treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-23aa15-ar-23aa15d.pkl. "
BLCA,,1.823529412,desert,R,"For a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a subsequent biopsy revealed an undetermined tumor mutational burden. Based on these findings, how likely is he to respond positively to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a subsequent biopsy revealed an undetermined tumor mutational burden. Based on these findings, how likely is he to respond positively to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Specifically, focus on identifying gene expression markers that signal reduced activity of natural killer cells and markers indicating exhaustion in T cells, B cells, and plasma cells. Once these markers are identified, integrate them into the overall COMPASS analysis to create a comprehensive immune profile that will help us tailor our treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-25510f-ar-25510f3.pkl. "
BLCA,12.0,1.529411765,inflamed,R,"For a white female patient with bladder urothelial carcinoma, whose lymph node biopsy transcriptomic profile of the tumor immune microenvironment reveals a tumor mutational burden of 12.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, whose lymph node biopsy transcriptomic profile of the tumor immune microenvironment reveals a tumor mutational burden of 12.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS system to conduct a transcriptomic analysis of the tumor microenvironment. Your focus should be on pinpointing gene expression markers associated with diminished natural killer cell activity and signs of exhaustion in T cells, B cells, and plasma cells. Once these markers are identified, integrate them into the overall COMPASS analysis to develop a comprehensive immune profile, which will inform and guide our treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2570ff-ar-2570ff4.pkl. "
BLCA,1.0,0.274509804,excluded,NR,"In a male Asian patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden of 1.0. Based on this information, what is the expected likelihood of a favorable response to Atezolizumab therapy?","In a male Asian patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden of 1.0. Based on this information, what is the expected likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS system to perform a transcriptomic evaluation of the tumor microenvironment. Specifically, identify gene expression markers that indicate reduced natural killer cell function as well as signs of exhaustion in T cells, B cells, and plasma cells. Once these markers are identified, incorporate them into the overall COMPASS analysis to create a comprehensive immune profile that will inform our therapeutic decision-making.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-26104d-ar-26104d5.pkl. "
BLCA,6.0,0.431372549,excluded,NR,"For a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile has been obtained and who has a TMB of 6.0, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile has been obtained and who has a TMB of 6.0, what is the expected likelihood of a positive response to Atezolizumab therapy? Utilize the COMPASS system to conduct a transcriptomic analysis of the tumor microenvironment. Your evaluation should focus on identifying gene expression markers that reflect diminished natural killer cell activity as well as markers indicating exhaustion in T cells, B cells, and plasma cells. Once identified, integrate these markers into the overall COMPASS analysis to generate a detailed immune profile that will guide our therapeutic strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-262422-ar-2624229.pkl. "
BLCA,8.0,0.745098039,excluded,R,"In a patient with bladder urothelial carcinoma (BLCA) and a tumor mutation burden (TMB) of 8.0, how likely is a positive response to Atezolizumab therapy, considering the transcriptomic profile of the tumor's immune microenvironment obtained from a bladder biopsy?","In a patient with bladder urothelial carcinoma (BLCA) and a tumor mutation burden (TMB) of 8.0, how likely is a positive response to Atezolizumab therapy, considering the transcriptomic profile of the tumor's immune microenvironment obtained from a bladder biopsy? Please use the COMPASS system to perform a transcriptomic analysis of the tumor microenvironment. Focus on identifying gene expression markers that signal reduced natural killer cell activity, along with markers that indicate exhaustion in T cells, B cells, and plasma cells. Once these markers are identified, integrate them into the overall COMPASS analysis to develop a comprehensive immune profile, which will help guide our therapeutic decision-making.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-27299a-ar-27299ae.pkl. "
BLCA,6.0,0.568627451,inflamed,NR,"For my white male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 6.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the estimated likelihood of a positive response to atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 6.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the estimated likelihood of a positive response to atezolizumab therapy? Use the COMPASS system to conduct a transcriptomic analysis of the tumor microenvironment. Focus on detecting gene expression markers that are associated with diminished natural killer cell activity, as well as markers that indicate exhaustion in T cells, B cells, and plasma cells. Once you've identified these markers, integrate them into the overall COMPASS analysis to create a detailed immune profile that will inform our therapeutic decision-making process.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-286870-ar-2868703.pkl. "
BLCA,22.0,,desert,NR,"For my Caucasian patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden (TMB) of 22.0, we performed transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my Caucasian patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden (TMB) of 22.0, we performed transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS system to perform a transcriptomic analysis of the tumor microenvironment. Specifically, focus on identifying gene expression markers linked to reduced natural killer cell activity, as well as markers that indicate exhaustion in T cells, B cells, and plasma cells. Once these markers are identified, incorporate them into the broader COMPASS analysis to develop a detailed immune profile that will support our therapeutic decision-making.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-28e603-ar-28e6031.pkl. "
BLCA,1.0,,excluded,NR,"In my Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 1.0. Given these findings, what is the likelihood that the patient will respond favorably to Atezolizumab therapy?","In my Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 1.0. Given these findings, what is the likelihood that the patient will respond favorably to Atezolizumab therapy? Please use the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. In this analysis, focus specifically on identifying gene expression markers that correlate with decreased natural killer cell activity and markers indicative of exhaustion in T cells, B cells, and plasma cells. Once you have identified these markers, integrate them into the overall COMPASS analysis to create a comprehensive immune profile that will guide our treatment decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-297c03-ar-297c030.pkl. "
BLCA,,0.490196078,desert,NR,"For my Caucasian female patient diagnosed with bladder urothelial carcinoma (BLCA), who underwent transcriptomic profiling of the tumor immune microenvironment via a ureter biopsy and has a reported tumor mutational burden (TMB) of 'nan,' what is the likelihood of a favorable clinical response to Atezolizumab therapy?","For my Caucasian female patient diagnosed with bladder urothelial carcinoma (BLCA), who underwent transcriptomic profiling of the tumor immune microenvironment via a ureter biopsy and has a reported tumor mutational burden (TMB) of 'nan,' what is the likelihood of a favorable clinical response to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Specifically, identify gene expression markers associated with reduced natural killer cell activity, as well as markers indicating exhaustion in T cells, B cells, and plasma cells. Once these markers are determined, integrate them into the overall COMPASS analysis to generate a comprehensive immune profile that will inform our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-29da92-ar-29da928.pkl. "
BLCA,2.0,0.156862745,desert,NR,"In a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 2.0 and whose tumor immune microenvironment was profiled via kidney biopsy, what is the likelihood of a positive response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 2.0 and whose tumor immune microenvironment was profiled via kidney biopsy, what is the likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to conduct a transcriptomic assessment of the tumor microenvironment. In particular, determine the gene expression markers that correspond to decreased natural killer cell activity and markers indicative of exhaustion in T cells, B cells, and plasma cells. After identifying these markers, incorporate them into the overall COMPASS analysis to develop a comprehensive immune profile that will help guide our treatment approach.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2b672f-ar-2b672f4.pkl. "
BLCA,11.0,1.294117647,excluded,NR,"For my white male patient diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden (TMB) of 11.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden (TMB) of 11.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Specifically, identify gene expression markers associated with reduced natural killer cell activity alongside markers of exhaustion in T cells, B cells, and plasma cells. Once these markers are identified, integrate them into the overall COMPASS analysis to generate a detailed immune profile that will inform our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2bba8c-ar-2bba8cb.pkl. "
BLCA,9.0,0.431372549,desert,NR,"In a white male patient with bladder urothelial carcinoma, the tumor’s immune microenvironment has been profiled via transcriptomic analysis from a bladder biopsy, and his tumor mutational burden is 9.0. Based on these findings, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, the tumor’s immune microenvironment has been profiled via transcriptomic analysis from a bladder biopsy, and his tumor mutational burden is 9.0. Based on these findings, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Please utilize the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. In this analysis, focus on identifying gene expression markers that indicate diminished natural killer cell activity and markers that signify exhaustion in T cells, B cells, and plasma cells. Once these markers are identified, incorporate them into the comprehensive COMPASS output to generate a detailed immune profile that will guide our treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2c9586-ar-2c95861.pkl. "
BLCA,,,inflamed,NR,"For my Caucasian male patient with bladder urothelial carcinoma, I have obtained transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy. Given that the tumor mutational burden is unavailable, what is the likelihood of a positive response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, I have obtained transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy. Given that the tumor mutational burden is unavailable, what is the likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Your objective is to identify gene expression markers that reflect reduced natural killer cell activity and signs of T cell, B cell, and plasma cell exhaustion. Once you have identified these markers, integrate them into the COMPASS output to develop a comprehensive immune profile that can inform our treatment decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2dc3f0-ar-2dc3f04.pkl. "
BLCA,14.0,2.705882353,excluded,NR,"For a Caucasian patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 14.0 and a transcriptomic profile of the tumor's immune microenvironment obtained via kidney biopsy, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a Caucasian patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 14.0 and a transcriptomic profile of the tumor's immune microenvironment obtained via kidney biopsy, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. Your goal is to identify gene expression markers that indicate decreased natural killer cell activity as well as signs of T cell, B cell, and plasma cell exhaustion. Once these markers are identified, incorporate them into the COMPASS results to create a detailed immune profile that will support our treatment decision-making process.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2e7aa8-ar-2e7aa8f.pkl. "
BLCA,18.0,1.764705882,,R,"In a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptome of the tumor immune microenvironment shows a tumor mutational burden of 18.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptome of the tumor immune microenvironment shows a tumor mutational burden of 18.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Focus on identifying gene expression markers that signal reduced natural killer cell activity and show evidence of exhaustion in T cells, B cells, and plasma cells. Once you have identified these markers, integrate them into the COMPASS report to create a comprehensive immune profile that will inform our treatment decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2e9ac0-ar-2e9ac0b.pkl. "
BLCA,13.0,1.137254902,inflamed,R,"For our white male patient with bladder urothelial carcinoma, we obtained transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden is 13.0. Considering these factors, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For our white male patient with bladder urothelial carcinoma, we obtained transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden is 13.0. Considering these factors, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. Your analysis should specifically target the identification of gene expression markers associated with diminished natural killer cell activity and evidence of exhaustion in T cells, B cells, and plasma cells. Once identified, integrate these markers into the COMPASS report to develop a comprehensive immune profile for guiding our treatment decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2eb07d-ar-2eb07de.pkl. "
BLCA,8.0,0.450980392,excluded,NR,"For a Black/African American female patient with bladder urothelial carcinoma, whose tumor immune microenvironment has been profiled transcriptomically and shows a tumor mutational burden of 8.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For a Black/African American female patient with bladder urothelial carcinoma, whose tumor immune microenvironment has been profiled transcriptomically and shows a tumor mutational burden of 8.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Please utilize the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Focus specifically on identifying gene expression markers that correlate with reduced natural killer cell activity and indicators of exhaustion in T cells, B cells, and plasma cells. Once these markers have been identified, incorporate them into the COMPASS report to generate a detailed immune profile that will inform our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-2f2289-ar-2f22893.pkl. "
BLCA,6.0,,excluded,R,"For a white female patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden of 6.0, what is the expected likelihood of achieving a positive response to Atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden of 6.0, what is the expected likelihood of achieving a positive response to Atezolizumab therapy? Please use the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. In this analysis, focus on identifying gene expression markers that are linked to reduced activity of natural killer cells, as well as markers that suggest exhaustion in T cells, B cells, and plasma cells. After identifying these markers, incorporate your findings into the COMPASS report to create a comprehensive immune profile that will guide our treatment decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-30b5c6-ar-30b5c6c.pkl. "
BLCA,,,excluded,NR,"For a white male patient diagnosed with bladder urothelial carcinoma (BLCA), whose bladder biopsy revealed the transcriptomic profile of the tumor immune microenvironment and with an undefined tumor mutational burden (TMB), what is the estimated likelihood of a favorable response to atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma (BLCA), whose bladder biopsy revealed the transcriptomic profile of the tumor immune microenvironment and with an undefined tumor mutational burden (TMB), what is the estimated likelihood of a favorable response to atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Focus on identifying gene expression markers associated with decreased natural killer cell activity, as well as markers indicative of exhaustion in T cells, B cells, and plasma cells. Once these biomarkers are identified, integrate your findings into the COMPASS report to construct a comprehensive immune profile that will inform our treatment decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-30cf07-ar-30cf07d.pkl. "
BLCA,23.0,4.235294118,inflamed,R,"For my white male patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy shows a transcriptomic profile of the tumor immune microenvironment and a tumor mutation burden of 23, how likely is he to have a positive response to atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, whose bladder biopsy shows a transcriptomic profile of the tumor immune microenvironment and a tumor mutation burden of 23, how likely is he to have a positive response to atezolizumab therapy? Use the COMPASS platform to conduct a detailed transcriptomic analysis of the tumor microenvironment. Specifically, focus on identifying gene expression markers associated with reduced natural killer cell activity, as well as markers that indicate exhaustion in T cells, B cells, and plasma cells. Once these biomarkers have been determined, integrate your findings into the COMPASS report to develop a comprehensive immune profile that will guide our treatment decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-31d917-ar-31d9176.pkl. "
BLCA,,0.705882353,,NR,"For my white female patient with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy. With the tumor mutation burden currently unavailable, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my white female patient with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy. With the tumor mutation burden currently unavailable, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform a comprehensive transcriptomic analysis of the tumor microenvironment. Focus on identifying gene expression markers that indicate diminished natural killer cell function and signs of exhaustion in T cells, B cells, and plasma cells. After identifying these biomarkers, incorporate your findings into the COMPASS report to generate an integrated immune profile that will assist in our treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-31f41d-ar-31f41dd.pkl. "
BLCA,2.0,,,NR,"In a white male patient with bladder urothelial carcinoma, a tumor mutational burden of 2.0, and transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy, what is the expected likelihood of a positive response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, a tumor mutational burden of 2.0, and transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy, what is the expected likelihood of a positive response to atezolizumab therapy? Utilize the COMPASS platform to conduct a comprehensive transcriptomic analysis of the tumor microenvironment. Specifically, identify gene expression markers that suggest reduced natural killer cell activity and evidence of exhaustion in T cells, B cells, and plasma cells. Once these biomarkers are identified, integrate your findings into the COMPASS report to develop an integrated immune profile that will guide our treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3330c0-ar-3330c03.pkl. "
BLCA,,,,NR,"In a Caucasian male patient with bladder urothelial carcinoma, for whom transcriptomic profiling of the tumor immune microenvironment has been performed and the tumor mutational burden is indeterminate, what is the expected likelihood of a positive response to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, for whom transcriptomic profiling of the tumor immune microenvironment has been performed and the tumor mutational burden is indeterminate, what is the expected likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform a thorough transcriptomic analysis of the tumor microenvironment. Your analysis should focus on detecting gene expression markers that indicate reduced activity of natural killer cells and signs of exhaustion in T cells, B cells, and plasma cells. Once identified, include these biomarkers in your COMPASS report to create an integrated immune profile that will inform our treatment planning strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-34430e-ar-34430ef.pkl. "
BLCA,7.0,0.333333333,excluded,NR,"For a white male patient with bladder urothelial carcinoma who has had transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 7.0 mutations per megabase, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who has had transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 7.0 mutations per megabase, what is the anticipated likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to conduct a detailed transcriptomic evaluation of the tumor microenvironment. Specifically, focus on identifying gene expression markers that signal diminished natural killer cell activity and features of exhaustion in T cells, B cells, and plasma cells. Once these biomarkers are detected, incorporate them into your COMPASS report to establish a comprehensive immune profile that will guide our treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-36851b-ar-36851bc.pkl. "
BLCA,1.0,0.607843137,inflamed,NR,"For an Asian male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutational burden (TMB) of 1.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For an Asian male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutational burden (TMB) of 1.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Utilize the COMPASS platform to carry out an in‐depth transcriptomic analysis of the tumor microenvironment. Pay particular attention to detecting gene expression markers that indicate reduced activity of natural killer cells, as well as signs of exhaustion in T cells, B cells, and plasma cells. Once these biomarkers have been identified, include them in your comprehensive COMPASS report to inform our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-36a922-ar-36a9225.pkl. "
BLCA,7.0,0.352941176,excluded,NR,"For my Caucasian male patient with bladder urothelial carcinoma, where transcriptomic profiling of the tumor immune microenvironment from a ureteral biopsy shows a TMB of 7.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, where transcriptomic profiling of the tumor immune microenvironment from a ureteral biopsy shows a TMB of 7.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform a detailed transcriptomic analysis of the tumor microenvironment. Focus specifically on identifying gene expression markers that suggest decreased activity in natural killer cells, as well as indicators of T cell, B cell, and plasma cell exhaustion. Once these biomarkers are detected, include them in your comprehensive COMPASS report to support our treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-36d873-ar-36d8739.pkl. "
BLCA,5.0,,excluded,NR,"For a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden of 5.0, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden of 5.0, what is the anticipated likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to conduct a comprehensive transcriptomic analysis of the tumor microenvironment. Specifically, identify gene expression signatures that indicate reduced natural killer cell activity, as well as markers of exhaustion in T cells, B cells, and plasma cells. Once these biomarkers are identified, include them in your final COMPASS report to inform our treatment strategic planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3894ac-ar-3894ac3.pkl. "
BLCA,6.0,,excluded,NR,"For my white male patient with bladder urothelial carcinoma, who has a tumor mutation burden of 6.0 and a transcriptomic profile of the tumor immune microenvironment from his bladder biopsy, what is the likelihood he will respond positively to atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, who has a tumor mutation burden of 6.0 and a transcriptomic profile of the tumor immune microenvironment from his bladder biopsy, what is the likelihood he will respond positively to atezolizumab therapy? Use the COMPASS platform to perform a detailed transcriptomic evaluation of the tumor microenvironment. Focus on detecting gene expression patterns that are associated with decreased natural killer cell activity and identify markers indicating exhaustion in T cells, B cells, and plasma cells. Once these biomarkers have been established, incorporate them into your final COMPASS report to support our treatment strategy decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-39eb94-ar-39eb94f.pkl. "
BLCA,,,,NR,"For my white male patient diagnosed with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a lung biopsy. The tumor mutational burden (TMB) is reported as ""nan."" Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a lung biopsy. The tumor mutational burden (TMB) is reported as ""nan."" Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to conduct a comprehensive transcriptomic analysis of the tumor microenvironment. Pay particular attention to identifying gene expression patterns linked to reduced natural killer cell activity, as well as markers that indicate exhaustion in T cells, B cells, and plasma cells. Once you have identified these biomarkers, include them in your final COMPASS report to help guide our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3a1c96-ar-3a1c963.pkl. "
BLCA,2.0,0.176470588,excluded,NR,"In a white male patient with bladder urothelial carcinoma, who has a tumor mutation burden of 2.0 and transcriptomic data from the tumor immune microenvironment obtained via lymph node biopsy, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, who has a tumor mutation burden of 2.0 and transcriptomic data from the tumor immune microenvironment obtained via lymph node biopsy, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to conduct a detailed transcriptomic examination of the tumor microenvironment. Focus on detecting gene expression signatures related to decreased natural killer cell function and on identifying markers that signal exhaustion in T cells, B cells, and plasma cells. Once these biomarkers are identified, include them in your final COMPASS report, as they will be important for guiding our treatment decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3b1066-ar-3b1066e.pkl. "
BLCA,44.0,5.823529412,inflamed,R,"For a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile shows a Tumor Mutational Burden (TMB) of 44, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile shows a Tumor Mutational Burden (TMB) of 44, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform an in-depth transcriptomic analysis of the tumor microenvironment. Concentrate on identifying gene expression signatures that indicate reduced natural killer (NK) cell function and on detecting markers that suggest exhaustion in T cells, B cells, and plasma cells. Be sure to include these biomarkers in your final COMPASS report, as they are essential for informing our treatment decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3b15b4-ar-3b15b4c.pkl. "
BLCA,15.0,2.235294118,excluded,NR,"For a white male patient with bladder urothelial carcinoma (BLCA), who has a tumor mutational burden (TMB) of 15.0 and transcriptomic profiling of the tumor immune microenvironment obtained from a kidney biopsy, what is the likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA), who has a tumor mutational burden (TMB) of 15.0 and transcriptomic profiling of the tumor immune microenvironment obtained from a kidney biopsy, what is the likelihood of a positive response to Atezolizumab therapy? Kindly use the COMPASS platform to conduct a comprehensive transcriptomic evaluation of the tumor microenvironment. Focus on identifying gene expression profiles that indicate diminished natural killer cell activity and on detecting molecular markers of exhaustion in T cells, B cells, and plasma cells. Please ensure these biomarkers are detailed in your final COMPASS report, as they are critical for guiding our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3cb94b-ar-3cb94b0.pkl. "
BLCA,17.0,1.411764706,excluded,R,"In a Caucasian patient with bladder urothelial carcinoma, a lymph node biopsy revealed a transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden of 17.0. Based on these findings, what is the likelihood that the patient will respond favorably to atezolizumab therapy?","In a Caucasian patient with bladder urothelial carcinoma, a lymph node biopsy revealed a transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden of 17.0. Based on these findings, what is the likelihood that the patient will respond favorably to atezolizumab therapy? Please use the COMPASS platform to perform a thorough transcriptomic analysis of the tumor microenvironment, focusing on detecting gene expression patterns that suggest reduced natural killer cell activity. Additionally, evaluate for molecular markers of exhaustion in T cells, B cells, and plasma cells. Ensure that your final COMPASS report includes detailed findings on these biomarkers, as they are crucial for informing our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3e04eb-ar-3e04eb9.pkl. "
BLCA,11.0,1.215686275,desert,NR,"In our Caucasian male patient with bladder urothelial carcinoma, a kidney biopsy yielded a transcriptomic profile of the tumor immune microenvironment, and his tumor mutation burden is 11.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","In our Caucasian male patient with bladder urothelial carcinoma, a kidney biopsy yielded a transcriptomic profile of the tumor immune microenvironment, and his tumor mutation burden is 11.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to conduct a comprehensive transcriptomic analysis of the tumor microenvironment. Your evaluation should prioritize identifying gene expression signatures indicative of reduced natural killer cell activity, as well as assessing molecular markers of exhaustion in T cells, B cells, and plasma cells. Make sure your final COMPASS report includes detailed findings on these biomarkers, as they are essential for informing our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3e8baf-ar-3e8baff.pkl. "
BLCA,,,desert,NR,"For my white male patient diagnosed with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Given that the tumor mutational burden (TMB) is not available, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. Given that the tumor mutational burden (TMB) is not available, what is the anticipated likelihood of a favorable response to Atezolizumab therapy? Kindly utilize the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Focus primarily on detecting gene expression profiles that suggest diminished activity of natural killer cells, and on identifying molecular markers indicative of exhaustion among T cells, B cells, and plasma cells. Please ensure that your final COMPASS report offers a comprehensive overview of these biomarkers, as the findings will be critical for guiding our treatment approach.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-3ee5dc-ar-3ee5dcd.pkl. "
BLCA,,0.431372549,excluded,NR,"For a Caucasian male patient with bladder urothelial carcinoma (BLCA), how do the transcriptomic findings from the tumor immune microenvironment and an unquantifiable tumor mutational burden (TMB) impact our prediction of a positive response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma (BLCA), how do the transcriptomic findings from the tumor immune microenvironment and an unquantifiable tumor mutational burden (TMB) impact our prediction of a positive response to Atezolizumab therapy? Please use the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. Concentrate on identifying gene expression patterns that indicate reduced natural killer cell activity and on detecting markers that suggest exhaustion in T cells, B cells, and plasma cells. Your final COMPASS report should provide a detailed summary of these biomarkers, as this information is crucial for informing our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-415f36-ar-415f36a.pkl. "
BLCA,12.0,0.392156863,desert,NR,"For my Caucasian male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 12.0 mutations per megabase. Based on these parameters, what is the expected likelihood of a positive response to atezolizumab therapy?","For my Caucasian male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 12.0 mutations per megabase. Based on these parameters, what is the expected likelihood of a positive response to atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Focus on detecting gene expression patterns that suggest reduced natural killer cell activity and on identifying markers of exhaustion in T cells, B cells, and plasma cells. The final COMPASS report should include a comprehensive summary of these biomarkers, as this data is critical for guiding our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4305ab-ar-4305ab9.pkl. "
BLCA,6.0,0.921568627,excluded,NR,"In a Caucasian male patient with bladder urothelial carcinoma, where transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a TMB of 6.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, where transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a TMB of 6.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Utilize the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. In your analysis, please focus on identifying gene expression profiles indicative of diminished natural killer cell activity, as well as assessing markers signaling exhaustion in T cells, B cells, and plasma cells. Incorporate a thorough summary of these biomarkers in the final COMPASS report, as this information is vital for informing our treatment decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4501e4-ar-4501e41.pkl. "
BLCA,5.0,1.392156863,inflamed,NR,"For my Caucasian patient with bladder urothelial carcinoma (BLCA), whose bladder biopsy transcriptomic profile indicates a tumor mutational burden (TMB) of 5.0, what are the prospects for a positive response to atezolizumab therapy?","For my Caucasian patient with bladder urothelial carcinoma (BLCA), whose bladder biopsy transcriptomic profile indicates a tumor mutational burden (TMB) of 5.0, what are the prospects for a positive response to atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Focus on identifying gene expression patterns that suggest reduced activity of natural killer cells and on evaluating markers associated with exhaustion in T cells, B cells, and plasma cells. Be sure to include a detailed summary of these biomarkers in the final COMPASS report, as this information is critical for guiding our treatment decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-45c8e6-ar-45c8e64.pkl. "
BLCA,8.0,,desert,NR,"For my white patient diagnosed with bladder urothelial carcinoma (BLCA), the transcriptomic profile of the tumor immune microenvironment obtained via nanobiopsy shows a tumor mutational burden (TMB) of 8.0. Given this profile, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","For my white patient diagnosed with bladder urothelial carcinoma (BLCA), the transcriptomic profile of the tumor immune microenvironment obtained via nanobiopsy shows a tumor mutational burden (TMB) of 8.0. Given this profile, what is the anticipated likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to analyze the tumor microenvironment at the transcriptomic level. Your primary objectives are to identify gene expression profiles that indicate reduced activity of natural killer cells and to assess markers of exhaustion in T cells, B cells, and plasma cells. Ensure that your final COMPASS report includes a detailed summary of these biomarkers, as this information is essential for informing our treatment decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-468a9e-ar-468a9e1.pkl. "
BLCA,8.0,0.803921569,inflamed,NR,"For a white male patient with bladder urothelial carcinoma, whose tumor biopsy reveals a transcriptomic profile of the immune microenvironment and a TMB of 8.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose tumor biopsy reveals a transcriptomic profile of the immune microenvironment and a TMB of 8.0, what is the likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. In this analysis, focus on identifying gene expression profiles that suggest diminished natural killer cell activity, and evaluate markers that may indicate exhaustion in T cells, B cells, and plasma cells. Ensure that your final report includes a comprehensive summary of these biomarkers, as this information is critical for guiding our treatment decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-47fc46-ar-47fc46c.pkl. "
BLCA,0.0,0.607843137,excluded,NR,"In a patient diagnosed with bladder urothelial carcinoma (BLCA) whose transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy reveals a tumor mutational burden (TMB) of 0.0, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","In a patient diagnosed with bladder urothelial carcinoma (BLCA) whose transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy reveals a tumor mutational burden (TMB) of 0.0, what is the anticipated likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform for a transcriptomic analysis of the tumor microenvironment. Concentrate on identifying gene expression patterns that indicate reduced activity of natural killer cells. Additionally, assess expression markers that may signify exhaustion in T cells, B cells, as well as plasma cells. The final report should include a detailed summary of these biomarkers since this data is essential for informing our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-49d487-ar-49d4875.pkl. "
BLCA,5.0,1.450980392,excluded,NR,"For my white male patient with bladder urothelial carcinoma, whose kidney biopsy transcriptomic profile of the tumor immune microenvironment shows a tumor mutation burden of 5.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, whose kidney biopsy transcriptomic profile of the tumor immune microenvironment shows a tumor mutation burden of 5.0, what is the likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Focus on detecting gene expression patterns that may indicate reduced natural killer cell activity. Additionally, evaluate biomarkers that could point to exhaustion in T cells, B cells, and plasma cells. Ensure your final report includes a comprehensive summary of these findings, as they are critical for guiding our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-49f9b2-ar-49f9b2e.pkl. "
BLCA,6.0,,desert,NR,"In a white male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 6.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the likelihood of a positive clinical response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 6.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the likelihood of a positive clinical response to Atezolizumab therapy? Please use the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. Focus on identifying gene expression patterns that might suggest decreased natural killer cell activity. Additionally, evaluate biomarkers that could indicate potential exhaustion in T cells, B cells, and plasma cells. Ensure your final report provides a detailed summary of these results, as they are critical for informing our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4b0175-ar-4b0175e.pkl. "
BLCA,,,excluded,NR,"In a Caucasian female patient with bladder urothelial carcinoma, for whom a transcriptomic profile of the tumor immune microenvironment was obtained from a kidney biopsy and with a tumor mutational burden reported as ""nan,"" what is the expected likelihood of a positive response to Atezolizumab therapy?","In a Caucasian female patient with bladder urothelial carcinoma, for whom a transcriptomic profile of the tumor immune microenvironment was obtained from a kidney biopsy and with a tumor mutational burden reported as ""nan,"" what is the expected likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Specifically, assess gene expression to detect any indications of reduced natural killer cell activity, and review biomarkers that might signal potential immunological exhaustion in T cells, B cells, and plasma cells. Your final report should include a comprehensive summary of these findings, as they are crucial for guiding our treatment decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4b7ea0-ar-4b7ea01.pkl. "
BLCA,59.0,11.68627451,excluded,R,"For my Caucasian male patient diagnosed with bladder urothelial carcinoma, what is the likelihood of a favorable response to Atezolizumab therapy given that his transcriptomic profile of the tumor immune microenvironment, obtained from a ureter biopsy, shows a tumor mutational burden of 59.0?","For my Caucasian male patient diagnosed with bladder urothelial carcinoma, what is the likelihood of a favorable response to Atezolizumab therapy given that his transcriptomic profile of the tumor immune microenvironment, obtained from a ureter biopsy, shows a tumor mutational burden of 59.0? Please log into the COMPASS platform and conduct a transcriptomic analysis focusing on the tumor microenvironment. In your analysis, quantify gene expression markers to identify any signs of decreased natural killer cell function. Additionally, evaluate biomarkers associated with potential immunological exhaustion in T cells, B cells, and plasma cells. Summarize all of your findings in a detailed report, as this information will be critical for informing our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-4caabd-ar-4caabd6.pkl. "
BLCA,13.0,0.31372549,desert,NR,"For my Caucasian male patient diagnosed with bladder urothelial carcinoma, the kidney biopsy transcriptomic profiling of the tumor immune microenvironment indicates a tumor mutational burden of 13.0. Based on these parameters, what is the estimated likelihood of a favorable response to atezolizumab therapy?","For my Caucasian male patient diagnosed with bladder urothelial carcinoma, the kidney biopsy transcriptomic profiling of the tumor immune microenvironment indicates a tumor mutational burden of 13.0. Based on these parameters, what is the estimated likelihood of a favorable response to atezolizumab therapy? Please sign into the COMPASS platform and perform a transcriptomic analysis specifically targeting the tumor microenvironment. In your analysis, quantify gene expression markers to evaluate potential reductions in natural killer cell activity. Additionally, assess biomarkers associated with immunological exhaustion in T cells, B cells, and plasma cells. Compile your findings into a detailed report, as this information is essential for informing our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-523468-ar-5234688.pkl. "
BLCA,12.0,0.745098039,excluded,NR,"For a patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a ureteral biopsy revealed a TMB of 12.0. Based on these findings, how likely is this patient to benefit from Atezolizumab therapy?","For a patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a ureteral biopsy revealed a TMB of 12.0. Based on these findings, how likely is this patient to benefit from Atezolizumab therapy? Please log in to the COMPASS platform and conduct a transcriptomic analysis that specifically examines the tumor microenvironment. In your analysis, quantify gene expression markers to determine if there is a reduction in natural killer (NK) cell activity. Additionally, evaluate biomarkers that indicate signs of immunological exhaustion in T cells, B cells, and plasma cells. Once completed, please compile and submit a detailed report, as these findings are crucial for guiding our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-52500c-ar-52500ca.pkl. "
BLCA,4.0,0.254901961,,NR,"For my Caucasian patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 4.0 and a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy, what is the likelihood of a positive response to Atezolizumab therapy?","For my Caucasian patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 4.0 and a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy, what is the likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS platform and conduct a transcriptomic study focusing on the tumor microenvironment. In this study, quantify gene expression markers to assess whether there is a decrease in natural killer cell activity. Additionally, analyze biomarkers associated with immunological exhaustion in T cells, B cells, and plasma cells. Once your analysis is complete, prepare and submit a comprehensive report, as these data are critical for our treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-52e3fa-ar-52e3fa3.pkl. "
BLCA,11.0,1.823529412,desert,R,"In a Caucasian patient with bladder urothelial carcinoma, exhibiting a tumor mutational burden of 11.0 and having undergone transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a favorable response to Atezolizumab therapy?","In a Caucasian patient with bladder urothelial carcinoma, exhibiting a tumor mutational burden of 11.0 and having undergone transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a favorable response to Atezolizumab therapy? Please log in to the COMPASS platform and perform a transcriptomic analysis of the tumor microenvironment. Focus on quantifying gene expression markers to determine if there is reduced activity of natural killer cells and evaluate biomarkers that indicate immune exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, compile a detailed report, as this data is essential for our treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-548551-ar-548551e.pkl. "
BLCA,5.0,,desert,NR,"For our white male patient with bladder urothelial carcinoma (BLCA), whose tumor biopsy reveals the immune transcriptomic profile and a tumor mutation burden (TMB) of 5.0, what is the expected likelihood of a favorable response to Atezolizumab therapy?","For our white male patient with bladder urothelial carcinoma (BLCA), whose tumor biopsy reveals the immune transcriptomic profile and a tumor mutation burden (TMB) of 5.0, what is the expected likelihood of a favorable response to Atezolizumab therapy? Please log in to the COMPASS platform and conduct a transcriptomic analysis of the tumor microenvironment. Specifically, quantify gene expression markers to assess whether natural killer cell activity is reduced and to identify biomarkers indicative of immune exhaustion in T cells, B cells, and plasma cells. After completing the analysis, compile a comprehensive report, as this information is critical for our treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-54e58f-ar-54e58f1.pkl. "
BLCA,,,,NR,"For a white female patient diagnosed with bladder urothelial carcinoma (BLCA), we obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy. The tumor mutation burden (TMB) was not determined (nan). Given these parameters, what is the likelihood that this patient will benefit from Atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma (BLCA), we obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy. The tumor mutation burden (TMB) was not determined (nan). Given these parameters, what is the likelihood that this patient will benefit from Atezolizumab therapy? Please access the COMPASS platform and perform a transcriptomic analysis focused on the tumor microenvironment. Your analysis should include quantifying gene expression markers to evaluate whether there is a reduction in natural killer cell activity, as well as identifying biomarkers that signal immune exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, prepare a detailed report, as the findings are essential for informing our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-553c3c-ar-553c3c3.pkl. "
BLCA,5.0,,excluded,NR,"For a white male patient with bladder urothelial carcinoma, whose ureter biopsy transcriptomic analysis of the tumor immune microenvironment and a tumor mutational burden of 5.0 have been evaluated, what is the likelihood of achieving a positive clinical response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose ureter biopsy transcriptomic analysis of the tumor immune microenvironment and a tumor mutational burden of 5.0 have been evaluated, what is the likelihood of achieving a positive clinical response to Atezolizumab therapy? Please log into the COMPASS platform and perform a transcriptomic analysis of the tumor microenvironment. In this analysis, quantify gene expression markers to assess any reduction in natural killer cell activity and identify biomarkers that indicate immune exhaustion in T cells, B cells, and plasma cells. Once completed, compile a comprehensive report detailing your findings, as these results are critical for guiding our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-557dde-ar-557dde1.pkl. "
BLCA,19.0,0.647058824,inflamed,R,"For my Native Hawaiian or other Pacific Islander male patient with bladder urothelial carcinoma (BLCA), whose transcriptomic profiling of the tumor immune microenvironment indicates a TMB of 19.0, what is the estimated likelihood of a positive response to atezolizumab therapy?","For my Native Hawaiian or other Pacific Islander male patient with bladder urothelial carcinoma (BLCA), whose transcriptomic profiling of the tumor immune microenvironment indicates a TMB of 19.0, what is the estimated likelihood of a positive response to atezolizumab therapy? Please log into the COMPASS platform and conduct a transcriptomic analysis of the tumor microenvironment. In your analysis, quantify gene expression markers to evaluate reductions in natural killer cell activity and to detect indicators of immune exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, prepare a detailed report summarizing your findings, as these results are essential for informing our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-560f23-ar-560f23d.pkl. "
BLCA,,0.607843137,,NR,"For a white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) reported as nan. Based on this information, how likely is the patient to respond positively to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) reported as nan. Based on this information, how likely is the patient to respond positively to Atezolizumab therapy? Please access the COMPASS platform and perform a transcriptomic analysis of the tumor microenvironment. In your analysis, please quantify gene expression markers to assess the reduction in natural killer cell activity and to identify signs of immune exhaustion in T cells, B cells, and plasma cells. Once completed, compile a detailed report of your results, as this information is crucial for guiding our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-563d62-ar-563d623.pkl. "
BLCA,,,,NR,"For my white female patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy was performed, and the tumor mutational burden (TMB) is reported as nan. Based on these parameters, what is the expected likelihood of a positive response to Atezolizumab therapy?","For my white female patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy was performed, and the tumor mutational burden (TMB) is reported as nan. Based on these parameters, what is the expected likelihood of a positive response to Atezolizumab therapy? Please log into the COMPASS platform and conduct a transcriptomic analysis of the tumor microenvironment. In your evaluation, quantify gene expression markers to determine any decrease in natural killer cell activity and to detect signs of immune exhaustion among T cells, B cells, and plasma cells. After completing your analysis, prepare a detailed report of the findings, as these results will play a key role in shaping our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-568ce1-ar-568ce16.pkl. "
BLCA,33.0,5.509803922,excluded,R,"For my Caucasian male patient with bladder urothelial carcinoma (BLCA), a transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy shows a tumor mutational burden of 33.0. Given these findings, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma (BLCA), a transcriptomic analysis of the tumor immune microenvironment from a kidney biopsy shows a tumor mutational burden of 33.0. Given these findings, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Please log into the COMPASS platform and perform a detailed transcriptomic analysis of the tumor microenvironment. As part of your evaluation, quantify gene expression markers to assess any reduction in natural killer cell functionality and to identify signs of immune exhaustion in T cells, B cells, and plasma cells. Once your analysis is complete, prepare a comprehensive report of your findings, as these results will significantly inform our treatment decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-572f19-ar-572f197.pkl. "
BLCA,32.0,,excluded,R,"For a white male patient with bladder urothelial carcinoma who has a tumor mutation burden of 32 and available transcriptomic profiling of the tumor immune microenvironment from a prior biopsy, what is the likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who has a tumor mutation burden of 32 and available transcriptomic profiling of the tumor immune microenvironment from a prior biopsy, what is the likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS platform and perform a comprehensive transcriptomic analysis of the tumor microenvironment. In your analysis, quantify relevant gene expression markers to determine any decrease in natural killer cell function and to assess for immune exhaustion in T cells, B cells, and plasma cells. After completing your analysis, compile a detailed report of your findings to support our treatment decision-making process.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5767dd-ar-5767dd7.pkl. "
BLCA,2.0,0.333333333,desert,R,"For a white male patient with bladder urothelial carcinoma who has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 2.0, what is the anticipated response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 2.0, what is the anticipated response to Atezolizumab therapy? Please log into the COMPASS platform and conduct a comprehensive transcriptomic profiling of the tumor microenvironment. Your analysis should focus on quantifying key gene expression markers that indicate decreased natural killer cell activity as well as signs of immune exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, compile a detailed report of your findings to aid in our treatment decision-making process.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-58e783-ar-58e7832.pkl. "
BLCA,14.0,,excluded,NR,"I have a patient with bladder urothelial carcinoma who underwent transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, and the tumor exhibits a TMB of 14.0. Given this data, how likely is the patient to respond favorably to atezolizumab therapy?","I have a patient with bladder urothelial carcinoma who underwent transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, and the tumor exhibits a TMB of 14.0. Given this data, how likely is the patient to respond favorably to atezolizumab therapy? Please access the COMPASS platform and perform a comprehensive transcriptomic analysis of the tumor microenvironment. Your evaluation should specifically quantify gene expression markers associated with reduced natural killer cell activity and immune exhaustion in T cells, B cells, and plasma cells. After completing the analysis, prepare a detailed report of your results to guide our treatment decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-59f392-ar-59f3928.pkl. "
BLCA,,,,NR,"In a white male patient with bladder urothelial carcinoma, where a transcriptomic profile of the tumor immune microenvironment has been obtained via nano biopsy and the tumor mutational burden is reported as nan, what is the likelihood of a positive response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, where a transcriptomic profile of the tumor immune microenvironment has been obtained via nano biopsy and the tumor mutational burden is reported as nan, what is the likelihood of a positive response to atezolizumab therapy? Please log into the COMPASS platform and conduct a comprehensive transcriptomic evaluation of the tumor microenvironment. Focus your analysis on quantifying gene expression markers that indicate reduced natural killer cell activity as well as signs of immune exhaustion in T cells, B cells, and plasma cells. Once you have completed the analysis, please compile a detailed report of your findings to help guide our treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-59fda9-ar-59fda90.pkl. "
BLCA,9.0,1.333333333,desert,NR,"For my Caucasian male patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. The patient has a tumor mutational burden of 9.0. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. The patient has a tumor mutational burden of 9.0. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy? Please log into the COMPASS platform and perform a thorough transcriptomic analysis of the tumor microenvironment. Your evaluation should specifically quantify gene expression markers that suggest reduced activity of natural killer cells and evidence of immune exhaustion among T cells, B cells, and plasma cells. Once you have completed your analysis, please prepare a detailed report summarizing your findings to inform our treatment decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5a2347-ar-5a2347c.pkl. "
BLCA,12.0,,,NR,"For our Asian female patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy, and her tumor mutational burden is 12.0. Based on these findings, how likely is she to experience a favorable response to Atezolizumab therapy?","For our Asian female patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy, and her tumor mutational burden is 12.0. Based on these findings, how likely is she to experience a favorable response to Atezolizumab therapy? Please access the COMPASS platform and conduct a comprehensive transcriptomic analysis of the tumor microenvironment. In your evaluation, pay particular attention to gene expression markers indicative of diminished natural killer cell activity and signs of immune exhaustion in T cells, B cells, and plasma cells. Once your analysis is complete, compile a detailed report summarizing your findings to guide our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5b57e4-ar-5b57e47.pkl. "
BLCA,,,excluded,NR,"For a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment reveals a non-quantifiable tumor mutation burden (TMB, reported as nan), what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment reveals a non-quantifiable tumor mutation burden (TMB, reported as nan), what is the estimated likelihood of a favorable response to Atezolizumab therapy? Please log into the COMPASS platform and perform a transcriptomic analysis of the tumor microenvironment. In your assessment, concentrate on identifying gene expression markers that signal reduced natural killer cell activity and evidence of immune exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, please prepare a thorough report summarizing your findings to inform our treatment approach.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5c139c-ar-5c139c5.pkl. "
BLCA,11.0,0.411764706,desert,NR,"For my white male patient with bladder urothelial carcinoma, a biopsy provided a transcriptomic profile of the tumor immune microenvironment, and his tumor mutation burden is 11.0. What is the likelihood that he will respond favorably to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, a biopsy provided a transcriptomic profile of the tumor immune microenvironment, and his tumor mutation burden is 11.0. What is the likelihood that he will respond favorably to Atezolizumab therapy? Please access the COMPASS platform and conduct a detailed transcriptomic analysis of the tumor microenvironment. Focus specifically on identifying gene expression markers that indicate reduced natural killer cell activity and signs of immune exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, compile a comprehensive report outlining your findings to support our treatment decision-making process.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5cc2d9-ar-5cc2d90.pkl. "
BLCA,10.0,1.215686275,,NR,"For my white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile was obtained from a liver biopsy and who has a TMB of 10.0, how likely is a positive response to atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile was obtained from a liver biopsy and who has a TMB of 10.0, how likely is a positive response to atezolizumab therapy? Please use the COMPASS platform to perform a detailed transcriptomic evaluation of the tumor microenvironment. In your analysis, concentrate on finding gene expression markers that suggest diminished activity of natural killer cells and evidence of immune exhaustion in T cells, B cells, and plasma cells. After completing the analysis, prepare a comprehensive report summarizing your findings to aid in our treatment decision-making process.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5cfa16-ar-5cfa169.pkl. "
BLCA,12.0,,,NR,"In a white male patient with bladder urothelial carcinoma whose bladder biopsy reveals a transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden of 12.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma whose bladder biopsy reveals a transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden of 12.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to conduct a comprehensive transcriptomic analysis of the tumor microenvironment. Focus on identifying gene expression markers that indicate reduced activity in natural killer cells, as well as signs of immune exhaustion in T cells, B cells, and plasma cells. Once your analysis is complete, prepare a detailed report summarizing your findings to support our treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5d1dfd-ar-5d1dfd5.pkl. "
BLCA,13.0,1.411764706,desert,NR,"In a patient diagnosed with bladder urothelial carcinoma, with a tumor mutational burden of 13.0 and transcriptomic profiling of the tumor immune microenvironment performed on a bladder biopsy specimen, what is the likelihood of a favorable response to Atezolizumab therapy?","In a patient diagnosed with bladder urothelial carcinoma, with a tumor mutational burden of 13.0 and transcriptomic profiling of the tumor immune microenvironment performed on a bladder biopsy specimen, what is the likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to perform a detailed transcriptomic analysis of the tumor microenvironment. In your analysis, pay specific attention to gene expression markers that may signify decreased natural killer cell activity and evidence of immune exhaustion in T cells, B cells, and plasma cells. Once you have completed your analysis, compile a thorough report outlining your results to aid our treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5d989c-ar-5d989c8.pkl. "
BLCA,6.0,0.823529412,excluded,NR,"For my white male patient with bladder urothelial carcinoma, a kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment, and the tumor has a TMB of 6.0. Based on these findings, what is his likelihood of responding favorably to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, a kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment, and the tumor has a TMB of 6.0. Based on these findings, what is his likelihood of responding favorably to Atezolizumab therapy? Please use the COMPASS platform to conduct an in-depth transcriptomic analysis of the tumor microenvironment. Focus particularly on assessing gene expression markers that may indicate reduced natural killer cell activity and signs of immune exhaustion in T cells, B cells, and plasma cells. After completing your analysis, prepare a detailed report summarizing your findings to support our treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5e3bae-ar-5e3bae0.pkl. "
BLCA,21.0,3.823529412,inflamed,NR,"In a white male patient with bladder urothelial carcinoma, with a tumor mutation burden of 21.0 and transcriptomic profiling of the tumor immune microenvironment from a ureteral biopsy, what is the estimated likelihood of a positive response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, with a tumor mutation burden of 21.0 and transcriptomic profiling of the tumor immune microenvironment from a ureteral biopsy, what is the estimated likelihood of a positive response to atezolizumab therapy? Please use the COMPASS platform to perform a comprehensive transcriptomic analysis of the tumor microenvironment. In your investigation, focus on gene expression markers that suggest diminished activity of natural killer cells and indicators of immune exhaustion in T cells, B cells, and plasma cells. Upon completion, compile a detailed report summarizing your findings to inform our treatment planning decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-5fe7a8-ar-5fe7a81.pkl. "
BLCA,14.0,,inflamed,R,"For a white male patient diagnosed with Bladder Urothelial Carcinoma (BLCA) and a tumor mutational burden of 14.0, based on the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For a white male patient diagnosed with Bladder Urothelial Carcinoma (BLCA) and a tumor mutational burden of 14.0, based on the transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to conduct an in-depth transcriptomic analysis of the tumor microenvironment. Focus your evaluation on gene expression markers that indicate reduced natural killer cell activity and signs of immune exhaustion in T cells, B cells, and plasma cells. Once your analysis is complete, prepare a detailed report summarizing your findings to help guide our treatment planning decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6083aa-ar-6083aac.pkl. "
BLCA,9.0,1.803921569,desert,R,"For a white male patient with bladder urothelial carcinoma (BLCA) who has undergone transcriptomic profiling of the tumor immune microenvironment and has a TMB of 9.0, what is the expected likelihood of a positive clinical response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) who has undergone transcriptomic profiling of the tumor immune microenvironment and has a TMB of 9.0, what is the expected likelihood of a positive clinical response to Atezolizumab therapy? Please use the COMPASS platform to perform a detailed transcriptomic analysis of the tumor microenvironment. In your analysis, concentrate on assessing gene expression markers that reflect decreased natural killer cell activity, as well as markers indicating immune exhaustion in T cells, B cells, and plasma cells. Once complete, kindly prepare a comprehensive report summarizing your findings to inform our treatment planning decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6157c8-ar-6157c8f.pkl. "
BLCA,27.0,5.882352941,inflamed,NR,"For my white male patient diagnosed with bladder urothelial carcinoma (BLCA), the transcriptomic profile of the tumor immune microenvironment has been analyzed from a bladder biopsy, and his tumor mutational burden (TMB) is 27.0. Based on these parameters, what is the likelihood of a favorable response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma (BLCA), the transcriptomic profile of the tumor immune microenvironment has been analyzed from a bladder biopsy, and his tumor mutational burden (TMB) is 27.0. Based on these parameters, what is the likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to conduct a detailed transcriptomic analysis of the tumor microenvironment. In your assessment, focus on gene expression markers that indicate reduced activity of natural killer cells, as well as markers of immune exhaustion in T cells, B cells, and plasma cells. After completing the analysis, prepare a comprehensive report summarizing your findings to help guide our treatment planning decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-61b9d4-ar-61b9d4d.pkl. "
BLCA,,,desert,NR,"For a Caucasian female with bladder urothelial carcinoma (BLCA), transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy has been performed, and the tumor mutational burden is reported as ""nan."" Based on these findings, what is the probability of a positive response to Atezolizumab therapy?","For a Caucasian female with bladder urothelial carcinoma (BLCA), transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy has been performed, and the tumor mutational burden is reported as ""nan."" Based on these findings, what is the probability of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform a comprehensive transcriptomic analysis of the tumor microenvironment. In your evaluation, concentrate on identifying gene expression markers that signify decreased activity of natural killer cells and indicators of immune exhaustion in T cells, B cells, and plasma cells. After the analysis, compile a detailed report summarizing your findings to assist in our treatment planning decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-61baf9-ar-61baf91.pkl. "
BLCA,5.0,0.784313725,,NR,"For my Caucasian female patient with bladder urothelial carcinoma, who has a tumor mutational burden of 5.0 and whose kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my Caucasian female patient with bladder urothelial carcinoma, who has a tumor mutational burden of 5.0 and whose kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to conduct a detailed transcriptomic analysis of the tumor microenvironment. In your assessment, focus on identifying gene expression markers that indicate reduced activity in natural killer cells, as well as signs of immune exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, prepare a comprehensive report summarizing your findings to support our treatment planning decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-62fb13-ar-62fb138.pkl. "
BLCA,,0.156862745,,NR,"For a Caucasian male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment was performed using a bladder biopsy. Given that the tumor mutation burden (TMB) is reported as ""nan,"" what is the likelihood of a favorable response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment was performed using a bladder biopsy. Given that the tumor mutation burden (TMB) is reported as ""nan,"" what is the likelihood of a favorable response to Atezolizumab therapy? Please utilize the COMPASS platform to perform a comprehensive transcriptomic analysis of the tumor microenvironment. Your assessment should specifically aim to identify gene expression markers that suggest diminished natural killer cell activity and signs of immune exhaustion among T cells, B cells, and plasma cells. Once your analysis is complete, compile a detailed report summarizing your findings to inform our treatment planning decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-63405b-ar-63405b0.pkl. "
BLCA,14.0,0.980392157,desert,NR,"For a Caucasian patient with bladder urothelial carcinoma, whose tumor biopsy reveals a transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden of 14.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a Caucasian patient with bladder urothelial carcinoma, whose tumor biopsy reveals a transcriptomic profile of the tumor immune microenvironment and a tumor mutational burden of 14.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to carry out a detailed transcriptomic analysis of the tumor microenvironment. In your evaluation, focus on identifying gene expression markers that indicate reduced natural killer cell activity as well as evidence of immune exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, prepare a comprehensive report of your findings to guide our treatment planning decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-63b218-ar-63b2189.pkl. "
BLCA,4.0,0.294117647,excluded,NR,"For my Caucasian patient diagnosed with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutation burden is 4.0. Based on these data, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my Caucasian patient diagnosed with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutation burden is 4.0. Based on these data, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform an in-depth transcriptomic analysis of the tumor microenvironment. In your analysis, specifically look for gene expression markers that indicate reduced natural killer cell activity, as well as signs of immune exhaustion in T cells, B cells, and plasma cells. Once completed, compile a detailed report of your findings to assist in guiding our treatment planning strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-65afda-ar-65afda2.pkl. "
BLCA,5.0,0.490196078,inflamed,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile reveals a tumor mutational burden of 5.0, what is the likelihood of a favorable response to atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment transcriptomic profile reveals a tumor mutational burden of 5.0, what is the likelihood of a favorable response to atezolizumab therapy? Please use the COMPASS platform to conduct a detailed transcriptomic analysis of the tumor microenvironment. In this evaluation, focus specifically on identifying gene expression markers for diminished natural killer cell activity and signs of immune exhaustion in T cells, B cells, and plasma cells. Once your analysis is complete, prepare a comprehensive report of your findings to support our treatment planning efforts.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6662f5-ar-6662f51.pkl. "
BLCA,15.0,2.68627451,excluded,R,"For a white female patient diagnosed with bladder urothelial carcinoma, with a transcriptomic profile of her tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 15.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma, with a transcriptomic profile of her tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 15.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please utilize the COMPASS platform to perform a detailed transcriptomic assessment of the tumor microenvironment. In your analysis, specifically target the identification of gene expression markers that suggest reduced natural killer cell activity and immune exhaustion within T cells, B cells, and plasma cells. After completing this evaluation, prepare a thorough report detailing your findings to assist with our treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-670649-ar-670649e.pkl. "
BLCA,13.0,1.254901961,desert,NR,"For my white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from his bladder biopsy revealed a tumor mutational burden of 13.0. Based on these findings, what is the estimated likelihood of a positive response to atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from his bladder biopsy revealed a tumor mutational burden of 13.0. Based on these findings, what is the estimated likelihood of a positive response to atezolizumab therapy? Please use the COMPASS platform to conduct an in-depth analysis of the tumor microenvironment at the transcriptomic level. Your evaluation should focus on identifying gene expression markers that indicate decreased natural killer cell activity as well as signs of immune exhaustion in T cells, B cells, and plasma cells. Once the assessment is complete, compile a comprehensive report detailing your findings to inform our treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-675a12-ar-675a12a.pkl. "
BLCA,14.0,2.549019608,inflamed,NR,"For a white female patient diagnosed with bladder urothelial carcinoma (BLCA) and a tumor mutation burden of 14.0, based on the transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma (BLCA) and a tumor mutation burden of 14.0, based on the transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform a detailed transcriptomic analysis of the tumor microenvironment. Focus on detecting gene expression markers associated with reduced natural killer cell activity, as well as evidence of immune exhaustion in T cells, B cells, and plasma cells. After completing your assessment, compile a thorough report of your findings to guide our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6780ed-ar-6780ed4.pkl. "
BLCA,17.0,1.117647059,desert,NR,"For my African American patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden (TMB) of 17.0, how should the transcriptomic profile of the tumor immune microenvironment from the bladder biopsy inform our expectations regarding the response to Atezolizumab therapy?","For my African American patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden (TMB) of 17.0, how should the transcriptomic profile of the tumor immune microenvironment from the bladder biopsy inform our expectations regarding the response to Atezolizumab therapy? Please use the COMPASS platform to conduct a comprehensive transcriptomic analysis of the tumor microenvironment. In your analysis, focus on identifying gene expression markers that indicate reduced activity of natural killer cells, as well as signs of immune exhaustion among T cells, B cells, and plasma cells. Once the analysis is complete, prepare a detailed report of your findings to inform our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6792d6-ar-6792d6e.pkl. "
BLCA,7.0,1.862745098,excluded,R,"For my Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), with a tumor mutational burden of 7.0 and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy completed, what is the estimated likelihood that he will respond positively to Atezolizumab therapy?","For my Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), with a tumor mutational burden of 7.0 and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy completed, what is the estimated likelihood that he will respond positively to Atezolizumab therapy? Please use the COMPASS platform for a comprehensive transcriptomic analysis of the tumor microenvironment. Specifically, examine the gene expression profiles to detect markers indicating diminished natural killer cell activity and signs of immune exhaustion in T cells, B cells, and plasma cells. After completing the analysis, compile a detailed report outlining your findings to guide our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-681e4b-ar-681e4bf.pkl. "
BLCA,5.0,1.176470588,,NR,"In my Caucasian male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy reveals a tumor mutational burden of 5. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy?","In my Caucasian male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy reveals a tumor mutational burden of 5. Based on these findings, what is the likelihood of a favorable response to atezolizumab therapy? Please use the COMPASS platform to perform a detailed transcriptomic analysis of the tumor microenvironment. Focus on identifying gene expression markers that indicate reduced natural killer cell activity and signs of immune exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, prepare a comprehensive report of your findings to inform our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6964a6-ar-6964a6d.pkl. "
BLCA,20.0,1.039215686,desert,R,"In a white male patient diagnosed with bladder urothelial carcinoma, where a lung biopsy revealed transcriptomic features of the tumor immune microenvironment and a tumor mutational burden of 20.0, what is the estimated likelihood of a positive therapeutic response to atezolizumab?","In a white male patient diagnosed with bladder urothelial carcinoma, where a lung biopsy revealed transcriptomic features of the tumor immune microenvironment and a tumor mutational burden of 20.0, what is the estimated likelihood of a positive therapeutic response to atezolizumab? Please use the COMPASS platform to conduct an in-depth transcriptomic analysis of the tumor microenvironment. Focus specifically on identifying gene expression markers that reflect diminished natural killer cell function and indications of immune exhaustion in T cells, B cells, and plasma cells. After completing the analysis, compile a detailed report of your findings to help guide our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6cb230-ar-6cb230f.pkl. "
BLCA,3.0,0.960784314,inflamed,NR,"In our white male patient with a diagnosis of bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutation burden (TMB) of 3.0, how likely is he to respond favorably to Atezolizumab therapy?","In our white male patient with a diagnosis of bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutation burden (TMB) of 3.0, how likely is he to respond favorably to Atezolizumab therapy? Please utilize the COMPASS platform to perform a comprehensive transcriptomic analysis of the tumor microenvironment. Your analysis should specifically aim to identify gene expression markers that indicate a reduction in natural killer cell activity, as well as signs of immune exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, please prepare a detailed report summarizing your findings to inform our treatment approach.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6cbc10-ar-6cbc10a.pkl. "
BLCA,,,excluded,NR,"For my African American male patient with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy, and the tumor mutation burden is reported as ""nan."" Given these findings, how likely is a positive response to atezolizumab therapy?","For my African American male patient with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from a lymph node biopsy, and the tumor mutation burden is reported as ""nan."" Given these findings, how likely is a positive response to atezolizumab therapy? Please use the COMPASS platform to conduct a thorough transcriptomic analysis of the tumor microenvironment. Focus on identifying gene expression markers that signal reduced natural killer cell activity and potential immune exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, compile a detailed report summarizing your findings to guide our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6d2ae0-ar-6d2ae0c.pkl. "
BLCA,,3.568627451,,NR,"For my white patient with bladder urothelial carcinoma, we have obtained transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, and the reported tumor mutational burden is ""nan."" Given these findings, what is the likelihood that the patient will respond favorably to Atezolizumab therapy?","For my white patient with bladder urothelial carcinoma, we have obtained transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, and the reported tumor mutational burden is ""nan."" Given these findings, what is the likelihood that the patient will respond favorably to Atezolizumab therapy? Please utilize the COMPASS platform to perform an in-depth transcriptomic evaluation of the tumor microenvironment. Your analysis should specifically target gene expression markers that indicate diminished natural killer cell activity and signs of immune exhaustion in T cells, B cells, and plasma cells. After completing the analysis, provide a comprehensive report detailing your findings to assist in refining our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6dd7ad-ar-6dd7ad1.pkl. "
BLCA,8.0,2.078431373,,R,"For my Caucasian female patient diagnosed with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a nano biopsy revealed a tumor mutational burden of 8.0. Based on these parameters, what is the estimated likelihood of a positive response to atezolizumab therapy?","For my Caucasian female patient diagnosed with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a nano biopsy revealed a tumor mutational burden of 8.0. Based on these parameters, what is the estimated likelihood of a positive response to atezolizumab therapy? Please use the COMPASS platform to conduct a detailed transcriptomic profile of the tumor microenvironment. In your analysis, focus on detecting gene expression markers that suggest reduced natural killer cell activity and immune exhaustion in T cells, B cells, and plasma cells. Once you have completed your evaluation, submit a detailed report outlining your findings to inform our treatment strategy adjustments.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6f2a10-ar-6f2a102.pkl. "
BLCA,6.0,1.039215686,excluded,R,"For our Caucasian male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment was profiled via a kidney biopsy and who has a tumor mutational burden of 6.0, what is the likelihood that he will respond positively to Atezolizumab therapy?","For our Caucasian male patient diagnosed with bladder urothelial carcinoma, whose tumor immune microenvironment was profiled via a kidney biopsy and who has a tumor mutational burden of 6.0, what is the likelihood that he will respond positively to Atezolizumab therapy? Please use the COMPASS platform to perform a comprehensive transcriptomic analysis of the tumor microenvironment. In your study, pay particular attention to identifying gene expression markers that point to diminished natural killer cell function and signs of immune cell exhaustion—in T cells, B cells, and plasma cells. After completing your analysis, provide a detailed report of your findings to support adjustments to our treatment plan.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-6ff654-ar-6ff654a.pkl. "
BLCA,17.0,2.176470588,,NR,"For a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 17.0 and available transcriptomic data from a bladder biopsy, what is the expected likelihood of a positive response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 17.0 and available transcriptomic data from a bladder biopsy, what is the expected likelihood of a positive response to atezolizumab therapy? Please utilize the COMPASS platform to conduct a comprehensive transcriptomic analysis of the tumor microenvironment. In your analysis, focus on detecting gene expression markers that indicate reduced natural killer cell activity as well as evidence of T cell, B cell, and plasma cell exhaustion. Once your work is complete, submit a detailed report of your findings to inform potential modifications to our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7114d9-ar-7114d99.pkl. "
BLCA,6.0,1.568627451,,NR,"For a white male patient with bladder urothelial carcinoma who has a tumor mutation burden of 6.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who has a tumor mutation burden of 6.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to perform a detailed transcriptomic evaluation of the tumor microenvironment. In this analysis, specifically look for gene expression patterns that suggest diminished natural killer cell activity, as well as markers of exhaustion in T cells, B cells, and plasma cells. Once you have completed the analysis, provide a comprehensive report of your findings to guide potential adjustments to our treatment approach.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-716f54-ar-716f54e.pkl. "
BLCA,1.0,0.333333333,,R,"For my white male patient diagnosed with bladder urothelial carcinoma (BLCA), a lymph node biopsy provided a transcriptomic profile of the tumor immune microenvironment, and his tumor mutational burden is 1.0. Based on these parameters, what is the expected likelihood of a favorable response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma (BLCA), a lymph node biopsy provided a transcriptomic profile of the tumor immune microenvironment, and his tumor mutational burden is 1.0. Based on these parameters, what is the expected likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to carry out an in-depth transcriptomic analysis of the tumor microenvironment. Your evaluation should focus on identifying gene expression patterns indicative of reduced natural killer cell activity, as well as markers suggesting exhaustion in T cells, B cells, and plasma cells. After completing your analysis, kindly compile a comprehensive report detailing your findings to assist in refining our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-727c0e-ar-727c0e9.pkl. "
BLCA,,,excluded,R,"For our Caucasian patient with bladder urothelial carcinoma, whose kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment and showed a TMB value listed as 'nan', what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For our Caucasian patient with bladder urothelial carcinoma, whose kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment and showed a TMB value listed as 'nan', what is the estimated likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to perform a comprehensive transcriptomic analysis of the tumor microenvironment. Focus your evaluation on detecting gene expression patterns that indicate diminished natural killer cell activity and markers of exhaustion in T cells, B cells, and plasma cells. Once your analysis is complete, compile a detailed report of your findings to help inform our treatment strategy.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-73663e-ar-73663ee.pkl. "
BLCA,7.0,0.274509804,excluded,NR,"In a Caucasian female patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment obtained from a kidney biopsy revealed a tumor mutational burden of 7.0. Based on these findings, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","In a Caucasian female patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment obtained from a kidney biopsy revealed a tumor mutational burden of 7.0. Based on these findings, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to conduct a detailed transcriptomic analysis of the tumor microenvironment. Specifically, examine gene expression profiles for indicators of reduced natural killer cell activity and signs of cellular exhaustion in T cells, B cells, and plasma cells. After completing the analysis, prepare a comprehensive report outlining your findings to inform our treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-75142f-ar-75142fc.pkl. "
BLCA,21.0,2.392156863,inflamed,NR,"For my white female patient with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment was profiled transcriptomically from a bladder biopsy and has a tumor mutational burden (TMB) of 21.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For my white female patient with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment was profiled transcriptomically from a bladder biopsy and has a tumor mutational burden (TMB) of 21.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Utilize the COMPASS platform to perform a comprehensive transcriptomic analysis of the tumor microenvironment. Focus on assessing gene expression profiles for indicators of diminished natural killer cell activity and signs of exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, compile a detailed report summarizing your findings to support our treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7538ad-ar-7538ad9.pkl. "
BLCA,7.0,,excluded,NR,"For a Caucasian patient with Bladder Urothelial Carcinoma (BLCA), a tumor mutational burden (TMB) of 7.0, and transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For a Caucasian patient with Bladder Urothelial Carcinoma (BLCA), a tumor mutational burden (TMB) of 7.0, and transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to conduct a thorough transcriptomic analysis of the tumor microenvironment. In your analysis, evaluate gene expression profiles to detect reduced activity of natural killer cells, as well as evidence of exhaustion in T cells, B cells, and plasma cells. Upon completing the analysis, prepare a comprehensive report detailing your findings to inform our treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-753d4b-ar-753d4bb.pkl. "
BLCA,6.0,0.333333333,inflamed,NR,"For a white male patient with bladder urothelial carcinoma who has a tumor immune microenvironment profile obtained from a lung biopsy and a tumor mutational burden of 6.0 mutations/Mb, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who has a tumor immune microenvironment profile obtained from a lung biopsy and a tumor mutational burden of 6.0 mutations/Mb, what is the expected likelihood of a positive response to Atezolizumab therapy? Using the COMPASS platform, please perform a detailed transcriptomic evaluation of the tumor microenvironment. In your analysis, carefully examine gene expression profiles to identify any diminished activity in natural killer cells and signs of exhaustion in T cells, B cells, and plasma cells. After completing your assessment, compile a comprehensive report of your findings to support our treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-75f12d-ar-75f12d1.pkl. "
BLCA,6.0,0.215686275,inflamed,NR,"In a white male patient with bladder urothelial carcinoma (BLCA), whose kidney biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden (TMB) of 6.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA), whose kidney biopsy transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden (TMB) of 6.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to conduct a comprehensive transcriptomic analysis of the tumor microenvironment. Focus on identifying reduced natural killer cell activity and signs of exhaustion in T cells, B cells, and plasma cells based on gene expression profiles. Once the analysis is complete, compile a detailed report of your findings to aid in treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-76a431-ar-76a431b.pkl. "
BLCA,,0.215686275,inflamed,R,"For a white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment was performed on a bladder biopsy, and the tumor mutation burden (TMB) is currently not available (nan). Given these findings, what is the likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment was performed on a bladder biopsy, and the tumor mutation burden (TMB) is currently not available (nan). Given these findings, what is the likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform an in-depth transcriptomic evaluation of the tumor microenvironment. Your analysis should specifically assess gene expression data to identify any decreases in natural killer cell activity, as well as evidence of exhaustion in T cells, B cells, and plasma cells. Once you have completed the analysis, please prepare a comprehensive report summarizing your findings to support our treatment planning efforts.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-771445-ar-771445e.pkl. "
BLCA,3.0,0.745098039,inflamed,NR,"For my White male patient with bladder urothelial carcinoma who has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 3.0, what is the expected likelihood of a positive response to Atezolizumab therapy?","For my White male patient with bladder urothelial carcinoma who has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden of 3.0, what is the expected likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform a thorough transcriptomic analysis of the tumor microenvironment. Focus on evaluating gene expression data to determine if there is a reduction in natural killer cell activity and evidence of exhaustion in T cells, B cells, and plasma cells. After your analysis is complete, compile a detailed report summarizing your findings to assist with treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7829a3-ar-7829a34.pkl. "
BLCA,5.0,0.941176471,,NR,"For an Asian male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic profile of the tumor immune microenvironment shows a TMB of 5.0, what is the likelihood that he will have a positive response to atezolizumab therapy?","For an Asian male patient with bladder urothelial carcinoma whose bladder biopsy transcriptomic profile of the tumor immune microenvironment shows a TMB of 5.0, what is the likelihood that he will have a positive response to atezolizumab therapy? Please use the COMPASS platform to conduct an in-depth transcriptomic analysis of the tumor microenvironment. Specifically, evaluate the gene expression profiles to determine if there is a decrease in natural killer cell activity and signs of functional exhaustion in T cells, B cells, and plasma cells. Once your analysis is complete, prepare a comprehensive report summarizing your findings to support treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-789319-ar-7893196.pkl. "
BLCA,,1.039215686,excluded,NR,"For my white male patient with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from his bladder biopsy. Given that his tumor mutation burden is not available (reported as “nan”), what is the likelihood that he will respond favorably to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from his bladder biopsy. Given that his tumor mutation burden is not available (reported as “nan”), what is the likelihood that he will respond favorably to Atezolizumab therapy? Please use the COMPASS platform to perform a detailed transcriptomic analysis of the tumor microenvironment. Specifically, assess the gene expression profiles for evidence of reduced natural killer cell activity and signs of functional exhaustion in T cells, B cells, and plasma cells. After completing the analysis, compile a comprehensive report summarizing your findings to assist with treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7aa01f-ar-7aa01fc.pkl. "
BLCA,12.0,,,R,"In a Caucasian female patient with bladder urothelial carcinoma (BLCA) who has a tumor transcriptomic profile from a ureter biopsy and a tumor mutational burden (TMB) of 12.0, what is the expected likelihood of a favorable response to Atezolizumab therapy?","In a Caucasian female patient with bladder urothelial carcinoma (BLCA) who has a tumor transcriptomic profile from a ureter biopsy and a tumor mutational burden (TMB) of 12.0, what is the expected likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to carry out a comprehensive transcriptomic evaluation of the tumor microenvironment. Focus specifically on analyzing gene expression to identify indicators of reduced natural killer cell activity and potential functional exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, prepare a detailed report summarizing your findings to inform future treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7b4000-ar-7b40007.pkl. "
BLCA,,0.725490196,,NR,"For my white male patient with bladder urothelial carcinoma, a ureter biopsy was performed to profile the tumor immune microenvironment, and the tumor mutational burden (TMB) was not quantifiable. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, a ureter biopsy was performed to profile the tumor immune microenvironment, and the tumor mutational burden (TMB) was not quantifiable. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform a detailed transcriptomic analysis of the tumor microenvironment. In your evaluation, focus on gene expression patterns to identify reduced natural killer cell activity, as well as signs of potential exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, compile a comprehensive report detailing your findings to support future treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7bff23-ar-7bff231.pkl. "
BLCA,5.0,0.529411765,,NR,"For my Caucasian female patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden of 5.0. Based on these findings, what is the predicted likelihood of a positive response to atezolizumab therapy?","For my Caucasian female patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden of 5.0. Based on these findings, what is the predicted likelihood of a positive response to atezolizumab therapy? Please utilize the COMPASS platform to conduct a comprehensive transcriptomic analysis of the tumor microenvironment. In your analysis, carefully examine gene expression data to assess whether there is diminished natural killer cell activity and signs of cellular exhaustion in T cells, B cells, and plasma cells. After completing your evaluation, please prepare a detailed report summarizing your findings to aid in future treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7c67b0-ar-7c67b05.pkl. "
BLCA,4.0,0.156862745,inflamed,NR,"For a white male patient with bladder urothelial carcinoma, the tumor immune microenvironment transcriptomic profile from a lymph node biopsy and a tumor mutational burden of 4.0 have been obtained. Based on these findings, what is the estimated likelihood that the patient will respond positively to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, the tumor immune microenvironment transcriptomic profile from a lymph node biopsy and a tumor mutational burden of 4.0 have been obtained. Based on these findings, what is the estimated likelihood that the patient will respond positively to Atezolizumab therapy? Please use the COMPASS platform to perform a detailed transcriptomic analysis of the tumor microenvironment. In your evaluation, scrutinize the gene expression data to determine whether there is reduced activity of natural killer cells and evidence of exhaustion in T cells, B cells, and plasma cells. Once your analysis is complete, compile a comprehensive report that summarizes your findings to support future treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7d2dfb-ar-7d2dfba.pkl. "
BLCA,8.0,2.098039216,excluded,R,"For my white male patient with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment transcriptomic profile indicates a tumor mutation burden (TMB) of 8.0 from the bladder biopsy, what is the likelihood of a favorable response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma (BLCA), whose tumor immune microenvironment transcriptomic profile indicates a tumor mutation burden (TMB) of 8.0 from the bladder biopsy, what is the likelihood of a favorable response to Atezolizumab therapy? Utilize the COMPASS platform to carry out a comprehensive transcriptomic evaluation of the tumor microenvironment. Specifically, review the gene expression profiles to assess if there is a decrease in natural killer cell activity and signs of functional exhaustion among T cells, B cells, and plasma cells. After concluding your analysis, prepare a detailed report summarizing your findings to inform and guide future treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7d7c54-ar-7d7c546.pkl. "
BLCA,,,excluded,NR,"For a white male patient with bladder urothelial carcinoma, whose bladder biopsy has provided transcriptomic profiling of the tumor immune microenvironment and an undetermined tumor mutation burden (recorded as ""nan""), what is the estimated likelihood of a positive therapeutic response to Atezolizumab?","For a white male patient with bladder urothelial carcinoma, whose bladder biopsy has provided transcriptomic profiling of the tumor immune microenvironment and an undetermined tumor mutation burden (recorded as ""nan""), what is the estimated likelihood of a positive therapeutic response to Atezolizumab? Please use the COMPASS platform to perform a detailed transcriptomic analysis of the tumor microenvironment. In this evaluation, carefully examine gene expression profiles to determine whether there is a reduction in natural killer cell activity and evidence of functional exhaustion in T cells, B cells, and plasma cells. Once your analysis is complete, compile a comprehensive report outlining your findings to support future treatment decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7f0d9c-ar-7f0d9cc.pkl. "
BLCA,1.0,,excluded,NR,"For a Black/African American patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 1.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the estimated likelihood of a positive response to atezolizumab therapy?","For a Black/African American patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 1.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the estimated likelihood of a positive response to atezolizumab therapy? Please use the COMPASS platform to conduct an in-depth transcriptomic evaluation of the tumor microenvironment. Focus your analysis on gene expression profiles to assess for diminished natural killer cell activity as well as any indications of functional exhaustion in T cells, B cells, and plasma cells. Once completed, please prepare a detailed report summarizing your findings to inform subsequent treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7fb698-ar-7fb6987.pkl. "
BLCA,11.0,0.764705882,excluded,NR,"For an Asian male patient with bladder urothelial carcinoma (BLCA), who has a tumor mutation burden (TMB) of 11.0 and transcriptomic data from a kidney biopsy of the tumor immune microenvironment, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For an Asian male patient with bladder urothelial carcinoma (BLCA), who has a tumor mutation burden (TMB) of 11.0 and transcriptomic data from a kidney biopsy of the tumor immune microenvironment, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Using the COMPASS platform, please conduct a comprehensive transcriptomic analysis of the tumor microenvironment. Focus on examining gene expression profiles to detect potential reductions in natural killer cell activity and signs of functional exhaustion in T cells, B cells, and plasma cells. After completing the analysis, compile a detailed report summarizing your findings to guide further treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-7fb7a1-ar-7fb7a13.pkl. "
BLCA,8.0,0.215686275,inflamed,NR,"For my white patient with bladder urothelial carcinoma (BLCA), we obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and the tumor mutation burden (TMB) is 8.0. Based on these parameters, what is the likelihood of a positive response to Atezolizumab therapy?","For my white patient with bladder urothelial carcinoma (BLCA), we obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and the tumor mutation burden (TMB) is 8.0. Based on these parameters, what is the likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform an in-depth transcriptomic analysis of the tumor microenvironment. Your assessment should focus on assessing gene expression profiles to identify any evidence of reduced activity in natural killer cells, as well as signs of functional exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, prepare a detailed report that summarizes your findings and offers insights to guide further treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-80c618-ar-80c6183.pkl. "
BLCA,7.0,1.078431373,,NR,"For my White female patient with bladder urothelial carcinoma, who has a tumor mutational burden of 7.0 and whose tumor immune microenvironment was profiled via transcriptomics from a biopsy, what is the likelihood of a positive response to Atezolizumab therapy?","For my White female patient with bladder urothelial carcinoma, who has a tumor mutational burden of 7.0 and whose tumor immune microenvironment was profiled via transcriptomics from a biopsy, what is the likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to conduct a comprehensive transcriptomic analysis of the tumor microenvironment. Specifically, evaluate the gene expression profiles for any signs of diminished activity in natural killer cells, as well as markers of functional exhaustion in T cells, B cells, and plasma cells. When the analysis is complete, compile a detailed report summarizing your findings and providing insights to support further treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-81b715-ar-81b7152.pkl. "
BLCA,,1.098039216,desert,NR,"For a Caucasian male patient with bladder urothelial carcinoma (BLCA), we obtained a transcriptomic profile of the tumor immune microenvironment from a recent biopsy, and the tumor mutation burden (TMB) is reported as ""nan."" Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma (BLCA), we obtained a transcriptomic profile of the tumor immune microenvironment from a recent biopsy, and the tumor mutation burden (TMB) is reported as ""nan."" Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform a detailed transcriptomic analysis of the tumor microenvironment. In your analysis, focus on identifying gene expression patterns that may indicate reduced natural killer cell activity, as well as markers that suggest functional exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, prepare a comprehensive report outlining your findings and offering insights to assist with future treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-822b22-ar-822b226.pkl. "
BLCA,5.0,1.725490196,desert,R,"For a white male patient diagnosed with bladder urothelial carcinoma who has a tumor mutational burden of 5.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the estimated likelihood of a positive response to atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma who has a tumor mutational burden of 5.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the estimated likelihood of a positive response to atezolizumab therapy? Use the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. In this analysis, please identify gene expression patterns suggesting diminished activity in natural killer cells and markers indicative of functional exhaustion in T cells, B cells, and plasma cells. After your analysis, compile a detailed report outlining your findings and providing insights to support future treatment planning.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8533e5-ar-8533e5e.pkl. "
BLCA,8.0,0.274509804,excluded,NR,"For my Caucasian male patient diagnosed with bladder urothelial carcinoma, a lung biopsy provided a transcriptomic profile of the tumor immune microenvironment, and the tumor mutation burden is 8.0. What is the expected likelihood of a positive response to atezolizumab therapy based on these findings?","For my Caucasian male patient diagnosed with bladder urothelial carcinoma, a lung biopsy provided a transcriptomic profile of the tumor immune microenvironment, and the tumor mutation burden is 8.0. What is the expected likelihood of a positive response to atezolizumab therapy based on these findings? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. In your evaluation, identify gene expression signatures suggestive of reduced natural killer cell activity and assess markers that may indicate functional exhaustion in T cells, B cells, and plasma cells. Once completed, compile a comprehensive report detailing your findings and offering insights to inform future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-85f0a3-ar-85f0a3a.pkl. "
BLCA,14.0,0.31372549,excluded,NR,"For a white female patient with bladder urothelial carcinoma who has a tumor mutation burden of 14.0, how predictive is the transcriptomic profile of her tumor immune microenvironment obtained from the bladder biopsy for a favorable response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma who has a tumor mutation burden of 14.0, how predictive is the transcriptomic profile of her tumor immune microenvironment obtained from the bladder biopsy for a favorable response to Atezolizumab therapy? Please use the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. In your analysis, focus on identifying gene expression signatures that could indicate diminished activity of natural killer cells. Additionally, evaluate markers that may reflect functional exhaustion in T cells, B cells, and plasma cells. Once your analysis is complete, compile a detailed report that summarizes your findings and offers insights to guide future therapeutic strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-87a8e1-ar-87a8e18.pkl. "
BLCA,13.0,6.0,inflamed,R,"For a white male patient with bladder urothelial carcinoma who has a tumor mutation burden of 13.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who has a tumor mutation burden of 13.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the expected likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. In your analysis, prioritize identifying gene expression signatures that suggest reduced natural killer cell activity. Also, assess specific markers indicative of functional exhaustion in T cells, B cells, and plasma cells. After completing your analysis, prepare a comprehensive report that summarizes the results and provides insights for future therapeutic strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8884fe-ar-8884fe4.pkl. "
BLCA,14.0,0.843137255,desert,R,"For my Asian male patient diagnosed with bladder urothelial carcinoma (BLCA), who has a tumor mutational burden (TMB) of 14.0 and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a positive response to atezolizumab therapy?","For my Asian male patient diagnosed with bladder urothelial carcinoma (BLCA), who has a tumor mutational burden (TMB) of 14.0 and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a positive response to atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. In this analysis, focus on detecting gene expression profiles that indicate decreased natural killer cell activity. Additionally, evaluate markers that reflect functional exhaustion in T cells, B cells, and plasma cells. Once your analysis is complete, compile a detailed report that summarizes your findings and discusses potential implications for future therapeutic strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8a1b0e-ar-8a1b0e0.pkl. "
BLCA,7.0,1.0,excluded,NR,"For my Caucasian male patient with bladder urothelial carcinoma who has a tumor mutation burden of 7.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma who has a tumor mutation burden of 7.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to conduct a transcriptomic evaluation of the tumor microenvironment. Focus on identifying gene expression signatures that suggest reduced natural killer cell activity and assess markers indicating functional exhaustion among T cells, B cells, and plasma cells. After completing the analysis, compile a comprehensive report summarizing your findings and discussing their potential implications for future therapeutic strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8b4b8b-ar-8b4b8b0.pkl. "
BLCA,6.0,,excluded,NR,"For my white male patient with diagnosed bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutation burden was determined to be 6.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","For my white male patient with diagnosed bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutation burden was determined to be 6.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Using the COMPASS platform, please perform a comprehensive transcriptomic analysis of the tumor microenvironment. Your evaluation should specifically look for gene expression patterns that indicate reduced activity of natural killer cells, and examine transcriptomic markers that signal functional exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, prepare a detailed report that summarizes your findings and explores their potential implications for future therapeutic approaches.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8e4698-ar-8e46983.pkl. "
BLCA,6.0,0.509803922,desert,NR,"In a white male patient with bladder urothelial carcinoma (BLCA), whose kidney biopsy transcriptomic profiling of the tumor immune microenvironment reveals a tumor mutational burden (TMB) of 6.0, what is the expected likelihood of a positive response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA), whose kidney biopsy transcriptomic profiling of the tumor immune microenvironment reveals a tumor mutational burden (TMB) of 6.0, what is the expected likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to conduct a detailed transcriptomic analysis of the tumor microenvironment. Focus on identifying gene expression signatures that suggest diminished activity of natural killer cells, as well as markers that indicate functional exhaustion in T cells, B cells, and plasma cells. Once your analysis is complete, compile a comprehensive report summarizing your findings and discussing their potential implications for future therapeutic strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8e8ef2-ar-8e8ef23.pkl. "
BLCA,5.0,,desert,NR,"For a Caucasian male patient with bladder urothelial carcinoma (BLCA) whose transcriptomic analysis of the tumor immune microenvironment (obtained via bladder biopsy) shows a tumor mutational burden (TMB) of 5.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma (BLCA) whose transcriptomic analysis of the tumor immune microenvironment (obtained via bladder biopsy) shows a tumor mutational burden (TMB) of 5.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please utilize the COMPASS platform to perform an in‐depth transcriptomic assessment of the tumor microenvironment. Your primary objectives are to detect gene expression patterns that indicate reduced activity of natural killer cells and to identify markers that reflect functional exhaustion in T cells, B cells, and plasma cells. After completing your analysis, please prepare a detailed report summarizing the findings and discussing their possible implications for future therapeutic interventions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-8f2275-ar-8f2275c.pkl. "
BLCA,49.0,2.705882353,inflamed,R,"For a white male patient with bladder urothelial carcinoma (BLCA) who has a high tumor mutation burden (TMB 49.0) and transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, what is the expected likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) who has a high tumor mutation burden (TMB 49.0) and transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy, what is the expected likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to conduct a comprehensive transcriptomic analysis of the tumor microenvironment. The goal is to identify gene expression patterns that indicate reduced activity in natural killer cells and to detect markers of functional exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, compile a detailed report that summarizes your findings and discusses their potential implications for future therapeutic strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-91c47b-ar-91c47b0.pkl. "
BLCA,12.0,2.235294118,inflamed,NR,"For our white male patient with bladder urothelial carcinoma, whose tumor biopsy revealed a transcriptomic profile of the immune microenvironment and a tumor mutational burden of 12.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For our white male patient with bladder urothelial carcinoma, whose tumor biopsy revealed a transcriptomic profile of the immune microenvironment and a tumor mutational burden of 12.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform a detailed transcriptomic analysis of the tumor microenvironment. Your primary objectives are to identify gene expression patterns that suggest diminished activity of natural killer cells and to detect markers indicative of functional exhaustion in T cells, B cells, and plasma cells. Once your analysis is complete, prepare a comprehensive report that clearly outlines your findings and discusses their potential implications for future therapeutic strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9306c5-ar-9306c5c.pkl. "
BLCA,,,,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutational burden is reported as nan. Based on this information, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutational burden is reported as nan. Based on this information, what is the expected likelihood of a positive response to Atezolizumab therapy? Please utilize the COMPASS platform to conduct a comprehensive transcriptomic evaluation of the tumor microenvironment. In your analysis, focus on identifying gene expression patterns that indicate reduced natural killer cell activity, as well as markers that suggest functional exhaustion in T cells, B cells, and plasma cells. After completing the analysis, compile a detailed report that outlines the findings and discusses the potential implications for future therapeutic approaches.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9410b8-ar-9410b86.pkl. "
BLCA,5.0,0.117647059,desert,NR,"In a white male patient with bladder urothelial carcinoma whose biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutation burden of 5.0 mutations per megabase, what is the estimated likelihood of a positive response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma whose biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutation burden of 5.0 mutations per megabase, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform a detailed transcriptomic analysis of the tumor microenvironment. Specifically, focus on detecting gene expression patterns that point to reduced natural killer cell activity and assess markers indicating functional exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, prepare a comprehensive report summarizing your findings and discussing their potential impact on future therapeutic strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-943df5-ar-943df5c.pkl. "
BLCA,11.0,0.215686275,excluded,NR,"For a Black or African American male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 11 and a transcriptomic profile of the tumor immune microenvironment derived from a kidney biopsy, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a Black or African American male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 11 and a transcriptomic profile of the tumor immune microenvironment derived from a kidney biopsy, what is the expected likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to conduct an in-depth transcriptomic analysis of the tumor microenvironment. In this analysis, specifically evaluate gene expression profiles for indicators of decreased activity in natural killer cells and for markers that suggest functional exhaustion in T cells, B cells, and plasma cells. After completing the analysis, compile a thorough report that summarizes your findings and discusses their possible implications for future therapeutic strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-94859b-ar-94859b4.pkl. "
BLCA,,0.431372549,desert,NR,"For a Caucasian male patient with bladder urothelial carcinoma who has undergone transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy and has a recorded tumor mutational burden value of nan, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma who has undergone transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy and has a recorded tumor mutational burden value of nan, what is the expected likelihood of a positive response to Atezolizumab therapy? Please employ the COMPASS platform to perform a comprehensive transcriptomic analysis of the tumor microenvironment. For this evaluation, focus on assessing gene expression profiles that may reveal reduced activity in natural killer cells, as well as markers indicative of functional exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, prepare a detailed report that summarizes your findings and outlines their potential impact on future therapeutic strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9539a4-ar-9539a4f.pkl. "
BLCA,,0.196078431,excluded,NR,"For my Caucasian male patient with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy. Given that the tumor mutational burden (TMB) data is unavailable, how likely is the patient to have a positive response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from a ureter biopsy. Given that the tumor mutational burden (TMB) data is unavailable, how likely is the patient to have a positive response to Atezolizumab therapy? Please use the COMPASS platform to conduct a thorough transcriptomic analysis of the tumor microenvironment. Your analysis should specifically evaluate gene expression profiles to determine if there is decreased activity in natural killer cells, as well as to identify markers of functional exhaustion in T cells, B cells, and plasma cells. After completing the study, compile a detailed report summarizing your findings and their potential implications for future therapeutic approaches.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-957378-ar-957378b.pkl. "
BLCA,17.0,1.725490196,excluded,NR,"For a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis shows the tumor immune microenvironment profile and a tumor mutational burden of 17.0 mutations per megabase, what is the anticipated likelihood of a favorable response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis shows the tumor immune microenvironment profile and a tumor mutational burden of 17.0 mutations per megabase, what is the anticipated likelihood of a favorable response to atezolizumab therapy? Please utilize the COMPASS platform to perform a comprehensive transcriptomic analysis of the tumor microenvironment. In your evaluation, please focus on examining gene expression profiles to assess whether natural killer cell activity is diminished and to detect markers indicative of functional exhaustion in T cells, B cells, and plasma cells. Once your analysis is complete, prepare a detailed report outlining your findings and discussing the potential implications for future therapeutic strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-961d04-ar-961d04c.pkl. "
BLCA,22.0,4.431372549,desert,NR,"For my white male patient diagnosed with bladder urothelial carcinoma (BLCA), transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 22.0. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma (BLCA), transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden (TMB) of 22.0. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to conduct a detailed transcriptomic analysis of the tumor microenvironment. Specifically, evaluate the gene expression profiles to determine if natural killer cell activity is reduced and to identify markers of functional exhaustion in T cells, B cells, and plasma cells. After completing your analysis, compile a comprehensive report that outlines your findings and discusses their potential impact on future therapeutic strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-972530-ar-9725303.pkl. "
BLCA,,1.921568627,excluded,NR,"For my White patient with bladder urothelial carcinoma, the transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy reported a tumor mutational burden (TMB) as ""nan."" Based on these findings, what is the likelihood of a positive response to atezolizumab therapy?","For my White patient with bladder urothelial carcinoma, the transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy reported a tumor mutational burden (TMB) as ""nan."" Based on these findings, what is the likelihood of a positive response to atezolizumab therapy? Utilize the COMPASS platform to perform a thorough transcriptomic examination of the tumor microenvironment. In this analysis, focus on evaluating gene expression profiles to determine if natural killer (NK) cell activity is diminished and to detect any markers indicating functional exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, please prepare a detailed report that summarizes your findings and discusses the potential implications for future therapeutic strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-978a58-ar-978a587.pkl. "
BLCA,18.0,2.862745098,excluded,R,"For my patient with bladder urothelial carcinoma, we obtained transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy, and the tumor mutational burden is 18.0. Based on these findings, what is the likelihood that the patient will respond favorably to Atezolizumab therapy?","For my patient with bladder urothelial carcinoma, we obtained transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy, and the tumor mutational burden is 18.0. Based on these findings, what is the likelihood that the patient will respond favorably to Atezolizumab therapy? Please use the COMPASS platform to conduct a detailed transcriptomic analysis of the tumor microenvironment. In your evaluation, focus on gene expression profiles to assess whether natural killer cell activity is reduced and to identify markers that suggest functional exhaustion in T cells, B cells, and plasma cells. Once you have completed the analysis, compile a comprehensive report that summarizes your findings and explores their potential implications for future therapeutic strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-97a00e-ar-97a00e0.pkl. "
BLCA,5.0,0.725490196,excluded,NR,"For a Caucasian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was characterized using transcriptomic analysis from a kidney biopsy and who has a tumor mutational burden of 5.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was characterized using transcriptomic analysis from a kidney biopsy and who has a tumor mutational burden of 5.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please utilize the COMPASS platform to perform a detailed transcriptomic analysis of the tumor microenvironment. Focus your analysis on gene expression profiles to determine if natural killer cell activity is diminished and to detect markers indicative of functional exhaustion in T cells, B cells, and plasma cells. Once your analysis is complete, prepare a comprehensive report that summarizes your findings and discusses their potential implications for future therapeutic strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-99a46b-ar-99a46b9.pkl. "
BLCA,4.0,0.862745098,inflamed,NR,"For my Caucasian male patient diagnosed with bladder urothelial carcinoma, a bladder biopsy provided a transcriptomic profile of the tumor immune microenvironment, and the tumor mutational burden (TMB) is 4.0. What is the estimated likelihood that he will have a favorable response to atezolizumab therapy?","For my Caucasian male patient diagnosed with bladder urothelial carcinoma, a bladder biopsy provided a transcriptomic profile of the tumor immune microenvironment, and the tumor mutational burden (TMB) is 4.0. What is the estimated likelihood that he will have a favorable response to atezolizumab therapy? Please use the COMPASS platform to conduct a detailed transcriptomic evaluation of the tumor microenvironment. Your analysis should focus on gene expression profiles to determine whether natural killer cell activity is reduced and to identify any markers of functional exhaustion in T cells, B cells, and plasma cells. After completing your analysis, prepare a comprehensive report summarizing your findings and outlining the potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9a2cf3-ar-9a2cf3c.pkl. "
BLCA,5.0,0.647058824,excluded,NR,"In a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 5.0 and a transcriptomic profile of the tumor immune microenvironment derived from a kidney biopsy, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 5.0 and a transcriptomic profile of the tumor immune microenvironment derived from a kidney biopsy, what is the anticipated likelihood of a favorable response to Atezolizumab therapy? Please perform a comprehensive transcriptomic analysis of the tumor microenvironment using the COMPASS platform. Focus specifically on gene expression profiles to evaluate whether natural killer cell activity is diminished and to identify any markers of functional exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, compile a detailed report that summarizes your key findings and discusses potential implications for future treatment options.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9aa6a0-ar-9aa6a09.pkl. "
BLCA,12.0,0.588235294,inflamed,NR,"For my Caucasian male patient with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and his tumor mutation burden is 12.0. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and his tumor mutation burden is 12.0. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to conduct a thorough transcriptomic assessment of the tumor microenvironment. In particular, focus on analyzing gene expression profiles to determine whether natural killer cell activity is reduced and to detect markers indicative of functional exhaustion in T cells, B cells, and plasma cells. Once your analysis is complete, prepare a detailed report summarizing your findings and discussing the potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9cafb9-ar-9cafb90.pkl. "
BLCA,,,,NR,"In a Caucasian male patient with bladder urothelial carcinoma, where transcriptomic profiling of the tumor immune microenvironment was performed on a liver biopsy and the tumor mutational burden is indeterminate, what is the expected likelihood of a positive response to atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, where transcriptomic profiling of the tumor immune microenvironment was performed on a liver biopsy and the tumor mutational burden is indeterminate, what is the expected likelihood of a positive response to atezolizumab therapy? Please use the COMPASS platform to perform a comprehensive transcriptomic analysis of the tumor microenvironment. Focus specifically on evaluating gene expression profiles to assess if natural killer cell activity is reduced and to identify markers of functional exhaustion in T cells, B cells, and plasma cells. Upon completion of your analysis, prepare a detailed report summarizing your findings and discussing their potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9d2494-ar-9d24941.pkl. "
BLCA,,,desert,NR,"For my white female patient diagnosed with bladder urothelial carcinoma, we performed transcriptomic profiling of the tumor immune microenvironment using a kidney biopsy, and her tumor mutational burden (TMB) is not available. Based on these parameters, what is her likelihood of a positive response to Atezolizumab therapy?","For my white female patient diagnosed with bladder urothelial carcinoma, we performed transcriptomic profiling of the tumor immune microenvironment using a kidney biopsy, and her tumor mutational burden (TMB) is not available. Based on these parameters, what is her likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to conduct a detailed transcriptomic analysis of the tumor microenvironment. Specifically, evaluate gene expression profiles to determine whether there is reduced natural killer cell activity and to identify markers of functional exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, prepare a comprehensive report summarizing your findings and discussing their potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9dacca-ar-9daccaf.pkl. "
BLCA,10.0,,inflamed,NR,"For my Caucasian male patient with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from his bladder biopsy, and his tumor mutational burden is 10 mutations per megabase. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from his bladder biopsy, and his tumor mutational burden is 10 mutations per megabase. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis focused on the tumor microenvironment. Specifically, analyze gene expression data to assess whether natural killer cell activity is reduced and to identify markers indicative of functional exhaustion in T cells, B cells, and plasma cells. Once the analysis is completed, compile a detailed report outlining your findings and discussing their potential implications for future therapeutic strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9e11ec-ar-9e11ec6.pkl. "
BLCA,6.0,0.431372549,desert,NR,"For a white female patient with bladder urothelial carcinoma who has a TMB of 6.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a positive response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma who has a TMB of 6.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS platform and carry out a transcriptomic analysis of the tumor microenvironment. Your objective is to evaluate gene expression data to determine if natural killer cell activity is diminished, and to identify markers that may indicate T cell, B cell, and plasma cell exhaustion. Once you have completed the analysis, prepare a comprehensive report detailing your findings and discussing their potential implications for future therapeutic approaches.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-9fb814-ar-9fb814c.pkl. "
BLCA,,3.333333333,desert,NR,"For my white female patient with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. The tumor mutational burden (TMB) is not available (reported as ""nan""). Considering these findings, what is the likelihood that she will respond favorably to Atezolizumab therapy?","For my white female patient with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy. The tumor mutational burden (TMB) is not available (reported as ""nan""). Considering these findings, what is the likelihood that she will respond favorably to Atezolizumab therapy? Please log into the COMPASS platform and conduct a transcriptomic analysis of the tumor microenvironment. Your analysis should focus on assessing gene expression profiles to determine whether natural killer cell activity is compromised and to identify any markers suggestive of exhaustion in T cells, B cells, and plasma cells. After completing the analysis, compile a detailed report summarizing your findings and discussing how these results may inform future therapeutic strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a1871f-ar-a1871f4.pkl. "
BLCA,15.0,0.921568627,inflamed,NR,"For my Caucasian female patient diagnosed with bladder urothelial carcinoma (BLCA), transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 15. Could you provide an assessment of her likelihood of responding favorably to atezolizumab therapy based on these findings?","For my Caucasian female patient diagnosed with bladder urothelial carcinoma (BLCA), transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutational burden of 15. Could you provide an assessment of her likelihood of responding favorably to atezolizumab therapy based on these findings? Please access the COMPASS platform and perform a transcriptomic evaluation of the tumor microenvironment. Your primary objectives are to analyze gene expression profiles to determine if natural killer cell activity is impaired and to identify any markers indicative of exhaustion in T cells, B cells, or plasma cells. Once the analysis is complete, please prepare a comprehensive report outlining your findings and discussing their potential implications for future therapeutic approaches.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a1e62d-ar-a1e62d3.pkl. "
BLCA,8.0,1.411764706,excluded,NR,"For a white male patient with bladder urothelial carcinoma, where transcriptomic analysis of the tumor immune microenvironment from a lymph node biopsy shows a tumor mutational burden of 8.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, where transcriptomic analysis of the tumor immune microenvironment from a lymph node biopsy shows a tumor mutational burden of 8.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please log in to the COMPASS platform and perform a transcriptomic assessment of the tumor microenvironment. Specifically, evaluate the gene expression profiles to determine whether natural killer cell activity is compromised and to identify any evidence of exhaustion in T cells, B cells, or plasma cells. After completing your analysis, compile a detailed report that summarizes your findings and discusses their potential impact on future therapeutic strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a32177-ar-a321770.pkl. "
BLCA,6.0,0.68627451,,NR,For a Caucasian male patient with bladder urothelial carcinoma—whose tumor biopsy has provided transcriptomic profiling of the immune microenvironment and a tumor mutational burden of 6.0—what is the likelihood of a favorable response to Atezolizumab therapy?,"For a Caucasian male patient with bladder urothelial carcinoma—whose tumor biopsy has provided transcriptomic profiling of the immune microenvironment and a tumor mutational burden of 6.0—what is the likelihood of a favorable response to Atezolizumab therapy? Please access the COMPASS platform and conduct a transcriptomic analysis of the tumor microenvironment. Your assessment should focus on evaluating gene expression profiles to determine if natural killer cell activity is reduced, and to assess for any signs of exhaustion in T cells, B cells, or plasma cells. Once the analysis is complete, please prepare a comprehensive report detailing your findings and discussing their potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a424c7-ar-a424c75.pkl. "
BLCA,19.0,0.882352941,,R,"In a Caucasian male with bladder urothelial carcinoma who has demonstrated a tumor mutational burden of 19.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the anticipated likelihood of a positive therapeutic response to atezolizumab?","In a Caucasian male with bladder urothelial carcinoma who has demonstrated a tumor mutational burden of 19.0 and a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, what is the anticipated likelihood of a positive therapeutic response to atezolizumab? Please log into the COMPASS platform and perform a transcriptomic analysis focused on the tumor microenvironment. Specifically, evaluate the gene expression profiles to determine whether natural killer cell activity is diminished and to identify any signs of exhaustion in T cells, B cells, or plasma cells. After completing your analysis, compile a detailed report that summarizes your findings and discusses their potential impact on future treatment options.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a535fc-ar-a535fcd.pkl. "
BLCA,12.0,0.725490196,,NR,"For my white male patient diagnosed with bladder urothelial carcinoma, whose tumor's transcriptomic profile from a recent biopsy indicates a tumor mutational burden of 12.0, what is the anticipated likelihood of a positive response to atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, whose tumor's transcriptomic profile from a recent biopsy indicates a tumor mutational burden of 12.0, what is the anticipated likelihood of a positive response to atezolizumab therapy? Please access the COMPASS platform and conduct a transcriptomic analysis of the tumor microenvironment. Focus on assessing gene expression profiles to verify if there is reduced natural killer cell activity and to detect any signs of exhaustion in T cells, B cells, or plasma cells. Once your analysis is complete, prepare a comprehensive report summarizing your findings and outlining the potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a90d73-ar-a90d73f.pkl. "
BLCA,,1.529411765,excluded,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and the tumor mutational burden is listed as not available. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and the tumor mutational burden is listed as not available. Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Access the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Your analysis should specifically evaluate gene expression to determine if there is reduced activity of natural killer cells and to identify markers indicating potential exhaustion in T cells, B cells, or plasma cells. After completing the analysis, please compile a detailed report that summarizes your findings and discusses the potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a913c6-ar-a913c61.pkl. "
BLCA,3.0,0.352941176,,NR,"For a white male patient with bladder urothelial carcinoma exhibiting a TMB of 3.0 on transcriptomic profiling of the tumor immune microenvironment, how likely is he to respond positively to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma exhibiting a TMB of 3.0 on transcriptomic profiling of the tumor immune microenvironment, how likely is he to respond positively to Atezolizumab therapy? Please log into the COMPASS platform to conduct a transcriptomic evaluation of the tumor microenvironment. Your analysis should focus on assessing gene expression levels to determine whether there is decreased activity of natural killer cells, and to detect markers that may indicate exhaustion in T cells, B cells, or plasma cells. Afterwards, prepare a comprehensive report detailing your findings along with a discussion on how these results could inform future treatment approaches.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-a9ca85-ar-a9ca853.pkl. "
BLCA,18.0,2.0,,NR,"For a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 18.0 and a lymph node biopsy transcriptomic profile of the tumor immune microenvironment, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 18.0 and a lymph node biopsy transcriptomic profile of the tumor immune microenvironment, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Your evaluation should quantify gene expression levels, specifically looking for reduced activity of natural killer cells and markers that might suggest exhaustion in T cells, B cells, or plasma cells. Once completed, prepare a detailed report summarizing your findings and discussing the potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-aabf4a-ar-aabf4af.pkl. "
BLCA,15.0,1.725490196,excluded,R,"For my white male patient with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and his tumor mutational burden is 15.0. Based on these findings, what is the likelihood that he will respond favorably to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and his tumor mutational burden is 15.0. Based on these findings, what is the likelihood that he will respond favorably to Atezolizumab therapy? Please log into the COMPASS platform and conduct a transcriptomic analysis of the tumor microenvironment. Focus on quantifying gene expression levels with an emphasis on identifying reduced activity in natural killer cells and markers indicating possible exhaustion in T cells, B cells, or plasma cells. Once the analysis is complete, compile a comprehensive report detailing your findings and discussing the implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-aaf505-ar-aaf505c.pkl. "
BLCA,,0.039215686,inflamed,NR,"For a Caucasian male patient with bladder urothelial carcinoma, based on transcriptomic analysis of the tumor immune microenvironment obtained from a lymph node biopsy and an indeterminate tumor mutation burden, what is the likelihood of a positive response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, based on transcriptomic analysis of the tumor immune microenvironment obtained from a lymph node biopsy and an indeterminate tumor mutation burden, what is the likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. In this analysis, quantify gene expression levels with a specific focus on detecting reduced activity in natural killer cells and identifying markers of exhaustion in T cells, B cells, or plasma cells. When the analysis is complete, compile a detailed report outlining your findings and discussing how they may influence future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ab8052-ar-ab8052a.pkl. "
BLCA,,,excluded,NR,"For my white female patient diagnosed with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy; however, the tumor mutational burden (TMB) is reported as 'nan'. How should I interpret this finding when assessing her likelihood of responding to Atezolizumab therapy?","For my white female patient diagnosed with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy; however, the tumor mutational burden (TMB) is reported as 'nan'. How should I interpret this finding when assessing her likelihood of responding to Atezolizumab therapy? Please log into the COMPASS platform to carry out a transcriptomic analysis of the tumor microenvironment. As part of this study, quantify gene expression levels with a focus on detecting decreased activity in natural killer cells and identifying exhaustion markers in T cells, B cells, or plasma cells. Once the analysis is complete, compile a comprehensive report detailing your findings and discussing their potential impact on future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-abc151-ar-abc151b.pkl. "
BLCA,6.0,0.745098039,,NR,"For my Caucasian male patient diagnosed with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a renal biopsy, and the tumor mutational burden is 6.0. What is the expected likelihood of a favorable response to Atezolizumab therapy based on these parameters?","For my Caucasian male patient diagnosed with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a renal biopsy, and the tumor mutational burden is 6.0. What is the expected likelihood of a favorable response to Atezolizumab therapy based on these parameters? Please access the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. In this study, you should focus on quantifying gene expression, specifically looking for reduced activity in natural killer cells as well as the presence of exhaustion markers in T cells, B cells, or plasma cells. After completing the analysis, prepare a detailed report summarizing your findings and discussing how these may influence future treatment approaches.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ad83c9-ar-ad83c9c.pkl. "
BLCA,,,,NR,"For a white female patient with bladder urothelial carcinoma, where the transcriptomic profile of the tumor immune microenvironment was obtained via kidney biopsy and tumor mutation burden data is not available, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, where the transcriptomic profile of the tumor immune microenvironment was obtained via kidney biopsy and tumor mutation burden data is not available, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. Your analysis should specifically quantify gene expression, with an emphasis on identifying reduced activity in natural killer cells and detecting exhaustion markers in T cells, B cells, or plasma cells. Once your analysis is complete, compile a comprehensive report outlining your findings and discussing the potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ae0262-ar-ae02629.pkl. "
BLCA,,,,NR,"For a Black or African American patient diagnosed with bladder urothelial carcinoma, with transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy showing a TMB value reported as ""nan,"" how likely is it that the patient will respond favorably to atezolizumab therapy?","For a Black or African American patient diagnosed with bladder urothelial carcinoma, with transcriptomic profiling of the tumor immune microenvironment from a ureter biopsy showing a TMB value reported as ""nan,"" how likely is it that the patient will respond favorably to atezolizumab therapy? Please utilize the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. In your analysis, focus on quantifying gene expression, particularly noting any decreases in natural killer cell activity and the presence of exhaustion markers in T cells, B cells, or plasma cells. After completing your analysis, prepare a detailed report that outlines your findings and discusses the potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ae1690-ar-ae16904.pkl. "
BLCA,,,,NR,"For my Caucasian patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor's immune microenvironment from a bladder biopsy, and the reported tumor mutational burden (TMB) is ""nan."" Based on these findings, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","For my Caucasian patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor's immune microenvironment from a bladder biopsy, and the reported tumor mutational burden (TMB) is ""nan."" Based on these findings, what is the anticipated likelihood of a favorable response to Atezolizumab therapy? Kindly use the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. Focus specifically on quantifying gene expression changes, with particular attention to any reduction in natural killer cell activity and the detection of exhaustion markers in T cells, B cells, or plasma cells. Once completed, please compile a detailed report outlining your findings and discussing the potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ae4da2-ar-ae4da27.pkl. "
BLCA,4.0,,excluded,R,"In a white male patient with bladder urothelial carcinoma (BLCA), whose transcriptomic analysis of the tumor immune microenvironment from a ureter biopsy shows a tumor mutational burden (TMB) of 4.0 mutations/Mb, what is the estimated probability of a positive response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA), whose transcriptomic analysis of the tumor immune microenvironment from a ureter biopsy shows a tumor mutational burden (TMB) of 4.0 mutations/Mb, what is the estimated probability of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Your primary objectives should include quantifying changes in gene expression, with a focus on evaluating any decreases in natural killer cell activity and identifying markers of exhaustion in T cells, B cells, or plasma cells. After completing the analysis, prepare a comprehensive report that details your findings and discusses their potential impact on future treatment approaches.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-aec738-ar-aec7380.pkl. "
BLCA,14.0,2.196078431,inflamed,NR,"For my Caucasian male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor's immune microenvironment from a bladder biopsy. With a tumor mutational burden of 14.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor's immune microenvironment from a bladder biopsy. With a tumor mutational burden of 14.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? Use the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. In this analysis, focus on quantifying changes in gene expression. Specifically, evaluate reductions in natural killer cell activity and examine T cells, B cells, and plasma cells for markers of exhaustion. After completing your analysis, prepare a detailed report that summarizes your findings and discusses their potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-af42c1-ar-af42c15.pkl. "
BLCA,7.0,0.352941176,,NR,"For my Caucasian male patient with bladder urothelial carcinoma (BLCA), a lung biopsy provided a transcriptomic profile of the tumor immune microenvironment, and the tumor mutation burden (TMB) is 7.0. Based on these findings, what is the estimated likelihood of achieving a positive response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma (BLCA), a lung biopsy provided a transcriptomic profile of the tumor immune microenvironment, and the tumor mutation burden (TMB) is 7.0. Based on these findings, what is the estimated likelihood of achieving a positive response to Atezolizumab therapy? Use the COMPASS platform to perform a transcriptomic evaluation of the tumor microenvironment, concentrating on quantifying alterations in gene expression. Specifically, assess whether there is a reduction in natural killer cell function and investigate the presence of exhaustion markers in T cells, B cells, and plasma cells. Upon completing your analysis, compile a comprehensive report that details your findings and explores their potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b0a83e-ar-b0a83e5.pkl. "
BLCA,3.0,0.843137255,inflamed,NR,"For a white female patient diagnosed with bladder urothelial carcinoma (BLCA), a transcriptomic analysis of the tumor immune microenvironment from a lung biopsy revealed a tumor mutational burden (TMB) of 3.0. Given these findings, what is the likelihood that she will have a positive response to Atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma (BLCA), a transcriptomic analysis of the tumor immune microenvironment from a lung biopsy revealed a tumor mutational burden (TMB) of 3.0. Given these findings, what is the likelihood that she will have a positive response to Atezolizumab therapy? Please use the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. Your evaluation should specifically focus on quantifying changes in gene expression, particularly by assessing whether natural killer cell function is impaired and by identifying any exhaustion markers present in T cells, B cells, and plasma cells. Once your analysis is complete, prepare a detailed report outlining your findings and discussing their potential implications for future therapeutic strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b0d11d-ar-b0d11db.pkl. "
BLCA,11.0,1.509803922,,R,"For my white male patient diagnosed with bladder urothelial carcinoma, the transcriptomic analysis of the tumor immune microenvironment from his bladder biopsy reveals a tumor mutational burden of 11.0. Based on these parameters, what is the likelihood that he will respond positively to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, the transcriptomic analysis of the tumor immune microenvironment from his bladder biopsy reveals a tumor mutational burden of 11.0. Based on these parameters, what is the likelihood that he will respond positively to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic evaluation of the tumor microenvironment. Your analysis should quantify gene expression changes with a specific focus on identifying potential impairments in natural killer cell functionality and detecting exhaustion markers within T cells, B cells, and plasma cells. Once you have completed the analysis, prepare a comprehensive report that details your findings and discusses their potential implications for future therapeutic approaches.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b15ac6-ar-b15ac6e.pkl. "
BLCA,4.0,,excluded,NR,"For my Caucasian patient diagnosed with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy has been performed, and the tumor mutational burden is 4.0 mutations per megabase. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my Caucasian patient diagnosed with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy has been performed, and the tumor mutational burden is 4.0 mutations per megabase. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy? Utilize the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. In your evaluation, quantify gene expression alterations with attention to identifying any impairments in natural killer cell function, as well as detecting exhaustion markers on T cells, B cells, and plasma cells. Upon completion of the analysis, compile a detailed report summarizing your findings and discussing their potential implications for future therapeutic interventions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b15ad0-ar-b15ad09.pkl. "
BLCA,,,,NR,"For my Caucasian female patient with bladder urothelial carcinoma (BLCA), a transcriptomic analysis of the tumor immune microenvironment was performed from a bladder biopsy. Given that the tumor mutation burden (TMB) is reported as nan, how likely is she to benefit from Atezolizumab therapy?","For my Caucasian female patient with bladder urothelial carcinoma (BLCA), a transcriptomic analysis of the tumor immune microenvironment was performed from a bladder biopsy. Given that the tumor mutation burden (TMB) is reported as nan, how likely is she to benefit from Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. In your analysis, quantify gene expression changes, paying special attention to any reductions in natural killer cell activity. Additionally, assess T cells, B cells, and plasma cells for markers indicative of cellular exhaustion. Once completed, please prepare a comprehensive report summarizing your findings and discussing their potential impact on future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b2e4a0-ar-b2e4a08.pkl. "
BLCA,,0.862745098,desert,R,"For my Caucasian male patient diagnosed with bladder urothelial carcinoma, we recently obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but the tumor mutational burden (TMB) is currently unavailable. Based on these findings, what is the likelihood that he will respond favorably to Atezolizumab therapy?","For my Caucasian male patient diagnosed with bladder urothelial carcinoma, we recently obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, but the tumor mutational burden (TMB) is currently unavailable. Based on these findings, what is the likelihood that he will respond favorably to Atezolizumab therapy? Please use the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. In your evaluation, quantify changes in gene expression—with particular attention to any observed decreases in natural killer cell activity. Additionally, examine T cells, B cells, and plasma cells for markers that suggest cellular exhaustion. Once your analysis is complete, compile a detailed report summarizing your findings and discussing their potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b2f1d0-ar-b2f1d0e.pkl. "
BLCA,18.0,,desert,R,"For my white male patient diagnosed with bladder urothelial carcinoma, whose tumor transcriptomic profiling of the immune microenvironment reveals a TMB of 18.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, whose tumor transcriptomic profiling of the immune microenvironment reveals a TMB of 18.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Focus on quantifying alterations in gene expression, especially any decreases in natural killer cell activity. Additionally, assess T cells, B cells, and plasma cells for markers indicative of cellular exhaustion. Once the analysis is complete, compile a comprehensive report detailing your findings and discussing their potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b3c022-ar-b3c0229.pkl. "
BLCA,19.0,,excluded,R,"For a Caucasian male with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden (TMB) of 19 and a biopsy-derived transcriptomic profile of his tumor immune microenvironment, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a Caucasian male with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden (TMB) of 19 and a biopsy-derived transcriptomic profile of his tumor immune microenvironment, what is the estimated likelihood of a positive response to Atezolizumab therapy? Using the COMPASS platform, please carry out a transcriptomic analysis of the tumor microenvironment. Your analysis should quantify changes in gene expression, with particular attention to any reductions in natural killer cell activity. Additionally, evaluate markers of cellular exhaustion in T cells, B cells, and plasma cells. After completing the study, prepare a detailed report that outlines your findings and discusses their potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b419a8-ar-b419a8f.pkl. "
BLCA,35.0,,excluded,R,"For my white male patient with bladder urothelial carcinoma (BLCA), whose tumor transcriptomic profile of the immune microenvironment shows a tumor mutational burden of 35.0, what is the likelihood that he will respond favorably to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma (BLCA), whose tumor transcriptomic profile of the immune microenvironment shows a tumor mutational burden of 35.0, what is the likelihood that he will respond favorably to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. In your study, quantify gene expression changes, focusing specifically on any observed reductions in natural killer cell activity. Additionally, assess markers of cellular exhaustion within T cells, B cells, and plasma cells. When your analysis is complete, compile a detailed report summarizing your findings and discussing their potential impact on future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b470eb-ar-b470eb8.pkl. "
BLCA,5.0,,inflamed,NR,"For a white male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 5.0 and a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 5.0 and a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. In this analysis, quantify gene expression changes and closely monitor for reductions in natural killer cell activity. Also, evaluate markers indicative of cellular exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, please compile a comprehensive report that summarizes your findings and discusses the potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b4c7a0-ar-b4c7a00.pkl. "
BLCA,5.0,0.333333333,desert,NR,"For my white male patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden is 5.0. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden is 5.0. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. In this analysis, quantify changes in gene expression, paying particular attention to any decreases in natural killer cell activity. Additionally, assess markers that indicate cellular exhaustion in T cells, B cells, and plasma cells. After completing your analysis, compile a detailed report summarizing your findings and discussing potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b8070b-ar-b8070b7.pkl. "
BLCA,16.0,3.764705882,inflamed,NR,"In a white male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 16.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the expected likelihood of a positive response to atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 16.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, what is the expected likelihood of a positive response to atezolizumab therapy? Access the COMPASS platform and conduct a transcriptomic analysis of the tumor microenvironment. Focus on measuring changes in gene expression, with particular attention to any reductions in natural killer cell activity. Additionally, evaluate markers that indicate cellular exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, please prepare a detailed report summarizing your findings and discussing how these results may influence future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b8101c-ar-b8101c5.pkl. "
BLCA,8.0,0.882352941,excluded,NR,"For my older male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden (TMB) is 8.0. Based on these findings, what is the probability of a favorable response to Atezolizumab therapy?","For my older male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden (TMB) is 8.0. Based on these findings, what is the probability of a favorable response to Atezolizumab therapy? Please log into the COMPASS platform and perform a transcriptomic analysis of the tumor microenvironment. Focus on assessing changes in gene expression, particularly any decrease in natural killer cell activity. In addition, evaluate markers that indicate cellular exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, compile a detailed report summarizing your findings and discussing their potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-b963dd-ar-b963dda.pkl. "
BLCA,5.0,0.901960784,inflamed,NR,"For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 5.0, and in whom transcriptomic profiling of the immune microenvironment was performed on a bladder biopsy, what is the anticipated likelihood of a positive response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma who has a tumor mutational burden of 5.0, and in whom transcriptomic profiling of the immune microenvironment was performed on a bladder biopsy, what is the anticipated likelihood of a positive response to atezolizumab therapy? Please access the COMPASS platform and perform a transcriptomic analysis of the tumor microenvironment. In your evaluation, primarily examine alterations in gene expression with particular attention to any reduction in natural killer cell activity. Additionally, assess markers indicative of cellular exhaustion in T cells, B cells, and plasma cells. After completing the analysis, please prepare a comprehensive report detailing your findings and discussing the potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ba1a34-ar-ba1a34b.pkl. "
BLCA,5.0,,excluded,NR,"For my Caucasian female patient with bladder urothelial carcinoma, who has a tumor mutational burden of 5.0 and for whom we obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, what is the expected likelihood of a favorable response to Atezolizumab therapy?","For my Caucasian female patient with bladder urothelial carcinoma, who has a tumor mutational burden of 5.0 and for whom we obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, what is the expected likelihood of a favorable response to Atezolizumab therapy? Please log into the COMPASS platform and conduct a transcriptomic analysis of the tumor microenvironment. Focus your examination on identifying changes in gene expression, emphasizing any observed decreases in natural killer cell activity. Additionally, evaluate the presence of exhaustion markers in T cells, B cells, and plasma cells. Once your analysis is complete, compile a comprehensive report that outlines your findings and discusses their potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ba7176-ar-ba7176a.pkl. "
BLCA,7.0,0.745098039,desert,NR,"For a white female patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile shows a TMB of 7.0, what is the anticipated likelihood of a positive therapeutic response to Atezolizumab treatment?","For a white female patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile shows a TMB of 7.0, what is the anticipated likelihood of a positive therapeutic response to Atezolizumab treatment? Please access the COMPASS platform and perform a transcriptomic analysis of the tumor microenvironment. Your evaluation should focus on identifying gene expression alterations, with particular attention to any decreases in natural killer cell activity. Additionally, please assess the expression of exhaustion markers in T cells, B cells, and plasma cells. Once completed, compile a detailed report outlining your findings and discussing their potential relevance to future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bc8dc3-ar-bc8dc3a.pkl. "
BLCA,,,excluded,NR,"For a Caucasian male patient with bladder urothelial carcinoma, whose biopsy-derived transcriptomic profiling of the tumor immune microenvironment shows a TMB reported as ""nan,"" how likely is he to respond positively to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, whose biopsy-derived transcriptomic profiling of the tumor immune microenvironment shows a TMB reported as ""nan,"" how likely is he to respond positively to Atezolizumab therapy? Please log into the COMPASS platform and conduct a transcriptomic analysis focusing on the tumor microenvironment. Your analysis should identify gene expression changes, with particular emphasis on assessing any reduction in natural killer cell activity. Additionally, evaluate the levels of exhaustion markers in T cells, B cells, and plasma cells. Once your analysis is complete, prepare a detailed report that summarizes your findings and discusses the potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bcb07b-ar-bcb07ba.pkl. "
BLCA,9.0,,desert,NR,"For my white male patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 9.0 and whose tumor immune microenvironment transcriptomic profile was obtained from a bladder biopsy, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden (TMB) of 9.0 and whose tumor immune microenvironment transcriptomic profile was obtained from a bladder biopsy, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS platform and perform a transcriptomic analysis with a focus on the tumor microenvironment. In your assessment, identify alterations in gene expression, particularly those that might indicate decreased natural killer cell activity. Additionally, evaluate the levels of exhaustion markers on T cells, B cells, and plasma cells. Once the analysis is complete, compile a comprehensive report outlining your findings and discussing their potential implications for future treatment approaches.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bcbc79-ar-bcbc795.pkl. "
BLCA,20.0,1.254901961,inflamed,NR,"For a Caucasian female patient diagnosed with bladder urothelial carcinoma, whose tumor mutational burden is 20.0 and whose bladder biopsy reveals a transcriptomic profile of the tumor immune microenvironment, what is the predicted likelihood of a positive response to Atezolizumab therapy?","For a Caucasian female patient diagnosed with bladder urothelial carcinoma, whose tumor mutational burden is 20.0 and whose bladder biopsy reveals a transcriptomic profile of the tumor immune microenvironment, what is the predicted likelihood of a positive response to Atezolizumab therapy? Please log into the COMPASS platform and conduct a transcriptomic analysis concentrating on the tumor microenvironment. Your evaluation should aim to detect changes in gene expression that could suggest reduced natural killer cell function. In addition, assess the expression of exhaustion markers on T cells, B cells, and plasma cells. When your analysis is complete, prepare a detailed report that summarizes your findings and discusses how these results might influence future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bda79f-ar-bda79f9.pkl. "
BLCA,10.0,0.784313725,excluded,NR,"In a Caucasian female patient with bladder urothelial carcinoma, whose lymph node biopsy provided a transcriptomic profile of the tumor immune microenvironment and who exhibits a tumor mutational burden of 10.0, what is the likelihood of a favorable response to atezolizumab therapy?","In a Caucasian female patient with bladder urothelial carcinoma, whose lymph node biopsy provided a transcriptomic profile of the tumor immune microenvironment and who exhibits a tumor mutational burden of 10.0, what is the likelihood of a favorable response to atezolizumab therapy? Please access the COMPASS platform and perform a transcriptomic analysis of the tumor microenvironment. In this analysis, focus on detecting gene expression changes that could indicate impaired natural killer cell function, and assess the levels of exhaustion markers on T cells, B cells, and plasma cells. Once you have completed the analysis, compile a detailed report that outlines your findings and explains how these results might inform potential changes to future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-be83ea-ar-be83eae.pkl. "
BLCA,35.0,3.745098039,excluded,R,"In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden of 35. How would you estimate the likelihood of a favorable response to Atezolizumab therapy in this context?","In a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment reveals a tumor mutational burden of 35. How would you estimate the likelihood of a favorable response to Atezolizumab therapy in this context? Please log into the COMPASS platform and conduct a transcriptomic evaluation of the tumor microenvironment. In your analysis, prioritize the identification of gene expression alterations that may reflect compromised natural killer cell activity. Additionally, evaluate the expression of exhaustion markers on T cells, B cells, and plasma cells. Once the analysis is complete, prepare a comprehensive report detailing your findings and discussing the potential implications for future treatment approaches.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bf1a3a-ar-bf1a3ae.pkl. "
BLCA,6.0,1.450980392,excluded,NR,"For a Caucasian female patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden (TMB) of 6.0, based on the transcriptomic analysis of the tumor immune microenvironment from her bladder biopsy, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For a Caucasian female patient with bladder urothelial carcinoma (BLCA) and a tumor mutational burden (TMB) of 6.0, based on the transcriptomic analysis of the tumor immune microenvironment from her bladder biopsy, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Please access the COMPASS platform and perform a transcriptomic analysis of the tumor microenvironment. Focus on detecting gene expression changes that could suggest reduced natural killer cell activity. In addition, evaluate the expression levels of exhaustion markers on T cells, B cells, and plasma cells. After completing the analysis, compile a detailed report that outlines your findings and discusses their potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-bfdffb-ar-bfdffb9.pkl. "
BLCA,3.0,0.294117647,desert,NR,"For my white female patient diagnosed with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and her tumor mutational burden is 3.0. Based on these parameters, how likely is she to respond favorably to Atezolizumab therapy?","For my white female patient diagnosed with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and her tumor mutational burden is 3.0. Based on these parameters, how likely is she to respond favorably to Atezolizumab therapy? Please log into the COMPASS platform and conduct a transcriptomic analysis of the tumor microenvironment. Your primary objective is to identify gene expression alterations that may indicate decreased natural killer (NK) cell activity. Additionally, assess the expression of exhaustion markers on T cells, B cells, and plasma cells. Upon completing the analysis, prepare a comprehensive report that details your findings and explores their potential impact on future treatment approaches.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c0d625-ar-c0d625a.pkl. "
BLCA,5.0,1.176470588,desert,NR,"For my White patient diagnosed with bladder urothelial carcinoma, the transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden of 5.0. Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy?","For my White patient diagnosed with bladder urothelial carcinoma, the transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy indicates a tumor mutational burden of 5.0. Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS platform and carry out a transcriptomic analysis of the tumor microenvironment. Focus primarily on identifying gene expression changes that may suggest reduced natural killer (NK) cell activity. In addition, evaluate the levels of exhaustion markers on T cells, B cells, and plasma cells. Once the analysis is complete, compile a detailed report outlining your findings and discussing their potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c0da5d-ar-c0da5d4.pkl. "
BLCA,5.0,0.960784314,desert,NR,"For a white male patient diagnosed with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment obtained via a nano-biopsy revealed a TMB of 5.0. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment obtained via a nano-biopsy revealed a TMB of 5.0. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please log in to the COMPASS platform and perform a transcriptomic analysis of the tumor microenvironment. Concentrate on detecting changes in gene expression that may indicate decreased natural killer (NK) cell activity. Additionally, assess the presence of exhaustion markers on T cells, B cells, and plasma cells. After completing the analysis, prepare a comprehensive report summarizing your findings and evaluating their possible implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c0ef41-ar-c0ef41a.pkl. "
BLCA,5.0,1.098039216,excluded,R,"For a white male patient with bladder urothelial carcinoma, we have a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, and the tumor mutation burden is 5.0. Based on these findings, what is the expected likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, we have a transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy, and the tumor mutation burden is 5.0. Based on these findings, what is the expected likelihood of a favorable response to Atezolizumab therapy? Please access the COMPASS platform and carry out a transcriptomic analysis of the tumor microenvironment. Focus on identifying gene expression changes that could signal reduced natural killer (NK) cell activity, and evaluate the presence of exhaustion markers in T cells, B cells, and plasma cells. Once your analysis is complete, prepare a comprehensive report detailing your findings and discussing their potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c1251c-ar-c1251c7.pkl. "
BLCA,5.0,1.411764706,excluded,R,"For my Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and the tumor exhibits a TMB of 5.0 mutations per megabase. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and the tumor exhibits a TMB of 5.0 mutations per megabase. Based on these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please log into the COMPASS platform and conduct a transcriptomic evaluation of the tumor microenvironment. Your primary focus should be on detecting gene expression changes that might indicate reduced natural killer (NK) cell activity. Additionally, assess exhaustion markers in T cells, B cells, and plasma cells. Once the analysis is complete, please compile a detailed report outlining your results and discussing their potential implications for future treatment options.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c1b27b-ar-c1b27bc.pkl. "
BLCA,,,excluded,R,"For my Caucasian male patient with confirmed bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden is reported as ""nan."" Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For my Caucasian male patient with confirmed bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden is reported as ""nan."" Based on these findings, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS platform and perform a transcriptomic analysis of the tumor microenvironment. Focus on identifying gene expression changes that may indicate a reduction in natural killer (NK) cell functionality. Additionally, evaluate markers of exhaustion in T cells, B cells, and plasma cells. Once you have completed your analysis, prepare a detailed report summarizing the findings and discussing their potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c2a182-ar-c2a1820.pkl. "
BLCA,3.0,0.196078431,desert,NR,"For a patient with bladder urothelial carcinoma who has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a TMB of 3.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For a patient with bladder urothelial carcinoma who has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a TMB of 3.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please log into the COMPASS platform and perform a transcriptomic analysis of the tumor microenvironment. Concentrate on detecting gene expression changes that could signal diminished functionality in natural killer cells. Additionally, assess exhaustion markers in T cells, B cells, and plasma cells. Once your analysis is complete, compile a comprehensive report that summarizes your findings and discusses their potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c57ead-ar-c57eadb.pkl. "
BLCA,10.0,,desert,NR,"For a white male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 10.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a ureter biopsy, what is the likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 10.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a ureter biopsy, what is the likelihood of a favorable response to Atezolizumab therapy? Please access the COMPASS platform to conduct a transcriptomic profiling of the tumor microenvironment. Focus specifically on identifying gene expression alterations that may suggest reduced activity of natural killer cells. In addition, evaluate the presence of exhaustion markers in T cells, B cells, and plasma cells. Once the analysis is complete, please prepare a detailed report summarizing your findings and discussing how they might influence future treatment approaches.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c69253-ar-c692536.pkl. "
BLCA,3.0,0.450980392,excluded,NR,"In a Caucasian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment profile was obtained from a lymph node biopsy and who has a tumor mutational burden of 3.0, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","In a Caucasian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment profile was obtained from a lymph node biopsy and who has a tumor mutational burden of 3.0, what is the anticipated likelihood of a favorable response to Atezolizumab therapy? Please log into the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Your primary objective is to identify gene expression changes that could indicate diminished activity among natural killer cells. Additionally, assess the presence of exhaustion markers in T cells, B cells, and plasma cells. Once your analysis is complete, compile a detailed report summarizing your findings and discussing their potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c6eff0-ar-c6eff05.pkl. "
BLCA,3.0,0.607843137,inflamed,R,"In a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment reveals a tumor mutational burden of 3.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment reveals a tumor mutational burden of 3.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Please access the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. Your main goal is to detect gene expression changes that might indicate reduced activity of natural killer cells. In addition, please evaluate the levels of exhaustion markers in T cells, B cells, and plasma cells. After completing the analysis, prepare a detailed report that summarizes your findings and explores their potential implications for future therapeutic strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-c919ae-ar-c919aeb.pkl. "
BLCA,11.0,1.352941176,inflamed,NR,"For my African American female patient diagnosed with bladder urothelial carcinoma, where transcriptomic profiling of the tumor immune microenvironment from a lung biopsy reveals a tumor mutation burden of 11.0, what is the anticipated likelihood of a positive response to atezolizumab therapy?","For my African American female patient diagnosed with bladder urothelial carcinoma, where transcriptomic profiling of the tumor immune microenvironment from a lung biopsy reveals a tumor mutation burden of 11.0, what is the anticipated likelihood of a positive response to atezolizumab therapy? Please log in to the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Your primary objective is to identify gene expression changes that may indicate reduced natural killer cell activity. Additionally, evaluate the expression of exhaustion markers on T cells, B cells, and plasma cells. Once the analysis is complete, prepare a comprehensive report that summarizes your findings and discusses their potential relevance to future therapeutic approaches.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cabb6d-ar-cabb6d5.pkl. "
BLCA,,0.843137255,desert,NR,"For a white male patient with bladder urothelial carcinoma, whose lymph node biopsy transcriptomic profiling of the tumor immune microenvironment has been performed and whose tumor mutational burden is reported as ""nan,"" what is the anticipated likelihood of a positive response to atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, whose lymph node biopsy transcriptomic profiling of the tumor immune microenvironment has been performed and whose tumor mutational burden is reported as ""nan,"" what is the anticipated likelihood of a positive response to atezolizumab therapy? Access the COMPASS platform and conduct a transcriptomic analysis of the tumor microenvironment. Your main goal is to detect gene expression patterns that could indicate diminished natural killer cell activity. At the same time, evaluate the expression of exhaustion markers on T cells, B cells, and plasma cells. Once you have completed the analysis, prepare a detailed report summarizing your findings and discussing how they might influence future therapeutic strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cb132b-ar-cb132b0.pkl. "
BLCA,,,,NR,"In a white male patient with bladder urothelial carcinoma who underwent a liver biopsy for transcriptomic profiling of the tumor immune microenvironment, the tumor mutation burden is reported as ""nan."" Given these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma who underwent a liver biopsy for transcriptomic profiling of the tumor immune microenvironment, the tumor mutation burden is reported as ""nan."" Given these findings, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please log in to the COMPASS platform and perform a transcriptomic analysis of the tumor microenvironment. Your primary objective is to identify gene expression signatures that may reflect reduced natural killer cell activity. Additionally, evaluate the presence of exhaustion markers on T cells, B cells, and plasma cells. Once the analysis is complete, prepare a comprehensive report detailing your findings and discussing the potential implications for future therapeutic strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cc4675-ar-cc4675f.pkl. "
BLCA,26.0,4.960784314,inflamed,R,"For a Caucasian female patient with bladder urothelial carcinoma, whose ureter biopsy transcriptomic profile of the tumor immune microenvironment shows a tumor mutational burden (TMB) of 26.0 mutations per megabase, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a Caucasian female patient with bladder urothelial carcinoma, whose ureter biopsy transcriptomic profile of the tumor immune microenvironment shows a tumor mutational burden (TMB) of 26.0 mutations per megabase, what is the expected likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS platform and conduct a transcriptomic analysis of the tumor microenvironment. Your goal is to detect gene expression patterns that may indicate diminished natural killer cell activity and to assess the expression of exhaustion markers in T cells, B cells, and plasma cells. After completing the analysis, compile a thorough report that summarizes your findings and discusses the potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cc7a42-ar-cc7a42d.pkl. "
BLCA,14.0,0.843137255,inflamed,NR,"For my Caucasian patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment shows a tumor mutational burden of 14.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For my Caucasian patient with bladder urothelial carcinoma, whose bladder biopsy transcriptomic profile of the tumor immune microenvironment shows a tumor mutational burden of 14.0, what is the likelihood of a favorable response to Atezolizumab therapy? Please log into the COMPASS platform and perform a transcriptomic analysis of the tumor microenvironment. Specifically, evaluate gene expression patterns that could suggest reduced natural killer cell activity, and assess markers indicative of exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, prepare a detailed report summarizing your findings and discussing their potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ce39dd-ar-ce39dd7.pkl. "
BLCA,,,excluded,NR,"For a white male patient with bladder urothelial carcinoma, where transcriptomic analysis of the tumor immune microenvironment was performed on a lung biopsy and the reported tumor mutational burden (TMB) is unavailable (nan), what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma, where transcriptomic analysis of the tumor immune microenvironment was performed on a lung biopsy and the reported tumor mutational burden (TMB) is unavailable (nan), what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS platform and conduct a transcriptomic analysis of the tumor microenvironment. Focus specifically on identifying gene expression profiles that might indicate diminished natural killer cell activity, and evaluate markers related to exhaustion in T cells, B cells, and plasma cells. After completing the analysis, compile a detailed report outlining your results and discussing how these findings could influence future treatment decisions.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-cf018f-ar-cf018fe.pkl. "
BLCA,4.0,0.764705882,desert,R,"In a white female patient with bladder urothelial carcinoma who underwent ureter biopsy for transcriptomic profiling of the tumor immune microenvironment and has a tumor mutational burden of 4.0, what is the expected likelihood of a favorable response to Atezolizumab therapy?","In a white female patient with bladder urothelial carcinoma who underwent ureter biopsy for transcriptomic profiling of the tumor immune microenvironment and has a tumor mutational burden of 4.0, what is the expected likelihood of a favorable response to Atezolizumab therapy? Access the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Specifically, assess gene expression profiles for indicators of reduced natural killer cell functionality and examine markers of exhaustion in T cells, B cells, and plasma cells. Once your analysis is complete, prepare a comprehensive report detailing your findings and discussing their potential impact on guiding future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d02712-ar-d027124.pkl. "
BLCA,3.0,0.607843137,excluded,NR,"For a Caucasian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was profiled via transcriptomics from a bladder biopsy and who exhibits a TMB of 3.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was profiled via transcriptomics from a bladder biopsy and who exhibits a TMB of 3.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please log into the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Your evaluation should focus on gene expression profiles that indicate impaired function in natural killer cells, as well as markers of cellular exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, compile a detailed report summarizing your findings and discussing how these results might influence future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d135d5-ar-d135d58.pkl. "
BLCA,22.0,,,NR,"For a white male patient diagnosed with bladder urothelial carcinoma who has a tumor mutation burden of 22.0 and whose tumor immune microenvironment transcriptomic profile was obtained from a bladder biopsy, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma who has a tumor mutation burden of 22.0 and whose tumor immune microenvironment transcriptomic profile was obtained from a bladder biopsy, what is the expected likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. Focus your evaluation on gene expression profiles that may indicate dysfunction in natural killer cells, as well as markers of cellular exhaustion in T cells, B cells, and plasma cells. Once your analysis is complete, please prepare a detailed report summarizing your findings and discussing the potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d1bd63-ar-d1bd637.pkl. "
BLCA,,,,NR,"For a Caucasian male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment was obtained from a bladder biopsy, and the tumor mutation burden (TMB) was reported as nan. Based on these findings, how likely is the patient to respond favorably to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, a transcriptomic analysis of the tumor immune microenvironment was obtained from a bladder biopsy, and the tumor mutation burden (TMB) was reported as nan. Based on these findings, how likely is the patient to respond favorably to Atezolizumab therapy? Please log on to the COMPASS platform and perform a transcriptomic analysis of the tumor microenvironment. In your evaluation, emphasize examining gene expression profiles that could signal altered functionality in natural killer cells, along with indicators of exhaustion in T cells, B cells, and plasma cells. When your analysis is complete, compile a detailed report summarizing your findings and discussing the potential implications these results might have on future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d215b5-ar-d215b50.pkl. "
BLCA,3.0,0.490196078,desert,NR,"For a white female patient with bladder urothelial carcinoma, who has a tumor immune microenvironment transcriptomic profile obtained from a lymph node biopsy and a tumor mutational burden of 3.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma, who has a tumor immune microenvironment transcriptomic profile obtained from a lymph node biopsy and a tumor mutational burden of 3.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? Access the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. Please focus on identifying gene expression patterns that may indicate altered functionality of natural killer cells as well as signs of exhaustion in T cells, B cells, and plasma cells. Upon completion, prepare a comprehensive report outlining your findings and discussing the potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d2492b-ar-d2492b2.pkl. "
BLCA,62.0,10.01960784,excluded,R,"For a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 62.0, based on transcriptomic profiling of the tumor immune microenvironment obtained from a kidney biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) who has a tumor mutation burden of 62.0, based on transcriptomic profiling of the tumor immune microenvironment obtained from a kidney biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please log in to the COMPASS platform and perform a transcriptomic analysis of the tumor microenvironment. Specifically, focus on examining gene expression patterns that may indicate altered functionality of natural killer cells, as well as evidence of exhaustion in T cells, B cells, and plasma cells. Once your analysis is complete, prepare a detailed report outlining your findings and discussing the potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d35318-ar-d353181.pkl. "
BLCA,14.0,0.784313725,excluded,R,"In a patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0 and a detailed transcriptomic profile of the tumor immune microenvironment from a recent biopsy, what is the anticipated likelihood of a positive response to atezolizumab therapy?","In a patient with bladder urothelial carcinoma who has a tumor mutational burden of 14.0 and a detailed transcriptomic profile of the tumor immune microenvironment from a recent biopsy, what is the anticipated likelihood of a positive response to atezolizumab therapy? Please access the COMPASS platform and conduct a transcriptomic profiling of the tumor microenvironment. Your analysis should specifically evaluate gene expression patterns that might reveal functional alterations in natural killer cells and signs of exhaustion in T cells, B cells, and plasma cells. Following the analysis, prepare a comprehensive report detailing your findings and discussing how these observations could inform future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d36012-ar-d360128.pkl. "
BLCA,7.0,1.568627451,excluded,R,"For our white male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 7.0 and transcriptomic data from a lymph node biopsy outlining the tumor immune microenvironment, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For our white male patient with bladder urothelial carcinoma, who has a tumor mutational burden of 7.0 and transcriptomic data from a lymph node biopsy outlining the tumor immune microenvironment, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please log into the COMPASS platform and perform a transcriptomic analysis of the tumor microenvironment. Focus your evaluation on gene expression profiles that may indicate functional alterations in natural killer cells, as well as markers of exhaustion in T cells, B cells, and plasma cells. After completing the analysis, compile a detailed report outlining your findings and discussing their potential implications for future treatment approaches.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d3bd67-ar-d3bd679.pkl. "
BLCA,15.0,1.882352941,inflamed,R,"For our patient with bladder urothelial carcinoma, who has a tumor mutational burden of 15.0 and transcriptomic data of the tumor immune microenvironment from a bladder biopsy, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For our patient with bladder urothelial carcinoma, who has a tumor mutational burden of 15.0 and transcriptomic data of the tumor immune microenvironment from a bladder biopsy, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Please log into the COMPASS platform and carry out a transcriptomic analysis of the tumor microenvironment. Concentrate on assessing gene expression profiles that could signal changes in the functionality of natural killer cells, as well as the presence of exhaustion markers in T cells, B cells, and plasma cells. After completing your analysis, compile a comprehensive report detailing your findings and their potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d43f89-ar-d43f893.pkl. "
BLCA,5.0,0.529411765,excluded,NR,"For my white male patient diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden of 5.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the probability that he will respond positively to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden of 5.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a kidney biopsy, what is the probability that he will respond positively to Atezolizumab therapy? Please sign into the COMPASS platform and perform a transcriptomic analysis of the tumor microenvironment. Focus on examining gene expression profiles that may indicate altered natural killer cell functionality and the presence of exhaustion markers in T cells, B cells, and plasma cells. Once your analysis is complete, prepare a detailed report outlining your findings and discussing their potential impact on future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d4c083-ar-d4c0837.pkl. "
BLCA,,0.196078431,inflamed,NR,"For our Caucasian patient diagnosed with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutational burden (TMB) is reported as not available. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy?","For our Caucasian patient diagnosed with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutational burden (TMB) is reported as not available. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy? Kindly log into the COMPASS platform to carry out a transcriptomic evaluation of the tumor microenvironment. Concentrate on analyzing gene expression patterns that could reflect modifications in natural killer cell activity and the expression of exhaustion markers in T cells, B cells, and plasma cells. After completing your analysis, compile a comprehensive report detailing your results and their potential implications for emerging treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d636e3-ar-d636e34.pkl. "
BLCA,,,excluded,NR,"For a White female patient with bladder urothelial carcinoma who underwent a ureter biopsy for transcriptomic profiling of the tumor immune microenvironment, and with an unavailable tumor mutational burden, what is the estimated likelihood of a positive response to atezolizumab therapy?","For a White female patient with bladder urothelial carcinoma who underwent a ureter biopsy for transcriptomic profiling of the tumor immune microenvironment, and with an unavailable tumor mutational burden, what is the estimated likelihood of a positive response to atezolizumab therapy? Please log in to the COMPASS platform to perform a transcriptomic assessment of the tumor microenvironment. Focus on examining gene expression profiles that may indicate alterations in natural killer cell function, as well as the presence of exhaustion markers in T cells, B cells, and plasma cells. After completing your analysis, please prepare a detailed report summarizing your findings and discussing their potential implications for emerging treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d697ba-ar-d697ba7.pkl. "
BLCA,24.0,,inflamed,R,"In a white male patient with bladder urothelial carcinoma (BLCA) who has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden (TMB) of 24.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","In a white male patient with bladder urothelial carcinoma (BLCA) who has a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden (TMB) of 24.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please access the COMPASS platform to conduct a transcriptomic evaluation of the tumor microenvironment. Focus your analysis on gene expression trends that might indicate altered natural killer cell functions and identify any signs of exhaustion in T cells, B cells, and plasma cells. Once your analysis is complete, compile a detailed report outlining your findings and discussing their potential impact on emerging treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d7d57e-ar-d7d57ee.pkl. "
BLCA,,1.411764706,desert,NR,"For my Caucasian patient with bladder urothelial carcinoma, who underwent transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy and has an unavailable tumor mutational burden, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For my Caucasian patient with bladder urothelial carcinoma, who underwent transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy and has an unavailable tumor mutational burden, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. In doing so, concentrate on identifying gene expression patterns that suggest potential dysfunction in natural killer cell activity, as well as indicators of exhaustion in T cells, B cells, and plasma cells. Once your analysis is complete, prepare a comprehensive report summarizing your findings and discussing their implications for new treatment approaches.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d86389-ar-d86389d.pkl. "
BLCA,8.0,0.725490196,desert,NR,"For my white male patient diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden of 8.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a ureter biopsy, what is the expected likelihood of a positive response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, who has a tumor mutational burden of 8.0 and a transcriptomic profile of the tumor immune microenvironment obtained from a ureter biopsy, what is the expected likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Focus specifically on detecting gene expression patterns that may indicate impaired natural killer cell function and signs of exhaustion in T cells, B cells, and plasma cells. Once your analysis is complete, compile a detailed report summarizing your findings and discussing how these results could inform potential new treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-d98bac-ar-d98bac0.pkl. "
BLCA,4.0,0.274509804,,NR,"In this Caucasian male patient with bladder urothelial carcinoma, where the transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy reveals a tumor mutational burden (TMB) of 4.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","In this Caucasian male patient with bladder urothelial carcinoma, where the transcriptomic profiling of the tumor immune microenvironment from a kidney biopsy reveals a tumor mutational burden (TMB) of 4.0, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. In your analysis, concentrate on identifying gene expression patterns that suggest reduced natural killer cell activity and markers of exhaustion in T cells, B cells, and plasma cells. Once you have completed your analysis, prepare a comprehensive report summarizing your findings and discussing how these results could potentially guide new treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-da4d89-ar-da4d892.pkl. "
BLCA,14.0,2.921568627,excluded,NR,"For a Caucasian male diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutational burden of 14.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a Caucasian male diagnosed with bladder urothelial carcinoma, whose bladder biopsy transcriptomic analysis of the tumor immune microenvironment shows a tumor mutational burden of 14.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis focused on the tumor microenvironment. In your study, emphasize the identification of gene expression patterns that indicate diminished activity of natural killer cells as well as signs of exhaustion in T cells, B cells, and plasma cells. After completing the analysis, prepare a detailed report that summarizes your findings and discusses the potential implications for developing new treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-dab9ca-ar-dab9ca8.pkl. "
BLCA,5.0,0.666666667,excluded,NR,"For my Caucasian male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy has been completed, and the tumor mutational burden is 5.0. Based on these parameters, what is the estimated likelihood that the patient will respond favorably to atezolizumab therapy?","For my Caucasian male patient diagnosed with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy has been completed, and the tumor mutational burden is 5.0. Based on these parameters, what is the estimated likelihood that the patient will respond favorably to atezolizumab therapy? Please utilize the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. In your analysis, focus on identifying gene expression profiles that signal reduced activity in natural killer cells and evidence of exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, compile a detailed report summarizing your findings and discussing their potential implications for developing new treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-dad5c2-ar-dad5c29.pkl. "
BLCA,10.0,0.509803922,excluded,NR,"For my white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment has been profiled from a bladder biopsy and who has a tumor mutational burden of 10.0, what is the likelihood of a favorable response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment has been profiled from a bladder biopsy and who has a tumor mutational burden of 10.0, what is the likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Your analysis should specifically target the identification of gene expression patterns that may indicate diminished activity in natural killer cells, as well as signs of exhaustion in T cells, B cells, and plasma cells. After completing your analysis, compile a detailed report that summarizes your findings and examines their potential implications for new treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-db3f50-ar-db3f50c.pkl. "
BLCA,,1.431372549,excluded,NR,"For my Caucasian patient with bladder urothelial carcinoma (BLCA), a transcriptomic analysis of the tumor immune microenvironment was performed on tissue obtained via kidney biopsy. Given that the tumor mutation burden (TMB) is reported as 'nan', how should we interpret this result in terms of predicting a positive response to Atezolizumab therapy?","For my Caucasian patient with bladder urothelial carcinoma (BLCA), a transcriptomic analysis of the tumor immune microenvironment was performed on tissue obtained via kidney biopsy. Given that the tumor mutation burden (TMB) is reported as 'nan', how should we interpret this result in terms of predicting a positive response to Atezolizumab therapy? Please use the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. Focus your investigation on detecting gene expression patterns that suggest reduced activity in natural killer cells and signs of exhaustion in T cells, B cells, and plasma cells. After completing the analysis, prepare a comprehensive report that details your findings and discusses their potential implications for developing new treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-dcae54-ar-dcae54f.pkl. "
BLCA,,,,NR,"For a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has undergone transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy and for whom the tumor mutation burden (TMB) is not available, what is the likelihood of a favorable response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma (BLCA) who has undergone transcriptomic profiling of the tumor immune microenvironment from a lymph node biopsy and for whom the tumor mutation burden (TMB) is not available, what is the likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Focus on assessing gene expression profiles that may indicate diminished activity of natural killer cells, along with signs of exhaustion in T cells, B cells, and plasma cells. Once your analysis is complete, compile a detailed report describing your findings and their potential impact on future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-dee101-ar-dee1011.pkl. "
BLCA,19.0,3.235294118,inflamed,NR,"For a Caucasian male patient diagnosed with bladder urothelial carcinoma, whose tumor biopsy transcriptomic profile of the immune microenvironment shows a tumor mutational burden of 19.0, how likely is a favorable response to Atezolizumab therapy?","For a Caucasian male patient diagnosed with bladder urothelial carcinoma, whose tumor biopsy transcriptomic profile of the immune microenvironment shows a tumor mutational burden of 19.0, how likely is a favorable response to Atezolizumab therapy? Utilize the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. Specifically, evaluate gene expression profiles to identify evidence of reduced natural killer cell activity, as well as markers of exhaustion in T cells, B cells, and plasma cells. After completing your analysis, prepare a comprehensive report summarizing your findings and discussing their potential implications for future treatment approaches.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-df3e42-ar-df3e42c.pkl. "
BLCA,5.0,0.549019608,desert,NR,"For a patient with bladder urothelial carcinoma whose tumor biopsy yielded a transcriptomic profile of the immune microenvironment and a tumor mutational burden of 5.0 mutations/Mb, what is the anticipated likelihood of responding favorably to atezolizumab therapy?","For a patient with bladder urothelial carcinoma whose tumor biopsy yielded a transcriptomic profile of the immune microenvironment and a tumor mutational burden of 5.0 mutations/Mb, what is the anticipated likelihood of responding favorably to atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. In this analysis, assess the gene expression profiles with a focus on detecting signs of diminished natural killer cell activity and identifying markers indicative of T cell, B cell, and plasma cell exhaustion. Once the analysis is complete, compile a detailed report outlining your findings along with a discussion of their potential implications for future therapeutic strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e07c45-ar-e07c456.pkl. "
BLCA,2.0,,excluded,NR,"For my Caucasian female patient with bladder urothelial carcinoma, a bladder biopsy provided a transcriptomic profile of the tumor immune microenvironment and revealed a tumor mutational burden of 2.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy?","For my Caucasian female patient with bladder urothelial carcinoma, a bladder biopsy provided a transcriptomic profile of the tumor immune microenvironment and revealed a tumor mutational burden of 2.0. Based on these findings, what is the likelihood of a favorable response to Atezolizumab therapy? Please utilize the COMPASS platform to conduct a transcriptomic evaluation of the tumor microenvironment. In this evaluation, analyze gene expression profiles to detect reduced activity in natural killer cells and identify exhaustion markers in T cells, B cells, and plasma cells. After completing the analysis, prepare a comprehensive report that details your findings and discusses the potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e0c49e-ar-e0c49ea.pkl. "
BLCA,14.0,2.274509804,inflamed,R,"For a white male patient with bladder urothelial carcinoma whose tumor biopsy transcriptomic profile of the immune microenvironment shows a tumor mutational burden of 14.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma whose tumor biopsy transcriptomic profile of the immune microenvironment shows a tumor mutational burden of 14.0, what is the estimated likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. Focus on evaluating gene expression profiles to assess for diminished activity in natural killer cells and the presence of exhaustion markers in T cells, B cells, and plasma cells. Once the analysis is complete, prepare a detailed report summarizing your findings and discussing their potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e1eb5d-ar-e1eb5d9.pkl. "
BLCA,17.0,0.862745098,inflamed,NR,"For a white female patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 17.0 and a transcriptomic profile of the tumor immune microenvironment obtained via nano-biopsy, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a white female patient diagnosed with bladder urothelial carcinoma (BLCA) who has a tumor mutational burden of 17.0 and a transcriptomic profile of the tumor immune microenvironment obtained via nano-biopsy, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Specifically, assess gene expression profiles to determine if there is reduced activity in natural killer cells and if exhaustion markers are present in T cells, B cells, and plasma cells. Once the analysis is complete, prepare a detailed report summarizing your findings and their potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e3210d-ar-e3210d3.pkl. "
BLCA,,,,NR,"For my white male patient with bladder urothelial carcinoma who has undergone transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy and presents with an unspecified tumor mutational burden, what is the likelihood of a positive response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma who has undergone transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy and presents with an unspecified tumor mutational burden, what is the likelihood of a positive response to Atezolizumab therapy? Please perform a transcriptomic analysis of the tumor microenvironment using the COMPASS platform. In this analysis, carefully evaluate the gene expression profiles to investigate whether natural killer cell activity is diminished and whether markers of cellular exhaustion are present in T cells, B cells, and plasma cells. After completing the analysis, compile a detailed report outlining your findings and discussing their potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e3d426-ar-e3d4266.pkl. "
BLCA,6.0,0.470588235,excluded,NR,"For a White male patient diagnosed with Bladder Urothelial Carcinoma (BLCA) who has a tumor mutational burden of 6.0 and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For a White male patient diagnosed with Bladder Urothelial Carcinoma (BLCA) who has a tumor mutational burden of 6.0 and transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. Focus on evaluating gene expression profiles to determine if natural killer cell activity is reduced and if markers of cellular exhaustion are present in T cells, B cells, and plasma cells. Once the analysis is complete, prepare a detailed report that summarizes your findings and discusses their potential implications for future treatment approaches.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e41b1e-ar-e41b1e7.pkl. "
BLCA,9.0,2.176470588,desert,R,"For my White female patient with bladder urothelial carcinoma, a bladder biopsy showed a tumor immune microenvironment profile and a tumor mutational burden of 9.0. Based on these findings, what is the likelihood that she will respond favorably to atezolizumab therapy?","For my White female patient with bladder urothelial carcinoma, a bladder biopsy showed a tumor immune microenvironment profile and a tumor mutational burden of 9.0. Based on these findings, what is the likelihood that she will respond favorably to atezolizumab therapy? Utilize the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. Specifically, assess gene expression to evaluate whether natural killer cell activity is diminished and to detect markers of cellular exhaustion in T cells, B cells, and plasma cells. After completing the analysis, compile a comprehensive report summarizing your findings and discussing their potential implications for future therapeutic strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e50d15-ar-e50d15f.pkl. "
BLCA,5.0,0.098039216,excluded,NR,"For my Caucasian female patient with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and the tumor mutational burden is 5.0. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy?","For my Caucasian female patient with bladder urothelial carcinoma, I have obtained a transcriptomic profile of the tumor immune microenvironment from a kidney biopsy, and the tumor mutational burden is 5.0. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Focus on evaluating gene expression to determine if natural killer cell activity is reduced and to identify signs of cellular exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, prepare a detailed report that summarizes your findings and discusses their potential impact on future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e56c96-ar-e56c96c.pkl. "
BLCA,5.0,0.274509804,excluded,NR,"For a Caucasian male patient with bladder urothelial carcinoma who underwent a liver biopsy for transcriptomic profiling of the tumor immune microenvironment and has a tumor mutational burden of 5.0, what is the expected likelihood of a favorable response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma who underwent a liver biopsy for transcriptomic profiling of the tumor immune microenvironment and has a tumor mutational burden of 5.0, what is the expected likelihood of a favorable response to Atezolizumab therapy? Use the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. Specifically, evaluate gene expression data to determine whether natural killer cell activity is diminished, and to detect evidence of cellular exhaustion among T cells, B cells, and plasma cells. After completing the analysis, please compile a comprehensive report summarizing your findings and discussing their implications for potential future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e5bc41-ar-e5bc417.pkl. "
BLCA,,,desert,R,"For a Caucasian male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutation burden is reported as 'nan'. Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutation burden is reported as 'nan'. Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. In your analysis, focus on determining whether there is a reduction in natural killer cell activity, and examine the gene expression profiles for signs of cellular exhaustion in T cells, B cells, and plasma cells. Once your analysis is complete, prepare a detailed report that summarizes your findings and discusses the potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e71235-ar-e712352.pkl. "
BLCA,,,,NR,"For my Caucasian patient with bladder urothelial carcinoma, whose kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment and whose tumor mutation burden is reported as ""nan,"" what is the likelihood of a positive response to atezolizumab therapy?","For my Caucasian patient with bladder urothelial carcinoma, whose kidney biopsy provided a transcriptomic profile of the tumor immune microenvironment and whose tumor mutation burden is reported as ""nan,"" what is the likelihood of a positive response to atezolizumab therapy? Please use the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. Focus on evaluating whether there is diminished natural killer cell activity and examine gene expression profiles for evidence of cellular exhaustion in T cells, B cells, and plasma cells. After completing your analysis, compile a comprehensive report that outlines your findings and discusses their potential impact on future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e7bcab-ar-e7bcab0.pkl. "
BLCA,7.0,1.37254902,inflamed,NR,"For my white male patient diagnosed with bladder urothelial carcinoma, with a tumor mutation burden of 7.0 and transcriptomic profiling of the tumor immune microenvironment obtained from a kidney biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For my white male patient diagnosed with bladder urothelial carcinoma, with a tumor mutation burden of 7.0 and transcriptomic profiling of the tumor immune microenvironment obtained from a kidney biopsy, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Your analysis should prioritize identifying any reduction in natural killer cell activity and assess gene expression profiles for signs of cellular exhaustion in T cells, B cells, and plasma cells. Once the analysis is complete, prepare a detailed report that presents your findings and discusses how these results might influence future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e7bf6c-ar-e7bf6c0.pkl. "
BLCA,1.0,0.196078431,inflamed,NR,"For my Caucasian male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy indicates a TMB of 1.0. Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, transcriptomic profiling of the tumor immune microenvironment from a bladder biopsy indicates a TMB of 1.0. Based on these findings, what is the expected likelihood of a positive response to Atezolizumab therapy? Utilize the COMPASS platform to carry out a transcriptomic analysis of the tumor microenvironment. Focus on detecting any decrease in the activity of natural killer cells and evaluate the gene expression profiles for indicators of exhaustion in T cells, B cells, and plasma cells. Once your analysis is complete, prepare a comprehensive report that details your findings and explores how these observations could impact future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e7e4f7-ar-e7e4f7c.pkl. "
BLCA,,,excluded,NR,"For my white male patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden is reported as ""nan."" Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden is reported as ""nan."" Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. In your assessment, specifically look for evidence of reduced activity in natural killer cells as well as signs of exhaustion in T cells, B cells, and plasma cells through their gene expression profiles. Once the analysis is complete, compile a detailed report outlining your findings and discussing their potential implications for future treatment approaches.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e9475f-ar-e9475f7.pkl. "
BLCA,6.0,1.019607843,excluded,NR,"For a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was characterized via transcriptomic profiling from a bladder biopsy and who presents with a TMB of 6.0, how likely is a positive response to Atezolizumab treatment?","For a white male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was characterized via transcriptomic profiling from a bladder biopsy and who presents with a TMB of 6.0, how likely is a positive response to Atezolizumab treatment? Please utilize the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Focus your evaluation on detecting any reduction in natural killer cell activity and examining gene expression profiles for signs of exhaustion in T cells, B cells, and plasma cells. After completing the analysis, prepare a comprehensive report that summarizes your findings and discusses the potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e94c30-ar-e94c30c.pkl. "
BLCA,3.0,0.705882353,excluded,NR,"For my Caucasian female patient diagnosed with bladder urothelial carcinoma (BLCA), the transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy reveals a tumor mutational burden (TMB) of 3.0. Could you provide an assessment of the likelihood of a positive response to Atezolizumab therapy based on these findings?","For my Caucasian female patient diagnosed with bladder urothelial carcinoma (BLCA), the transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy reveals a tumor mutational burden (TMB) of 3.0. Could you provide an assessment of the likelihood of a positive response to Atezolizumab therapy based on these findings? Please use the COMPASS platform to conduct a transcriptomic evaluation of the tumor microenvironment. Specifically, look for any reductions in natural killer cell activity and assess gene expression profiles for markers of exhaustion in T cells, B cells, and plasma cells. After completing your analysis, compile a detailed report that outlines your findings and discusses how these results might influence future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e97af0-ar-e97af0f.pkl. "
BLCA,7.0,1.333333333,desert,NR,"For a Caucasian male patient diagnosed with bladder urothelial carcinoma, a bladder biopsy revealed a tumor immune microenvironment transcriptomic profile and a tumor mutation burden of 7.0. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy?","For a Caucasian male patient diagnosed with bladder urothelial carcinoma, a bladder biopsy revealed a tumor immune microenvironment transcriptomic profile and a tumor mutation burden of 7.0. Based on these findings, what is the likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. In your evaluation, assess for any decreases in natural killer cell activity and examine gene expression profiles for exhaustion markers in T cells, B cells, and plasma cells. Once completed, prepare a detailed report outlining your findings and discussing the potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-e9ae8b-ar-e9ae8be.pkl. "
BLCA,14.0,2.764705882,inflamed,R,"For a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden of 14. Could you clarify the likelihood of a positive response to Atezolizumab therapy based on these findings?","For a white male patient with bladder urothelial carcinoma, transcriptomic analysis of the tumor immune microenvironment from a bladder biopsy revealed a tumor mutation burden of 14. Could you clarify the likelihood of a positive response to Atezolizumab therapy based on these findings? Please use the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. Focus on identifying any reductions in natural killer cell activity and evaluate the gene expression profiles of T cells, B cells, and plasma cells for markers of exhaustion. After completing your analysis, compile a comprehensive report detailing your findings and discussing the potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-eaa477-ar-eaa477a.pkl. "
BLCA,2.0,0.058823529,excluded,NR,"For a white male patient diagnosed with bladder urothelial carcinoma who underwent a kidney biopsy for transcriptomic analysis of the tumor immune microenvironment and has a tumor mutational burden of 2.0, what is the expected likelihood of a positive response to Atezolizumab therapy?","For a white male patient diagnosed with bladder urothelial carcinoma who underwent a kidney biopsy for transcriptomic analysis of the tumor immune microenvironment and has a tumor mutational burden of 2.0, what is the expected likelihood of a positive response to Atezolizumab therapy? Please perform a transcriptomic analysis of the tumor microenvironment using the COMPASS platform. In your analysis, assess whether there is a reduction in natural killer cell activity and examine the gene expression profiles of T cells, B cells, and plasma cells to identify markers of exhaustion. Once completed, compile a detailed report summarizing your findings and outlining the potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-eb2962-ar-eb29625.pkl. "
BLCA,,,,NR,"For my white male patient with bladder urothelial carcinoma, a transcriptomic profile of the tumor immune microenvironment has been obtained from a bladder biopsy. With a reported tumor mutational burden of nan, what implications might these findings have regarding the likelihood of a positive response to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, a transcriptomic profile of the tumor immune microenvironment has been obtained from a bladder biopsy. With a reported tumor mutational burden of nan, what implications might these findings have regarding the likelihood of a positive response to Atezolizumab therapy? Using the COMPASS platform, please carry out a transcriptomic analysis of the tumor microenvironment. Specifically, assess for any reduction in natural killer cell activity and evaluate the gene expression patterns of T cells, B cells, and plasma cells to identify markers of immune exhaustion. Once you have completed the analysis, compile a comprehensive report that details your findings and discusses their potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-eb587a-ar-eb587a6.pkl. "
BLCA,,,,NR,"For a white male patient with bladder urothelial carcinoma (BLCA) who has undergone transcriptomic profiling of the tumor immune microenvironment via lymph node biopsy and whose tumor mutational burden (TMB) is reported as ""nan,"" what is the estimated likelihood of a favorable response to Atezolizumab therapy?","For a white male patient with bladder urothelial carcinoma (BLCA) who has undergone transcriptomic profiling of the tumor immune microenvironment via lymph node biopsy and whose tumor mutational burden (TMB) is reported as ""nan,"" what is the estimated likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. Focus on determining whether there is a decline in natural killer cell activity and on analyzing the gene expression profiles of T cells, B cells, and plasma cells to detect signs of immune exhaustion. After you complete the analysis, prepare a detailed report that outlines your findings and discusses their potential impact on future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ee3844-ar-ee3844c.pkl. "
BLCA,1.0,0.039215686,inflamed,NR,"For my Caucasian male patient with bladder urothelial carcinoma, based on a lung biopsy that provided a transcriptomic analysis of the tumor immune microenvironment and a tumor mutation burden of 1.0, what is the likelihood of a positive response to Atezolizumab therapy?","For my Caucasian male patient with bladder urothelial carcinoma, based on a lung biopsy that provided a transcriptomic analysis of the tumor immune microenvironment and a tumor mutation burden of 1.0, what is the likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to conduct a transcriptomic analysis of the tumor microenvironment. Specifically, assess whether natural killer cell activity is reduced and examine the gene expression profiles of T cells, B cells, and plasma cells for any signs of immune exhaustion. Once you have completed your analysis, please compile a comprehensive report detailing your findings and discussing the implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ef0e3d-ar-ef0e3d2.pkl. "
BLCA,14.0,,desert,NR,"For a Caucasian patient with bladder urothelial carcinoma, a tumor mutational burden of 14.0, and available transcriptomic data from a ureter biopsy outlining the tumor immune microenvironment, what is the anticipated likelihood of a favorable response to Atezolizumab therapy?","For a Caucasian patient with bladder urothelial carcinoma, a tumor mutational burden of 14.0, and available transcriptomic data from a ureter biopsy outlining the tumor immune microenvironment, what is the anticipated likelihood of a favorable response to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. In this analysis, evaluate if there is a decrease in natural killer cell activity and review the gene expression of T cells, B cells, and plasma cells for markers of immune exhaustion. Once completed, compile a detailed report that outlines your findings and discusses the potential impact on future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-eff2ce-ar-eff2ce3.pkl. "
BLCA,14.0,1.098039216,inflamed,NR,"For my White male patient with bladder urothelial carcinoma who underwent transcriptomic profiling of the tumor immune microenvironment via a kidney biopsy and has a tumor mutational burden of 14.0, what is the likelihood of a positive response to Atezolizumab therapy?","For my White male patient with bladder urothelial carcinoma who underwent transcriptomic profiling of the tumor immune microenvironment via a kidney biopsy and has a tumor mutational burden of 14.0, what is the likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to conduct a transcriptomic evaluation of the tumor microenvironment. In this analysis, specifically assess whether natural killer cell activity is diminished. Additionally, evaluate the gene expression profiles of T cells, B cells, and plasma cells to identify markers of immune exhaustion. Once the analysis is complete, prepare a comprehensive report detailing your findings and discussing their potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f20b82-ar-f20b827.pkl. "
BLCA,9.0,,excluded,R,"For my African American patient with bladder urothelial carcinoma (BLCA), we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutational burden (TMB) is 9.0. Based on these parameters, what is the anticipated likelihood of a positive response to Atezolizumab therapy?","For my African American patient with bladder urothelial carcinoma (BLCA), we obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and the tumor mutational burden (TMB) is 9.0. Based on these parameters, what is the anticipated likelihood of a positive response to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic evaluation of the tumor microenvironment. Focus on determining if natural killer cell activity is reduced. Additionally, assess the gene expression profiles of T cells, B cells, and plasma cells to identify any markers of immune exhaustion. Once the analysis is complete, compile a detailed report summarizing your findings and discussing the potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f275eb-ar-f275eb8.pkl. "
BLCA,8.0,,desert,NR,"For my Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden is 8.0. Based on these findings, what is the likelihood that he will respond positively to atezolizumab therapy?","For my Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), I obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy, and his tumor mutational burden is 8.0. Based on these findings, what is the likelihood that he will respond positively to atezolizumab therapy? Please use the COMPASS platform to carry out a transcriptomic analysis of the tumor microenvironment. Specifically, assess whether natural killer cell activity is diminished and evaluate the gene expression profiles of T cells, B cells, and plasma cells for evidence of immune exhaustion. After completing the analysis, prepare a detailed report that summarizes your findings and outlines the potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f28c01-ar-f28c015.pkl. "
BLCA,7.0,0.803921569,desert,NR,"For a Caucasian female patient with bladder urothelial carcinoma, based on the transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy and a tumor mutational burden of 7.0, what is the anticipated likelihood of responding favorably to Atezolizumab therapy?","For a Caucasian female patient with bladder urothelial carcinoma, based on the transcriptomic profile of the tumor immune microenvironment obtained from a bladder biopsy and a tumor mutational burden of 7.0, what is the anticipated likelihood of responding favorably to Atezolizumab therapy? Please use the COMPASS platform to perform a transcriptomic analysis of the tumor microenvironment. In your analysis, evaluate natural killer cell activity to determine if there is reduced functionality. Additionally, assess gene expression profiles of T cells, B cells, and plasma cells for indicators of immune exhaustion. Once the analysis is complete, prepare a comprehensive report that details your findings and discusses the potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f2aae1-ar-f2aae14.pkl. "
BLCA,4.0,,excluded,NR,"For my Asian female patient with bladder urothelial carcinoma, whose tumor immune microenvironment was profiled via kidney biopsy and exhibits a tumor mutational burden of 4.0, what is the likelihood of a positive response to Atezolizumab therapy?","For my Asian female patient with bladder urothelial carcinoma, whose tumor immune microenvironment was profiled via kidney biopsy and exhibits a tumor mutational burden of 4.0, what is the likelihood of a positive response to Atezolizumab therapy? Please utilize the COMPASS platform to conduct a transcriptomic evaluation of the tumor microenvironment. During this analysis, assess the activity of natural killer cells to determine if there is a decline in function. In addition, evaluate the gene expression profiles of T cells, B cells, and plasma cells for signs indicative of immune exhaustion. After completing the analysis, compile a detailed report outlining your findings and discussing the potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f3a9bc-ar-f3a9bce.pkl. "
BLCA,7.0,0.529411765,desert,NR,"For a Caucasian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was profiled via transcriptomic analysis from a kidney biopsy and who has a measured TMB of 7.0, what is the expected likelihood of a positive response to atezolizumab therapy?","For a Caucasian male patient with bladder urothelial carcinoma, whose tumor immune microenvironment was profiled via transcriptomic analysis from a kidney biopsy and who has a measured TMB of 7.0, what is the expected likelihood of a positive response to atezolizumab therapy? Using the COMPASS platform, please perform a transcriptomic analysis of the tumor microenvironment. Specifically, evaluate the activity of natural killer cells to determine whether their function is reduced. Additionally, review the gene expression profiles of T cells, B cells, and plasma cells to identify any markers of immune exhaustion. Once the analysis is complete, prepare a comprehensive report detailing your findings and discussing the potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-f82bbd-ar-f82bbdc.pkl. "
BLCA,,5.921568627,inflamed,R,"For my white male patient with bladder urothelial carcinoma, for whom I have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden reported as ""nan,"" what is the estimated likelihood that he will respond positively to Atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, for whom I have obtained a transcriptomic profile of the tumor immune microenvironment from a bladder biopsy and a tumor mutational burden reported as ""nan,"" what is the estimated likelihood that he will respond positively to Atezolizumab therapy? Please use the COMPASS platform to conduct a transcriptomic evaluation of the tumor microenvironment. In your analysis, focus on assessing natural killer cell activity to determine if there is any reduction in their functionality. Additionally, analyze the gene expression profiles of T cells, B cells, and plasma cells to detect markers indicative of immune exhaustion. After completing your analysis, compile a detailed report that summarizes your findings and discusses the potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-fb7aec-ar-fb7aec7.pkl. "
BLCA,5.0,,desert,NR,"For my Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), whose bladder biopsy transcriptomic analysis indicates a tumor mutational burden (TMB) of 5.0, what is the estimated likelihood of a positive response to Atezolizumab therapy?","For my Caucasian male patient diagnosed with bladder urothelial carcinoma (BLCA), whose bladder biopsy transcriptomic analysis indicates a tumor mutational burden (TMB) of 5.0, what is the estimated likelihood of a positive response to Atezolizumab therapy? Please utilize the COMPASS platform to perform a detailed transcriptomic analysis of the tumor microenvironment. In this evaluation, specifically assess the functional status of natural killer cells to determine if there is evidence of reduced activity. Additionally, review the gene expression profiles of T cells, B cells, and plasma cells to identify markers associated with immune exhaustion. Once the analysis is complete, prepare a comprehensive report summarizing your findings and discussing the potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-fd9476-ar-fd94761.pkl. "
BLCA,7.0,0.352941176,desert,NR,"For a white female patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile from a bladder biopsy shows a TMB of 7.0, what is the estimated likelihood of achieving a positive response to Atezolizumab therapy?","For a white female patient with bladder urothelial carcinoma whose tumor immune microenvironment transcriptomic profile from a bladder biopsy shows a TMB of 7.0, what is the estimated likelihood of achieving a positive response to Atezolizumab therapy? Please use the COMPASS platform to conduct a comprehensive transcriptomic analysis of the tumor microenvironment. Focus on evaluating the activity of natural killer cells to determine if there is any indication of diminished function. Additionally, examine the gene expression profiles of T cells, B cells, and plasma cells for markers that may indicate immune exhaustion. After completing the analysis, compile a detailed report that summarizes your findings and discusses the potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-fed609-ar-fed6099.pkl. "
BLCA,10.0,,desert,R,"For my white male patient with bladder urothelial carcinoma, who has a tumor immune microenvironment transcriptomic profile from a recent biopsy and a tumor mutational burden of 10.0 mutations per megabase, what is the likelihood of a positive response to atezolizumab therapy?","For my white male patient with bladder urothelial carcinoma, who has a tumor immune microenvironment transcriptomic profile from a recent biopsy and a tumor mutational burden of 10.0 mutations per megabase, what is the likelihood of a positive response to atezolizumab therapy? Use the COMPASS platform to perform a detailed transcriptomic analysis of the tumor microenvironment. In your analysis, specifically assess the functional status of natural killer cells to determine if there is a decline in their activity. Additionally, review the gene expression profiles of T cells, B cells, and plasma cells to identify any markers suggestive of immune exhaustion. Once the analysis is complete, please prepare a comprehensive report summarizing your findings and discussing the potential implications for future treatment strategies.  The patient's transcriptomic profile (TME) is stored in the file /root/MedeaDB/immune-compass/patients/IMVigor210-ffa5c7-ar-ffa5c7c.pkl. "
